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The presence of blood-brain barrier restricts the entry of many drugs for the 
treatment of central nervous system diseases which generally cannot be cured 
but its symptoms can be controlled by drug treatment. The presence of p-
glycoprotein and multi-drug resistance transporters in the blood-brain barrier 
has been implicated in preventing the entry of some drugs for the treatment of 
central nervous system diseases into the brain, causing treatment failure in 
some patients. To overcome this problem and enhance the drug permeability 
into brain, we propose using carboxymethyl chitosan and chitosan 
nanoparticles as carriers to deliver drugs intra-nasally with the purpose to 
bypass the blood-brain barrier thus to enhance the brain drug concentration 
and the treatment efficacy.
At the same time, to further improve the treatment efficacy of certain drugs, 
HP-β-CD that can increase drug solubility, improve drug-loading rate and 
entrapment efficiency and/or enhance absorption of drug was used to modify 
the carbamazepine/scutellarin loaded chitosan nanoparticles. To evaluate the 
feasibility of developing brain-targeted nasal delivery system, drug loaded 
chitosan nanoparticles with or without HP-β-CD were prepared by a modified 
emulsion evaporation method. The physicochemical properties of these 
nanoparticles were characterized. A high performance liquid choromatography 
(HPLC) method was set up to determine the drug-loading in the developed 
nanoparticles and drug concentrations in the mice plasma and brain after the 
VII
treatment with the respective dosage forms. The pharmacokinetic parameters 
were calculated with the WinNonlin software. The brain-targeted trends were 
evaluated by the indices of AUCbrain / AUCplasma.
Our results showed that the nanoparticles prepared in our study had small 
particle size and high drug loading. The drug release from these nanoparticles 
in vitro appeared to be in accordance with either the Korsmeyer-peppas or 
Higuchi model. The results indicated that the presence of chitosan and HP-β-
CD derivatives had no critical impact in the NPs formation process. However, 
the mean diameter, zeta potential, drug-loading rate and drug release were 
influenced by the concentration of chitosan and CDs added during the 
preparation process. After intranasal administration of those NPs, the highest 
drug concentrations were reached faster and lasted for longer duration in the 
brain than in the plasma. Compared with oral administration, inranasal 
administration has an AUCbrain / AUCplasma ratio higher than one indicating 
that intranasal administration has brain targeting properties.
To sum up, using chitosan and HP-β-CD to prepare nanoparticles could result 
in smaller particle sizes, higher drug loadings, more stable in vitro release and 
better brain targeting. Moreover, intranasal administration was found to have 
preferential targeting of brain when compared to oral administration, 
indicating that it could be an advantage of administering HP-β-CD/modified 
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1Chapter 1 Introduction
1.1 General description of Central Nervous System Diseases
Currently over 1.5 billion people all over the world suffer from various central 
nervous system (CNS) diseases such as Alzheimer disease, Parkinson’s 
diseases, ischemic cerebrovascular disease and epilepsy. These diseases 
represent the largest and fastest growing market of unmet medical needs [1]. 
But these medical problems remain extremely difficult to treat because most 
of the current therapeutics could not be easily delivered from the blood into 
the brain and spinal cord. It is due to the existence of various barriers which 
could protect the CNS, regulate nervous tissue homeostasis and control the 
selective and specific uptake, efflux and metabolism of endogenous and 
exogenous compounds [2]. The blood-brain barrier (BBB) is one of these 
barriers which controls the entry of compounds from blood into the CNS, and 
protects nervous tissue from exposure to the harmful substances circulating 
outside in the blood [3]. Unfortunately, the BBB also prevents the entry of the 
most of potential drugs to reach their targeted sites in the brain. Because of 
this barrier, more than 90% of the drugs for the treatment of CNS diseases 
developed by the pharmaceutical industries are abandoned in clinical Phases I 
to III due to its ineffectiveness and high cost involved in research and 
development [3]. Some current CNS drugs that are mostly lipid-soluble small 
organic compounds have high treatment efficacy for certain CNS diseases 
2such as chronic pain, insomnia, epilepsy and affective disorders including 
depression and schizophrenia. In comparison, drugs for stroke, neu-
rodegenerative diseases and many other CNS disorders are rather limited [4]. 
Hence, it is more important than ever to develop therapeutic drugs that can 
penetrate the CNS effectively, safely, and conveniently and elicit the desired 
drug effects. In the last decades, nanotechnology has been extensively applied 
in biomedical and pharmaceutical research and developments and many of 
them have greatly facilitated the delivery drugs to CNS and improved the 
treatment of CNS diseases.
1.1.1 General description of Epilepsy
Epilepsy has been defined as a common and diverse set of chronic 
neurological disorders. The main symptoms are recurrent and unprovoked 
seizures or a single seizure together with brain alterations which increase the 
chance of future seizures [5, 6]. Epileptic seizures are triggered by abnormal, 
excessive or hypersynchronous neuronal activity in the brain [6]. About 50 
million people worldwide have epilepsy, but epilepsy responds to treatment 
only at about 70% of the time [7]. Epilepsy becomes more common as people 
become older [8]. Epileptic seizures may also occur in recovering patients 
after brain surgery [9]. Epilepsy generally cannot be cured but its symptoms 
can be controlled with antiepileptic drugs (AEDs). However, even with those 
drugs, many patients with epilepsy still could not control such disorders [7]. 
Surgery will only be taken into consideration under difficult situation. Some 
3epilepsy syndromes are not life-long; they might be confined to particular 
stages of childhood [10]. 
A great challenge to develop therapeutics for CNS diseases is to deliver them 
into the CNS through the BBB [11]. A lot of strategies have been investigated 
to overcome this challenge including direct injection into the brain, osmotic 
and chemical opening of the BBB or developing new formulation that can 
cross the BBB. Another possible option is to deliver drugs to the CNS using 
polymeric nanoparticles (NPs) [12] as carriers that will be discussed later. 
1.1.2 General description of Ischemic cerebrovascular disease
Ischemic cerebrovascular disease is considered as a disease when a blood 
vessel is blocked by clots formed from fat and cholesterol. Such block will, as 
a result, induce an ischemic stroke when brain cannot get enough blood supply 
and cells in the brain will suffer from the lack of nutrients and oxygen. 
Ischemic stroke may also be caused by deformity in the valves of the heart or 
as a result of a condition called endocarditis, in which the lining inside the 
heart becomes inflamed. Clots can form on these abnormal surfaces and later 
travel to and lodge in small artery in the brain resulting to cerebrovascular 
disease [13]. The symptoms of ischemic cerebrovascular disease include: 
a) Numbness or weakness of the face, arm or leg, especially on one side of the 
body
b) Confusion, trouble speaking or understanding
c) Trouble seeing in one or both eyes
4d) Trouble walking, dizziness, loss of balance or coordination
e) Severe headache with no known cause
Although these symptoms are only temporary but it still brings severe pain to 
patients and sometimes will lead to death. 
These symptoms could be temporary but the medical problem very often 
brings severe pain to patients and sometimes could lead to death. 
In recent years, ischemic cerebrovascular disease has become one of the most 
severe causes of death and disability that affecting people all around the world. 
In some situations, it will also result in severe neuronal injury and loss of brain 
functions [14]. As an important phenomenon for ischemic stroke, ischemic 
brain edema is caused by the dysfunction of Na+, K+-ATPase in the cell 
membrane which leads to the excessive influx of Na+ and water [15]. It has 
been proved in previous studies that oxidative damage and excitotoxicity play 
a crucial role in the pathogenesis of ischemic cerebrovascular disease [16-18]. 
In this regard, several reports indicated that scuellarin was shown to have a 
protective effect against oxidative damage in synaptosomes induced by 
superoxide [19]. Thus it could be considered as a good treatment for ischemia 
cerebrovascular diseases.
1.2 Problem definition: the Blood Brain Barrier (BBB)
1.2.1 Structure and function of BBB 
The CNS is well protected by the BBB which protects the internal 
environment of brain from outside toxic substances，but meanwhile，it 
5restricts entry of most drugs for brain disease therapy [20, 21]. The BBB is 
composed of high-density cells restricting passage of substances from the 
bloodstream much more than endothelial cells in capillaries that located 
elsewhere in the body [22]. At the interface between blood and the brain, 
endothelial cells are stitched together by these tight junctions, which are 
composed of smaller subunits, mostly the biochemical dimers（Figure1-1）. 
Such structure provides an insurmountable obstacle for drugs to deliver into 
brain. It has been proved by former studies that almost 100% high molecular 
weight drugs and more than 98% of low molecular weight drugs could not 
pass this barrier [12]. Thus, most of the drugs that have been developed so far 
could only enter the CNS in a small amount thus they are unable to reach their 
therapeutic levels in the brain [13]. In addition, BBB processes a number of 
outwardly directed transport mechanisms that forbid drugs from entering the 
CNS. These mechanisms include P-glycoprotein (P-gp) that prevents 
lipophilic compounds from entering the cells and multidrug resistance-related 
protein [MRP] and breast cancer resistance protein [BCRP] that actively 
extrude a variety of therapeutic drugs, and diminishes their pharmacological 
efficacy in the brain [13].
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Figure 1-1 Structure of the blood-brain barrier (BBB) which separates the 
circulating blood from the cerebrospinal fluid by the endothelial cells in the 
tight junction [23]
1.2.2 Administration routes of drugs across the BBB
To bypass the BBB and deliver drugs to the brain, several methods have been 
used such as osmotic and chemical opening of the BBB, intracerebral injection 
or implantation, intravenous (IV) injection, and intranasal delivery [24], etc. 
Basically, the drug administration strategies can be divided into two major 
categories: local drug delivery and systemic administration. For local drug 
delivery, it could offer effective therapeutic concentrations in the brain 
however it requires surgeries or invasive ways to place or remove drugs or 
drug reservoir implants. For example, to achieve a controlled release of certain 
drugs, drug reservoir implants can be directly placed in the brain after surgery 
and the drug effect there can last longer than that after the systemic delivery. 
7On the other hand, most of the polymer-based brain drug delivery systems 
containing large molecules are administered systemically, in most cases via 
intravenous (IV) injection in order to avoid the first pass effect in 
gastrointestinal tract [25]. Following systemic administration, receptor-
mediated transcytosis and adsorptive transcytosis are two main ways for NPs 
to be transported into the brain. Recently, intranasal drug administration has 
been widely studied as an alternative to IV administration since it could 
directly deliver drugs into the brain by bypassing the BBB. For instance, a 
liposomal formulation following intranasal administration has been prepared 
to deliver rivastigmine into the brain [26]. Delivery of proteins to the brain by 
cationic liposomes via intranasal route has also been studied [27]. As a result, 
intranasal administration route, as a non-invasive drug administration route, 
could be a new option for treatment of central nervous system diseases. 
1.2.3 Mechanism of drugs across the BBB
Substances can cross the BBB through paracellular aqueous pathway, 
transcellular lipophilic pathway, transport proteins, receptor-mediated 
transcytosis, or adsorptive transcytosis (Figure 1-2) [27]. Only a few transport 
systems are able to deliver certain endogenous water-soluble compounds to 
the brain by crossing the BBB. For example, hexose transport protein is 
involved in delivery of glucose and mannose into brain [28]. To address the 
problem in delivering therapeutics to brain, structure modification has been 
employed to modify some drugs to mimic certain endogenous molecules and 
8use such transport proteins to deliver drugs into brain. For example, 
gabapentin is a γ-amino acid, but it could mimic an α-amino acid after 
modification and be recognized by the BBB LAT1 large neutral amino acid 
transporter [29]. Without the presence of LAT1-mediated transport system, 
only a small amount of gabapentin could cross the BBB thus treatment 
efficacy in the brain could not be achieved. Other than structure modification, 
nanoparticles as drug carriers have been used to deliver a wide range of CNS 
drugs including large molecular weight biological therapeutic peptides, 
proteins, and genes into the brain. Two major routes of the transportation of 
nanoparticles to the brain are receptor-mediated transcytosis and adsorptive 
transcytosis. For adsorptive transcytosis, it relies on the interaction of a ligand 
with moieties expressed at the luminal surface of cerebral endothelial cells. 
Cell-penetrating peptides (e.g. TAT-derived peptides) and cationic proteins 
(e.g. albumin) were used to improve the adsorptive transcytosis across the 
BBB [30]. While for receptor-mediated transcytosis, it has also been widely 
employed to deliver nanoparticles to the brain. Being highly specific in 
delivery and avoiding the effects of the multidrug efflux system are two main 
advantages of such approach [31]. A good example of receptor-mediated 
transcytosis is that recently, nanoparticles with covalently conjugated 
lactoferrin have been used to penetrate the BBB through the lactoferrin 
receptor present on cerebral endothelial cells [31, 32]. 
9Figure 1-2 The main routes for transport of substances across the BBB
(a: Paracellular aqueous pathway, b : transcellular lipophilic pathway, c: 
transport proteins, d: receptormediated transcytosis, e: adsorptive-mediated 
transcytosis) [33]
1.3 Nanotechnology in CNS treatment
Development in nanotechnology and nanoscience has brought up various 
applications in pharmaceutical research. Generally speaking, nanoparticles 
(NPs) are colloidal particles with sizes less than 1000 nm. Such particles with 
small size can be used for better drug delivery. In most cases, the 
nanoparticles are prepared by encapsulating the drug within a vesicle and or 
by dispersing the drug molecules within a matrix [34]. NPs, as a drug carrier, 
have significant advantages including better bioavailability and stability in the 
system, higher drug loading, longer blood circulation time and targeted 
delivery to the desired organs/tissues [35]. Among all these advantages, 
nanoparticulate drug delivery systems have been extensively studied in recent 
10
years for spatial and temporal delivery, especially in brain targeting [36, 37]. 
Enhancing permeability and retention effect (EPR-effect), attaching specific 
ligands, and making selective distribution are the main causes to enhance drug 
targeting characteristics to specific sites [38]. Among them, the mechanism of 
selective distribution appears to be receptor-mediated endocytosis in brain 
capillary endothelial cells [39]. For the receptor-mediated uptake, modification 
of the nanoparticle surface with covalently attached targeting ligands or 
coating with certain surfactants enables the adsorption of specific plasma 
proteins [40]. 
1.3.1 Types of NPs for drug delivery
Nowadays, it becomes more and more important to find new ways to deliver 
therapeutic drugs to the CNS effectively, safely, and conveniently. With the 
development of nanotechnology, a number of nanoparticulate delivery systems 
such as liposome, polymeric micelle, iron oxide nanoparticle etc. have been 
developed and proved to be efficient in drug delivery [41] (Figure1-3). Among 
these, NPs which possesses brain targeting characteristics would be ideal 
carriers for drug delivery into brain.
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Figure 1-3 Types of nanocarriers for drug delivery.
（A: polymeric nanoparticles; B: polymeric micelles; C: dendrimers; 
D: liposomes; E: viral-based nanoparticles; F: carbon nanotubes: carbon 
cylinders composed of benzene rings.） [42]
1.3.1.1 Surface-modified NPs
After intravenous injection, unmodified NPs will be rapidly adsorbed onto 
plasma components, namely the opsonins present in the blood serum [43]. As 
a result of opsonization, the NPs will be rapidly cleared from the blood stream 
by the macrophages of the reticuloendothelial systems (RES). Former studies 
in mice showed that the clearance of NPs after intravenous administration can 
occur in a short period of time. Thus it is necessary to improve the surface 
properties of nanoparticles in order to avoid the adsorption by the opsonin 
proteins and the subsequent removal by RES cells [44, 45].
For brain targeting, it is known that the amount of drugs that could be 
delivered to the brain is equally proportional to the BBB permeability 
coefficient and the area under curve concentration of plasma versus time 
(AUC) [46]. Delivery of the NPs across the BBB through intravascular 
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administration is mainly achieved by the following ways: a) covalent 
attachment of PEG moieties to the core polymer, b) coating with certain 
surfactants, c) covalent attachment or adsorption of targeting molecules [47]. 
Namely, with certain surfactants or by attaching PEG chains to the core 
polymer, circulation time in the blood of such surface modified nanoparticles 
can be considerably prolonged by avoiding the recognition of phagocytic cells. 
Till now, it has been proved in a variety of the biodistribution studies that 
PEGylation of the NPs can significantly improve the drug delivery to the brain 
[48]. For example, an endogenous ligand glutathione was used by a 
pharmaceutical company to deliver the drug-loaded liposomes (glutathione-
PEG-LPs) to the brain [49, 50]. 
Other than PEG, there are more hydrophilic polymers (poloxamers, 
polysorbate 80, polysorbate 20, polysaccharides etc.) and different type of 
copolymers that can be used to change the surface properties of nanoparticles 
by coating the conventional nanoparticles [51]. Capsulution Pharma, a 
company that conducts research on nano science and technology, has 
developed a novel polysorbate 80-coated nanoparticle for CNS drug delivery 
[52]. The drug were delivered using intravenous administration and after 
which, the surface of these nanoparticles would be further coated with 
apolipoprotein E (Apo-E), one of the absorbed plasma proteins [53]. Such 
nanoparticles are thought to mimic low-density lipoproteins (LDL) thus they 
could penetrate the BBB through the LDL-receptor (LDLR) uptake [54]. 
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Moreover, doxorubicin has been loaded into poly (butylcyanoacrylate) 
nanoparticles coated with polysorbate 80 and the research is in preclinical 
development [55]. 
1.3.1.2 Receptor-mediated NPs
Endothelial cells in the brain contain many endogenous transportation systems 
which could absorb some nutrition into brain from peripheral circulation 
system. Such absorption is mediated by specific carriers in blood-brain barrier 
among which glucose and amino acid are the most capable ones. Such 
strategies for brain targeting using nanoparticles rely on nanoparticle’s 
interaction with the specific receptor-mediated transport systems in the BBB. 
For example, through receptor-mediated transcytosis, polysorbate 80/LDL, 
transferrin receptor binding antibody (such as OX26), lactoferrin, cell 
penetrating peptides and melanotransferrin have been shown to be available to 
deliver a self non transportable drug into the brain via a chimeric construct 
[56]. Because of the high specificity, discoveries of CNS receptors have 
opened up a new application to effectively deliver drugs into the brain. For 
instance, receptor-mediated nanoparticles have been used for delivering 
insulin, insulin-like growth factors (IGF-1 and IGF-2), leptin, transferrin, the 
low-density lipoprotein receptor-related protein (LRP) [57]. Certain 
monoclonal antibodies (mAbs) could mimic peptide structure thus undergo 
receptor-mediated transcytosis. A study showed that by preparing poly 
(butylcyanoacrylate) nanoparticles, hexapeptide dalargin which is difficult to 
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cross the BBB by itself can now be easily delivered into the brain [58]. It has 
also been reported that by using polysorbate-80 coated poly-
(alkylcyanoaceylate) (PACA) nanoparticles, several drugs could be 
successfully delivered into the brain through the BBB [59]. Sun et al also 
demonstrated the effects of polysorbate-80 on drug transportation through the 
BBB with PLA nanoparticles (Figure 1-4) [60].  
Figure 1-4 Structural and design considerations for drug delivery using 
receptor-mediated NPs. Targeting ligands such as antibodies, peptides, 
proteins, carbohydrates, and various other small molecules can be used to 
promote receptor-mediated endocytosis through PEGylation. [61]
1.3.2 Carrier materials of NPs
Biodegradable NPs have been used for site-specific delivery of drugs. One of 
the most extensively used biodegradable polymer matrices for preparation of 
NPs is Poly-D-L-lactide-co-glycolide (PLGA). The hydrolysis of PLGA in the 
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body could produce biodegradable metabolite monomers such as lactic acid 
and glycolic acid [51]. However, in this thesis, we will focus on other two 
polymers—chitosan (CS) and cyclodextrin (CD).  
Chitosan (CS) is a linear polysaccharide extracted from chitin and has been 
widely studied for drug delivery system because of its specific characteristics 
including good bioavailability, non-toxic, biodegradability, and mucoadhesive 
[62]. The free amino groups resultant from the deacetylation process of chitin 
enable the formation of positively charged chitosan salts with organic and 
inorganic acids (Figure 1-5). It is also an excipient that could enhance the 
dissolution rate of hydrophobic drugs. Studies have shown that CS can 
transiently open tight junctions, resulting in a paracellular pathway of material 
through the epithelial barrier. Therefore, CS may be a good option in nasal 
delivery as it binds to the nasal mucosal membrane with an increased retention 
time and as a good absorption enhancer. Nevertheless, CS still possesses 
limitations according to its own structure [62]. Firstly, CS is insoluble in 
neutral or alkaline pH because of its very stable crystalline structure arising 
from strong hydrogen bonds. Secondly, its solubility could only be observed 
in acidic aqueous solution below pH 6.5. To improve the solubility of CS in 
water at neutral pH, which limits its application, chemical modification with O 
(N)-carboxymethylation has been studied. O-carboxymethylchitosan (CMC) is 
a water-soluble CS derivative, in which the original o-hydroxyl group of each 
monomer is substituted by carboxymethyl group through ether bond. 
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Consequently, the carboxyl and amino groups in CMC significantly improve 
its solubility and physicochemical properties including biodegradability, 
biocompatibility and interactions with different substances. 
Figure 1-5 Structure of chitosan and O-carboxymethyl chitosan in which the 
original o-hydroxyl group of each monomer is substituted by carboxymethyl 
group through ether bond
Cyclodextrins (CD) are cyclic oligosaccharides that are composed of sugar 
molecules bound together to form a ring (Figure 1-6). Being simply produced 
by enzymatic conversion of the amylose helix from starch [63], CD has been 
widely used in food, biotechnology, chemical industries, pharmaceuticals and 
drug delivery. The three most typical commonly used CDs consist of 6, 7 and 
8 glucose monomers units in a ring respectively, called α-, β- and γ-CD. These 
compounds have a cone-shaped three-dimensional structure where numbers of 
hydroxyl moieties (18, 21 and 24, respectively) are facing outside to make a 
hydrophilic surface while the inner side of the cavity is hydrophobic because 
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of the glucosidic oxygen bonds [64]. Because of the hydrophilic outside and 
hydrophobic inside structure, CD can include hydrophobic drugs into the 
cavity and as a result improving the solubility, stability and bioavailability of 
such drugs. 
Figure 1-6 Structure of cyclodextrin. The most common cyclodextrins are α-
cyclodextrin, β-cyclodextrin, and γ-cyclodextrin which consist of six, seven, 
and eight glucopyranose units respectively [65]
The natural CD has limited aqueous solubility, which is the main problem in 
developing therapeutically relevant drug formulations. New derivatives of the 
natural CD have been developed that have improved complexation efficiency. 
Among those derivatives, 2-hydroxypropyl- β -CD (HP-β-CD) is the cheapest, 
mostly used and have been extensively studied in pharmaceutical research. 
HP-β-CD, a hydrophilic cyclodextrin derivative can make a 75% (w/v) 
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solution in water while the aqueous solubility for β-CD is only 1.85% (w/v) 
[66]. Thus compared with β-CD, HP- β-CD could increase water solubility, 
bioavailability and stability for certain drugs [67]. Based on former 
researchers [68-70], HP- β-CD was assumed to be a permeation enhancer to 
deliver drugs into brain because it can cross the blood–brain barrier (BBB). 
Indeed, CD are widely used to increase the delivery or bioavailability of drugs 
in oral, ocular [68], dermal [69], and most importantly in nasal administration 
[70]. Ye et al prepared a β-CD based nano-drug delivery system and tested it 
on mice. Results showed that this nano-drug delivery system is a potential 
brain-targeting drug carrier for the treatment of neurological diseases [71]. 
Nonaka et al compared the drug concentrations in plasma, spleen and brain 
regions after the respective intravenous and intranasal injections; and they 
demonstrated that compared with intravenous administration, intranasal 
administration provided about a 40 to 100 fold improvement in brain targeting 
versus peripheral tissues. Moreover, the authors also concluded that targeting 
of various brain regions may be manipulated by the use of various CDs [72]. 
Some researchers also use β-CD to make micro-particles to deliver drug which 
is unable to cross BBB into brain. Such microparticles also appear to have 
great efficacy in inducing the drug absorption at the cerebrospinal fluid (CSF) 
level, probably across the neuronal component of the olfactory mucosa [73]. 
All the findings mentioned above testify that by using CD and intranasal 
delivery, drug permeability into brain through the nasal route could be 
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increased.
According to the advantages of both CD and CS or CMC, incorporating CD 
into CS or CMC-NPs may lead to a drug carrier that possesses the advantages 
of absorption enhancing effects of CD and mucoadhesive properties of CS or 
CMC.
1.3.3 Preparation of nanoparticles
Nanoparticles can be prepared by using varieties of methods. To find out the 
most suitable method for the preparation of NPs, not only the physicochemical 
properties such as the aqueous solubility and stability of the drug but also the 
proposed targeted site of the drug to be formulated should be considered. In 
this section, some preparation methods of nanoparticles will be discussed.
1.3.3.1 Polymerization method
For this method, NPs are prepared from monomers which are polymerized to 
form NPs in an aqueous solution [51]. The two-step method is as follows: 
firstly, drugs are dissolved in the polymerization medium thus they could be 
absorbed/ attached onto the polymerized and fully formed NPs; secondly, the 
stabilizer in the nanoparticle suspension is removed to purify the whole 
mixture while for the surfactants, they could be recycled for subsequent 
polymerization. The size of the final product of the nanoparticles depends on 
the concentration of the surfactant and the stabilizer (Figure 1-7). This method 
has been adopted previously for the preparation of polybutylcyanoacrylate or 
poly-alkyl-cyanoacrylate NPs [74]. 
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drug+monomer   acidic medium in          purification          NPs
               the presence of surfactant
Figure 1-7 Schematic representation for the production of poly-
(alkylcyanoaceylate) nanoparticles by anion polymerization 
1.3.3.2 Ionic gelation method 
For ionic gelation method, in most cases, materials that used in this method 
are natural hydrophilic polymers such as gelatin, alginate, chitosan and 
agarose. These polymers were firstly dissolved in water (chitosan in acetic 
acid). Then the surfactant such as TPP dissolved in water was added into the 
mixture with continuous stirring. Ionic gelation will happen spontaneously, 
leading to the formation of nanoparticles. The formation of nanoparticles 
depends on the TPP concentration which has to be optimized. It has been 
reported that chitosan NPs are prepared by spontaneous formation of 
complexes between chitosan and polyanions or by the gelation of a chitosan 
solution dispersed in an oil emulsion (Figure 1-8) [75].
Figure 1-8 Schematic representation for the production of chitosan 
nanoparticles by ionic gelation method [76]
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1.3.3.3 Solvent evaporation method
The preparation processes for solvent evaporation method are as follows. 
Firstly, the polymer is dissolved in an organic solvent such as dichloromethane, 
chloroform or ethyl acetate. Secondly the drug is dissolved in another organic 
solvent. Thirdly, the drug solution is added in the preformed polymer solution. 
After formation of a stable emulsion by magnetic stirring, the organic solvent 
is evaporated by continuous stirring of the solution (Figure 1-9) [51]. Using 
this method, Cheng et al. made (Z-)-4-bromo-5- (bromomethylene)-2(5H)-
furanone (BBF)-loaded poly (L-lactic acid) (PLLA) nanoparticles. The 
product has a small particle size (408 ± 14 nm), a low polydispersity index 
(0.140 ± 0.008), a high encapsulation efficiency (72.44% ± 1.27%), and a fine 
spherical shape with a smooth surface [77].
Figure 1-9 Schematic representation of the emulsification evaporation 
technique. [51]
1.3.3.4 Solvent diffusion method
For this method, firstly, the polymer is dissolved in a partially water soluble 
solvent and saturated with water. Then the mixture is emulsified in an aqueous 
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solution containing stabilizer, leading to solvent diffusion to the external phase 
and the formation of nanoparticles (Figure 1-10) [78]. Finally, the organic 
solvent is removed by evaporation. The concentration of water-soluble solvent 
could affect the particles size of the formed NPs [79].
Figure 1-10 Drug loading of polymeric micelles by (a) the dialysis; and (b) the 
oil-in-water methods. 
1.3.3.5 Nanoprecipitation method
This method is mainly used for preparation of hydrophobic drug loaded 
nanoparticles, but it has been employed for hydrophilic drugs as well. Firstly, 
polymers and drugs are dissolved together in a polar, water-miscible solvent of 
intermediate polarity. Then the solution of the mixture is slowly added into a 
stirred aqueous solution with surfactant. Nanoparticles are formed 
spontaneously by polymer deposition on the interface between the water and 
the organic solvent. Finally, the solvent is removed under reduced pressure 
[80]. To enhance the encapsulation as well as to avoid the irreversible 
functional changes, Moraima Morales-Cruz et al. described a two-step 
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nanoprecipitation method to make a production of protein-loaded PLGA 
nanospheres [81]. In this paper, a protein nanoprecipitation step is used first 
and followed by a second polymer nanoprecipitation step. With this method, 
the model enzymes, lysozyme and α–chymotrypsin are encapsulated with 
efficiencies of over 70%. 
1.3.4 Characterization of nanoparticles
After preparation of nanoparticles, the drug distribution behavior in vivo will 
depend on many factors of the final products, such as particle size, surface 
property, drug loading and the drug release profile. All these factors will be 
discussed in this section.
1.3.4.1 Particle size and morphology
Particle size plays an important role in determining the delivery pattern of NPs 
in vivo. Particles less than 200 nm in diameter have slow rate of clearance and 
thus extend their circulation times when compared to those with larger 
diameters [82]. There are several technology used for nanoparticle size 
evaluation, including coulter counter (CC), dynamic light scattering (DLS), 
chemical force microscopy (CFM), atomic force microscopy (AFM), cryo-
field emission scanning electron microscopy (cryo-FESEM). The Malvern 
Zetasizer was developed using the dynamic light scattering (DLS) technology 
to measures particle and molecule size from below a nanometer to several 
microns. The diameter polydispersity index and zeta potential could also be 
determined by DLS. For example, the diameters of PLGA-nanocapsules 
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loaded with diverse drugs were tested using DLS at a scattering angle of 173° 
and 25° [83]. Atomic force microscopy (AFM) is a new method used 
nowadays to quantify the adhesive or repulsive forces of the samples and to 
determine the surface chemistry information of the nanoparticles [84]. The 
resolution of AFM techniques could be up to 0.01nm for imaging by using the 
force between a surface and a probing tip. Chemical force microscopy (CFM) 
has become one of the famous tools among AFM techniques. CFM is based on 
AFM tips which are chemically modified with specific exposed functional 
groups [84]. For cryo-FESEM technique, a former study conducted by Tan 
and co-workers has shown that an aerosol consisting of a OT/l-α- 
phosphatidylcholine/isooctane/water system that formed a rigid mesophase 
can be distinguished and imaged in high clarity using this technique.  
Moreover, cryo-FESEM could not only test the size of the particles but also 
provide a deep insight into the multilamellar organization of spherical particles 
that disclosed in certain micrographs [85].
To test the morphology of the nanoparticles, transmission electron microscopy 
(TEM) and scanning electron microscopy (SEM) was used. In order to 
perform the TEM observations, the nanoparticle formulation was diluted with 
water. A drop of the diluted nanoparticle suspension was then directly placed 
on the holey film grid, stained by 1% aqueous solution of phosphotungestic 
acid and observed after drying [86]. For the sphere characterization of DNA-
loaded zein nanospheres, field-emission scanning electron microscopy (SEM) 
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and dynamic light scattering (DLS) were employed by Regier et al [87]. 
1.3.4.2 Surface properties
Surface properties of NPs are critical in determining their drug delivery 
potential. These properties not only modulate the in vitro performance such as 
stability, drug entrapment efficiency and drug release kinetics but also 
determine the overall in vivo performance of the drug delivery system [88]. 
The surface charge on the nanoparticles is quantified by measuring the zeta 
potential using a Zetasizer. Zeta potential, as an indicator of surface change 
can be used to predict and control the stability of nanoparticles. The 
measurement of zeta potential is often the key to illustrate the dispersion and 
aggregation processes of the nanoparticles. For instance, the effect of zeta 
potential on stability was investigated on triamcinolone acetonide acetate 
loaded SLN-carbopol gel [89]. All the SLN-carbopol gel formulations 
prepared in that study showed a zeta potential less than 40mV, and the 
nanoparticles were then shown to be stable for at least three months with little 
changes in particle size and zeta potential [90]. On the other hand, aggregation 
of particles occurred on storage with increase in particle sizes when the zeta 
potential value of the nanoparticles was too high [91]. 
1.3.4.3 Entrapment efficiency (EE) and drug loading 
To prepare a successful nanoparticle preparation, it is essential to load 
sufficient drugs into the particles for the expected drug effect. Thus drug 
loading is one important property of nanoparticle preparation, indicating its 
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efficacy. A high drug loading means that less polymers would be required for 
the nanoparticle preparation, leading to lower cost of preparation. For the 
preparation of nanoparticles, drugs could be 1) encapsulated inside the 
polymer matrix, 2) absorbed onto the surface of the polymeric nanoparticles, 
or 3) chemically conjugated to the polymer before nanoparticle formulation. 
To determine the amount of drugs that could absorb/attach into/onto the 
polymer and what kind of interactions are between drugs and nanoparticles, 
the drug loading conditions should be taken into consideration [92].
Ideally NPs should have high entrapment efficiency and drug loading. The 
entrapment efficiency (EE) is determined by spectrophotometric method after 
centrifugation of the aqueous dispersion. Briefly, the amount of free drug was 
detected in the supernatant and the amount of incorporated drug was 
determined as a result of the initial drug added minus the free drug in the 
supernatant [93]. For example, the EE and drug loading of doxorubicin 
encapsulated nanoparticles prepared by solvent emulsification diffusion 
method was determined by spectrophotometric method and the results were 
more than 70% and 3% respectively [94]. The EE% and drug loading 
percentage were calculated using Equation (1) and Equation (2): 
EE (%) = (Initial drug – free drug) / Initial drug ×100               (1)
Drug loading (%) = （Initial drug – free drug ）/ Amount of NPs ×100    
(2)
1.3.4.4 In vitro release of drugs from Nanoparticles
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The drug release mechanisms should be considered as an important factor that 
affects the drug delivery in human body. It will affect the drug effect at the 
targeted site. Basically, the drug release rate depends on the solubility of the 
drug, desorption of the surface bound drug, drug diffusion through the 
polymer matrix, NP matrix degradation and combination of the erosion 
diffusion process [95]. To improve the drug release conditions, using polymers 
as matrices to load drugs into/onto them could be a good option. After 
preparation of the drug loaded nanoparticles, the drug release rate will also 
depend on the size and drug loading of the final products. If the diffusion of a 
drug is faster than the matrix erosion, the release mechanism is predominately 
through a diffusion process. If there is a burst release of drug at the start of the 
release study, then it is because drugs might just be loaded on the surface of 
the nanoparticles [96, 97]. 
1.3.5 Evaluation on the feasibility of using nanoparticles for brain targeting 
Rodents such as mice, are used widely as model animals for in vivo study and 
the animals are usually been divided into experimental group and control 
group. For the experimental group, drug loaded formulations are given 
through different administration routes. For the control group, a prepared drug 
solution is administered using the same volume and dose as the experimental 
group. For all the groups tested, blood samples are withdrawn at 
predetermined time intervals after administration and were centrifuged 
immediately. Then plasma is then separated and stored at -20 °C until analysis. 
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To determine the brain targeting characteristics of the drug formulation, the 
scull of the mouse is opened, and the whole brain is collected after collection 
the blood sample. The brain samples are then rinsed with normal saline and 
immediately stored at -80°C until analysis. In order to determine the drug 
concentration in the brain, the brain is homogenized in PBS and analyzed 
using HPLC. Male albino rats of Wistar strain have been used for the in vivo 
study of carbamazepine solid-lipid nanoparticles containing chitosan (CBZ-
CT SLNs) conducted by Nair et al. [98]. The rats were housed in 
polypropylene cages under standard laboratory conditions with a 12–12 h 
light–dark cycle as well as free access to diet and drinking water. They were 
acclimatized to laboratory conditions for 10 days before starting the 
experiment. Results showed that CBZ-CT SLNs have better activity compared 
to control group. The time for onset of convulsions in treated group took more 
time than the control one [98].
To evaluate the accumulation of drugs at their targeted sites, advanced 
imaging instruments including computed tomography (CT); magnetic 
resonance imaging (MRI); positron emission tomography (PET) have been 
employed for the in vivo drug release study in animals. MRI appears to be 
better than CT for soft tissue scanning. However, PET/CT could scan for the 
whole body evaluation of metabolic activity. So it is important to choose the 
most suitable instrument to carry out the study. Li et al. constructed a PET 
trackable nanoplatform for cancer imaging and proved the imaging capability 
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of these targeting agents. They also demonstrated that the choice of chelator 
could have significant impact on imaging results [99]. Similarly, imaging 
techniques can also be applied to trace delivery of nanoparticles to the brains. 
For example, superparamagnetic iron oxide nanoparticles have been applied 
for magnetic resonance imaging (MRI) for diverse diagnostic and potential 
therapeutic applications in the central nervous systems [100].  
1.4 Mechanism and advantages of nasal delivery
Nasal drug delivery system, in general, is an administration route to deliver 
drugs from the nasal cavity to the blood circulation system or to specific 
targets which cannot be reached by conventional administration routes. In 
particular, recent studies showed that nasal delivery is superior to other routes 
of administration in bypassing BBB to target brain effectively [101-103]. 
These studies indicate that intranasal drug administration route could be a 
possible alternate route to the conventional administration methods. Compared 
to injections, intranasal drug administration is easy to administer, causes less 
pain, and does not require intravenous access and special trainings for patients. 
Compared with oral administration, intranasal drug administration could 
deliver drugs faster to the brain due to the large number of vascular plexus in 
the nasal cavity and also last longer at the targeted sites. Meanwhile, with a 
direct absorption in the blood circulation system, intranasal delivery could 
avoid the gastrointestinal destruction and hepatic first-pass metabolism, 
allowing more drugs to be bioavailable (Figure 1-11). Most importantly, as the 
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transfer of drugs from the olfactory bulb to the brain is considered as the nose-
brain pathway, intranasal administration could also bypass the BBB, making it 
a potential therapeutic alternative for the treatment of CNS diseases [104]. 
Figure 1-11 Delivery of drug-loaded CS-NPs through intranasal administration. 
[105]
Advantages of this new route could be proved by the structure and specific 
characteristics of nasal cavity, such as: the fully vascularized epithelium and a 
relatively large surface available for drug absorption, the porous endothelial 
basement membrane, the direct transport of absorbed drugs into the systemic 
circulation meaning overcoming the first-pass effect present in oral 
administration, the lower enzymatic activity compared with the 
gastrointestinal tract and the liver [106, 107]. Thus intranasal drug delivery 
system could be more compliable to patients and might enhance the drug 
effect in brain. 
Nevertheless, there are still limitations for intranasal administration route. The 
mucociliary clearance is one such limitation that determines a limited time for 
drug absorption in the nasal cavity [108]. Thus to overcome this limitation 
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strategies that could prevent the rapid clearance, meaning prolong the drug 
absorption time in nasal cavity should be adopted. Using mucoadhesive 
materials, such as starch and chitosan could be one such strategy [109]. 
1.5 Selection of model drugs 
Carbamazepine (CBZ) is a widely used antiepileptic agent, which has been 
effective in the therapy of psychomotor seizures and trigeminal neuralgia for 
almost 40 years [110]. However, in most cases, CBZ given by systemic 
administration could have dramatic side effects including “carbamazepine-
hypersensitivity-syndrome” in hematologic, hepatic, renal, and pulmonary 
systems. Severe skin reactions as well as hepatic abnormalities, ranging from 
an asymptomatic rise in liver function tests to acute liver failure will also 
happen after administration [111]. Furthermore, due to the hepatic enzyme-
inducing character of CBZ, ambulatory children who received CBZ 
monotherapy might suffer from early alteration in bone metabolism [112]. 
What’s worse, CBZ has poor water solubility (< 200 μg/mL) thus the delivery 
of CBZ will generally result in a slow and irregular absorption [113]. Thus it 
is essential to develop a new drug delivery system for CBZ.
Scutellarin (SCU) is a flavone, extracted from Erigeron breviscapus which 
could raise brain blood flux, decrease cardiac muscle flux, enhance phagocytic 
function etc. and showed remarkable pharmacological activities in improving 
kidney function, preventing liver fibrosis and protecting ocular nerve of 
experimental high pressure eye [114]. Its current clinical implications are 
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mainly for coronary heart disease, angina, myocardial ischemia and cerebral 
thrombosis [115, 116]. However, it is poorly absorbed due to its low solubility 
below pH 6.0 so that its bioavailability is very limited. Its absolute 
bioavailability in Beagle dog when administered orally was merely 0.2%~0.75% 
[117]. Therefore, it is valuable to develop a new pharmaceutical technology to 
improve its bioavailability.
As a result, CBZ and SCU (Figure 1-12) are selected as the drugs in this study 
for reformulation, since CBZ with its problems associated with systemic 
administration is used extensively for the treatment of seizure disorders and 
SCU with its extremely low bioavailability  is however, one of the few drugs 
that can be used for the treatment of ischemic cerebrovascular disease [118]. 
However, according to the records, there are only oral or IV dosage forms of 
CBZ and SCU in the market. Thus, we propose to develop a nasal formulation 
of CBZ and SCU respectively with the objective to enhance their delivery to 
the brain by bypassing the blood-brain barrier. 
Figure 1-12 The Structure of model drug CBZ and SCU
1.6 Purpose and scope
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Chitosan (CS) and cyclodextrin (CD) are two bio-polymer materials that have 
the advantages of being good biodegradability and good safety profile. Thus 
using CS and its derivatives and CD as a drug carrier to prepare nanoparticles 
possesses both the advantages of CD which could a) increase the solubility 
and improve the stability of drugs; b) extend the drug release time; c) increase 
the entrapment efficacy and drug loading of nanoparticles, and also the 
mucoadhesive characteristics of CS which could improve the absorption of 
drugs in the nasal cavity. Based on the characteristics of CS and CD, these two 
materials have been widely used in sustained-release, controlled-release and 
specific site-targeting delivery of drugs in pharmaceutical researches.
In this thesis, we will use carboxymethyl chitosan (CMC), CD/CMC and 
CD/CS as drug carriers, carbamazepine (CBZ) and scutellarin (SCU) as model 
drugs to prepare a novel chitosan nanoparticlulate drug delivery system. The 
main objectives are as follow:
(1) Synthesis and characterization of water-soluble chitosan derivatives - 
CMC: Chitosan will be grafted with carboxymethyl groups to form the water 
soluble chitosan derivative. The physicochemical characteristics of the product 
will then be studied. The potential uses of CMC, as the polymer materials in 
drug delivery system, will be further discussed. 
(2) Preparation and evaluation of CMC-CBZ-NPs in vitro and in vivo: Firstly, 
CBZ was used as a model drug and CMC as a drug carrier to prepare a 
nanoparticulate drug delivery system. Secondly, the particle form, particle size, 
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zeta potential, drug loading and drug release mechanism of the nanoparticles 
were evaluated. Then, the in vivo study using intranasal administration of the 
prepared nanoparticles was conducted in mice. The results after intranasal 
administration of the nanoparticle preparation and the corresponding drug 
solution were than compared with that after oral administration of the drug 
solution. In the studies, the pharmacokinetic data were analyzed and the brain 
targeting characteristics were estimated to determine their suitability for 
treatment of central nervous system diseases.     
(3) Preparation and evaluation of CD/CMC-CBZ-NPs in vitro and in vivo: 
Taking the advantages of CMC and HP-β-CD, CBZ loaded CD/CMC-NPs 
were prepared. The particle size, drug loading, in vitro release mechanism and 
brain targeting characteristics using intranasal delivery of the prepared 
nanoparticles were studied. According to the results, we demonstrated a new 
nanoparticulate drug delivery system with higher drug loading and better brain 
targeting characteristics. 
(4) Preparation and evaluation of CD/CS-SCU-NPs in vitro and in vivo: SCU 
was chosen as a model drug. Chitosan and HP-β-CD were chosen as drug 
carriers to prepare the SCU loaded CD/CS-NPs using ionic gelation method. 
The in vitro and in vivo studies were carried out to investigate the brain 
targeting characteristics of the nanoparticles with positive charges. 
The specific approaches of this study were as follows: firstly, a water soluble 
chitosan derivative--CMC was synthesized by etherification method; secondly, 
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CS, CMC and HP-β-CD were used separately or together as drug carriers; 
thirdly, both chemical drug (CBZ) and natural drug (SCU) were chosen as 
model drugs; fourthly two nanoparticulate drug delivery systems with the 
respective positive and negative charge were prepared and optimized; finally, 
an intranasal drug delivery system was developed and its pharmaceutical 
properties were compared with that of an oral formulation in a control group. 
The brain targeting characteristics of the nanoparticles after intranasal 
administration were estimated. In conclusion, our study provided new ideas 
and experimental evidences of the brain-targeting nanoparticulate intransal 
delivery system for the treatment of central nervous system diseases.
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Chapter 2 Synthesis and Characterization of Carboxymethyl Chitosan
 
2.1 Introduction
In recent decades, biodegradable and biocompatible polymers have attracted 
attention of researchers as potential carriers for the drug delivery system [119]. 
Among these polymers, chitosan (CS), one of the most widely used 
biomaterials prepared from N-deacetylation of chitin, has attracted significant 
interest because of its well-known characteristics including low toxicity, 
excellent biocompatibility and good biodegradability [120]. Studies up to date 
have shown that CS can transiently open tight junctions meaning that open a 
paracellular pathway of material through the epithelial barrier [121]. However, 
the poor water solubility of CS (only soluble in weak acidic solution) is one of 
main drawbacks for its application in drug delivery system. Thus to optimize 
the physicochemical and biological properties of CS, which has abundant -OH, 
-NH2, making it possible for grafting other groups, a number of CS derivatives 
which are water soluble around neutral pH have been synthesized and used as 
carriers in drug delivery systems. Carboxymethyl chitosan (CMC) is a water-
soluble CS derivative in which the carboxyl groups and amino groups 
significantly improve its solubility and physicochemical properties including 
the biodegradability, biocompatibility, film-formation and interactions with 
different substances [122]. For these advantages, CMC has received much 
attention in biomedical applications, especially for drug delivering systems 
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[123-125]. In this chapter, CMC was synthesized using an alternative method 
and its chemical structure was characterized by FT-IR and NMR spectroscopy.
2.2 Materials 
Medium molecular weight CS was supplied by Aldrich Chemical Company; 
Sodium hydroxide (1mol/L) was obtained from Merck Chemicals Co., Ltd 
(Germany). All other chemical solvents and reagents used were of analytical 
grade.
2.3 Methods
2.3.1 Synthesis of CMC
Preparation of CMC was according to the method reported previously [126]. 
Briefly, 10g of CS was suspended in 100 mL isopropanol to fully swell for 1h. 
Then 30mL of 12.5 mol/L sodium hydroxide was added drop by drop into the 
suspension to alkalize at room temperature for 2 h. After that, 10 g of 
monochloro acetic acid (ClCH2COOH) was added gradually into the mixture 
and the reaction mixture was stirred to react for 4 h at 55 °C. Then the reaction 
was stopped and the pH of the mixture was adjusted to pH 7-8 using acetic 
acid. The precipitate was filtered and washed with 80% Ethyl alcohol, 95% 
ethyl alcohol, methanol, respectively, and vacuum-dried at 50 °C. The product, 
CMC was obtained afterwards. Synthetic scheme of CMC was shown in 
Figure 2-1.
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Figure 2-1 Synthetic scheme of CMC (1. O-CMC; 2. N-CMC; 3. O, N-CMC) 
[126]
2.3.2 Characterization of CMC
2.3.2.1 Overall yield 
The overall yield of CMC from the synthetic scheme was calculated by the 
following formula:
Product yield= (Amount of CMC × Molecular weight of CS)/ (Amount of CS 
× Molecular weight of CMC) × 100%
2.3.2.2 The degree of substitution of CMC
The degree of substitution (DS) of CMC was determined by pH titration. The 
accurately weighed CMC was dissolved in water, and then the pH was 
adjusted to less than 2 with hydrochloric acid (12mol/L). The standard sodium 
hydroxide solution (1mol/L) was used for titration. The amount of aqueous 
sodium hydroxide was determined by the second order differential method 
[127]. The DS can be calculated by the following equation:
DS = 161×A/ (mCMC -58A)
A= VNaOH× CNaOH
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Where mCMC was the mass of CMC (g), 161 and 58 were the molecular 
weights of glucosamine (chitosan skeleton unit) and a carboxymethyl group 
respectively, VNaOH and CNaOH were the respective volume and molarity of 
aqueous sodium hydroxide solution for the titration [127].
2.3.2.3 FT-IR spectroscopy
Fourier transform infrared spectroscopy (FT-IR) was used to verify the 
chemical structure of the synthesized CMC. The measurements were carried 
out on a FT-IR (Perkin Elmer, Model 100). Samples were analyzed in the 
atmospheric environment, and the FT-IR curves of CS and CMC were 
acquired [127]. The degree of substitution of the synthesized CMC was 
estimated by way of an elemental analysis using a Perkin Elmer PE2400 
Series II CHNS/O analyzer. 
2.3.2.4 NMR spectroscopy
Nuclear magnetic resonance (NMR) analyses were carried out as described 
previously [128]: 15mg of the CMC sample was dissolved in 1mL of 
deuterated water before analyzed using an AC-400 Bruker spectrometer at 353 
K. Elemental analysis data were obtained using a Carlo Erba elemental 
analyzer. Samples were tested in both 1H NMR and 13C NMR. 
2.4 Results and discussion
2.4.1 Synthesis of CMC 
CMC was prepared by etherification method using CS and monocholoroacetic 
acid in a NaOH-isopropanol system. The main factor which influenced the 
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preparation of CMC was the mass ratio of CS, NaOH and ClCH2COOH [127] 
while for the reaction time and temperature, there was no significant impact on 
the preparation process. When the mass ratio of NaOH: ClCH2COOH was less 
than 1:1, it was difficult to start the reaction meaning the reaction only started 
under strong alkaline condition. Moreover, with the increase of CS: 
ClCH2COOH mass ratio, the degree of substitution increased and the overall 
yield decreased indicating that the carboxymethyl reaction would start first on 
the -OH group rather than the - NH2 group. According to the results stated 
above, when the mass ratio of the CS: NaOH: ClCH2COOH was 2: 3: 2, the 
overall yield of CMC from the synthetic scheme was 84.6%.
2.4.2 Degree of substitution of CMC
The changes of pH value in response to the addition of sodium hydroxide were 
shown in Figure 2-2. There were two sharp rises of pH values in the curve: the 
first one was at the volume of 13mL of sodium hydroxide and the second one 
was at the volume of 19mL. Thus according to the formulation, the degree of 




Figure 2-2 Estimation of degree of substitution of CMC by titration with 
NaOH solution 
2.4.3 FT-IR spectroscopy
As shown in Figure 2-3, peaks at 3433 cm−1 (O–H stretch), 2923-2920 cm−1 
(C–H stretch), 1656 cm−1 (bridge-O stretch), and 1155-897 cm−1 (C–O stretch) 
were basic characteristic peaks of chitosan [127]. The spectrum of CMC was 
evidently different from that of chitosan (Figure 3 and Table 2). The IR 
spectrum of CMC showed the grafted carboxymethyl group at 1598～1415 
cm−1. Compared with the peaks of chitosan, the bands at 1598～1650 cm−1 
and 1415 ～1401 cm−1 (corresponding to the symmetric and asymmetric 
deformation of –COO, respectively) were more intense in the spectrum of 
CMC, indicating carboxymethylation on both the amino and hydroxyl groups 
of chitosan. It was also noted that the peaks at the 1155～897 cm−1 (C -O 
stretch) were increased. These findings were in agreement with the result of a 
previous study [128]. 
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Figure 2-3 FT-IR spectroscopy of CS (a) and CMC (b)
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The proton NMR spectrum of CMC in D2O was shown in Figure 2-4. The 
resonance of H–1D (4.8 ppm), H–1A (4.622 ppm), 3 acetyl-protons (2.051 
ppm), H3–6 protons (3.5–3.9 ppm), H–2D proton (3.305 ppm) were the basic 
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assignments of chitosan resonance which could be found in the 1H NMR 
spectrum of chitosan described previously. The proton resonances of the 3- 
and 6-substituted carboxymethyl (–O–CH2COOD) of CMC could be observed 
between 4.05 and 4.55 ppm. The result proved that the amino groups were 
partly carboxymethylated along with the hydroxyl groups, indicating that our 
product complied with the previously reported parameters of CMC [127, 128]. 
Figure 2-4 1H NMR spectrum of CMC
2.4.5 13C NMR
The 13C NMR spectrum of CMC was shown in Figure 2-5. In the spectrum, 
the obvious signals at 168.409 and 171.133 ppm which were signals for -
*CH2COOH substituted on -OH and –NH could be observed. Three chemical 
shifts at 70.9, 69.500 and 52.756 ppm further proved -*CH2COOH groups 
substituted on O-6, O-3 and N-2 positions as described previously [127, 128]. 
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Figure 2-5 13C NMR spectrum of CMC
2.5 Conclusions
One commonly used method for the synthesis of CMC was using the 
monocloro acetic acid to react with chitin which needed a long reaction time 
with a low product yield. While in this chapter, a chitosan derivative -- CMC 
was chemically synthesized in a homogeneous reaction system using chitosan 
reacted with the monocloro acetic acid under strong alkaline condition which 
had a short reaction time and high product yield. This homogeneous system 
made an easy synthesis, high yield (84.6%) and good substitution degree 
(0.364). 
The physicochemical properties of CMC were then characterized by FT-IR, 
1H-NMR, 13C-NMR. Taking advantage of water solubility, the CMC could be 
used as an effective excipient for brain targeting drug delivery. The potential 
uses of CMC, as the polymer materials of nanoparticles, would be studied in 
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the following chapters. As a result, the findings from this study may be used to 
promote the utilization of CS and to improve the efficacy and safety of the 
formulation preparation process.
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Chapter 3 Preparation and In Vitro/In Vivo Evaluation of 
Carbamazepine-loaded Carboxymethyl Chitosan Nanoparticles 
3.1 Introduction
Drug delivery into the brain is strictly regulated by the presence of the blood-
brain barrier (BBB). Due to this barrier, many potential drugs for the treatment 
of diseases of the central nervous system (CNS) cannot reach the brain in 
sufficient concentrations [129]. Therefore research on enhancing drug delivery 
into the brain is on focus. 
Compared with other routes of drug administration, nasal delivery possesses 
many advantages and has been widely explored recently [130-132]. Therefore, 
it is considered as an attractive alternative to traditional administration routes. 
However, there are still some limitations for nasal administration. To improve 
the nasal bioavailability, co-administration of drugs with absorption enhancers 
is always adopted. Alternatively, mucoadhesive microspheres which can 
enhance the deposition of drugs on nasal mucosa and extend the residence 
time in the nasal cavity have been frequently used for nasal delivery of 
bioactive agents [133]. Chitosan (CS) is one such material that has been 
shown to be mucoadhesive. Thus it may be an ideal option in nasal delivery as 
it binds to the nasal mucosal membrane with an increased retention time and it 
is a good absorption enhancer. However, the applications of CS (only soluble 
in weak acidic solution) suffer severe limitations. Many water-soluble 
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derivatives have been prepared by introducing carboxyalkyl groups as 
carboxymethyl, carboxyethyl, carboxybutyl substituents into the molecules. 
Compared with other water-soluble chitosan derivatives, carboxymethyl 
chitosan (CMC) has been widely studied because of its ease of synthesis, 
ampholytic character and possibilities of ample applications. In this chapter, 
carbamazepine (CBZ) was chosen as a model drug due to its poor water 
solubility and dramatic side effects when used for systemic therapy. The main 
object was to prepare a novel CBZ-loaded CMC-NPs brain targeting delivery 
system following intranasal administration.
3.2 Materials 
3.2.1 Chemical and reagents
Carbamazepine USP-grade was purchased from Sigma–Aldrich; CMC was 
synthesized in the lab. Sodium hydroxide (1mol/L) was obtained from Merck 
Chemicals Co., Ltd (Germany); Phosphate buffer (pH7.4) was purchased from 
Vivantis Technologies Sdn Bhd (USA). Methanol and acetonitrile were HPLC 
grade and purchased from Merck Chemicals Co., All other chemical solvents 
and reagents used were of analytical grade.
3.2.2 Animals
Adult male C57BL mice aged between 6 and 7 weeks and weighing 20–30 g 
were supplied by local certified animal facility (Comparative Medicine, Center 
for Life Science, National University of Singapore). Mice were housed under 
controlled environment with free access to tap water and standard rodent diet. 
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All the experiments involving animals and their care were approved by the 
Institutional Animal Care and Use Committee (IACUC), National University 
of Singapore with the protocol number of R13-4467(A2)14.
3.3 Methods
3.3.1 Preformulation of CBZ
3.3.1.1 HPLC method for CBZ
High-performance liquid chromatography (HPLC) analyses were performed 
using a variable wavelength UV detector and an autosampler. The analytes 
were detected at 285 nm after separation on a reversed-phase C18 column, 150 
× 4.5 mm. The mobile phase was consisted of 70% methanol and 30% water, 
and was delivered at a flow rate of 0.4 mL/min. The injection volume was 
10µL by an autosampler and the retention time was 6.5 min [134]. 
Quantification of the compounds was carried out by measuring the peak areas 
in relation to those of standards chromatographed under the same conditions. 
Standard samples using methanol as the solvent were analyzed by the same 
method. 
3.3.1.2 Calibration curve 
Primary standard stock solution of CBZ was prepared by dissolving 10 mg 
accurately weighted standard compounds in 10mL methanol. The stock 
solutions were then diluted with methanol to obtain a series of working 
solutions of 2.5, 5.0, 10, 15, 20 and 25µg/mL, respectively. The CBZ 
calibration curve was constructed by plotting the peak area versus 
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concentrations.
3.3.1.3 Assay precision and accuracy 
Precision and accuracy of the assay were determined by replicated analyses 
(n=5) of three different concentrations of CBZ (2.5, 10, 25µg/mL) on the same 
day (intra-day) and also on 5 consecutive days (inter-day). The precision was 
expressed as the intra-day and inter-day coefficient of variation (%). The 
accuracy was calculated as the percent of the determined concentration to the 
nominal concentration.
3.3.1.4 Recovery
To determine the recovery of CBZ by the HPLC method, the samples in 
triplicates were spiked with CBZ at concentrations of 5, 15, 20µg/mL. The 
resulting peak areas were used to calculate the concentrations by referring to 
the calibration curve, and the recovery values were estimated by comparing 
the measured concentrations to the added concentrations.
3.3.1.5 Solubility and stability of CBZ
For determination of the saturation solubility in different solvents, excessive 
CBZ was added to buffers of different pH value (pH 1.2, 2.5, 4.5, 6.2, 7.0, 8.9) 
and shaken well to ensure a full dissolution of drug in each solution at 37°C. 
The samples were centrifuged and then each of the supernatant was collected 
and filtered through a 0.45µm membrane filter. The filtrate was injected into 
the HPLC to test for its concentration. 
The stability of CBZ during the sample storing and processing procedures was 
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fully evaluated by analyzing the filtrate stored under room temperature for 
different times (0, 2, 4, 8, 12, 24h) respectively. The obtained results were 
compared with the 0h concentration of CBZ to determine the stability.
3.3.1.6 Oil /water partition coefficient 
Oil/water partition coefficient was the ratio of concentrations of CBZ in a 
mixture of two immiscible phases at equilibrium. These coefficients were a 
measure of the difference in solubility of the compound in these two phases. 
For this experiment, octanol in 5 mL was used as the oil phase and water, 
0.1mol/L HCL and phosphate buffer (pH 7.4) also in 5 mL were used as the 
respective water phases. Generally speaking, the larger the coefficient, the 
more soluble the compound will be in the oil phase and vice versa. To conduct 
the experiment, octanol was first added to the respective water, 0.1mol/L HCL 
and phosphate buffer (pH 7.4) and the resultant mixture was then shaken 
overnight. The water phase was separated from the octanol after equilibrium. 
Then CBZ was added to the respective water phase and returned to the octanol. 
The mixture was shaken for another 24h. The water phase was separated after 
centrifugation at 3000rpm for 10min and the concentration of CBZ in the 
water phase was tested using HPLC and was compared with the water phase 
without the drug. The experiment was repeated for three times. The formula 
for calculating the partition coefficient was as follow:
P= (C0-Cw)/ Cw
where P was Oil /water partition coefficient, C0 was initial concentration of 
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drug in water phase, Cw was drug concentration in water phase after 
equilibrium.
3.3.2 Preparation of CMC-CBZ-NPs
Drug-loaded nanoparticles were prepared by a modified method reported 
previously [135]. Briefly, CBZ was dissolved in one part of acetone; and the 
CMC was separately dissolved in one part of distilled water. The CBZ 
solution was dropped into the polymer solution stirred with a magnetic stirrer. 
After forming the completely dispersed particles, the dispersions were 
sonicated using a sonic dismembrator (Fisher Scientific Co., Model 500) for 
about 30min. Then the mixture was stirred with the magnetic stirrer for about 
another 4h to evaporate off the organic solvent. The obtained nanoparticle 
suspension was filtered through a 0.45 µm filter membrane to remove the 
unincorporated CBZ aggregates, and the drug-loaded nanoparticle suspensions 
were obtained. The dried product was obtained after freeze-drying and kept 
under vacuum for 48 h.
On the other hand, the CBZ-solution was prepared by dissolving CBZ in 2% 
HP-β-CD solution. The concentration of CBZ-solution was the same as the 
CMC-CBZ-NPs.
3.3.2.1 Influence of CBZ/CMC mass ratio
To determine the influence of CBZ/CMC mass ratio on the characteristics of 
CMC-CBZ-NPs, the concentration of CMC was kept as 0.2% and the volume 
of acetone as 5mL respectively. The different CBZ/CMC mass ratios (1:1, 1:2, 
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1:3) were used to prepare the CMC-CBZ-NPs. NP products from the different 
formulations would be tested for their particle sizes, PDIs, zeta potentials and 
drug loading. The results were then compared.
3.3.2.2 Influence of CMC concentration 
To determine the influence of the concentration of CMC on the characteristics 
of CMC-CBZ-NPs, we kept the CBZ/CMC mass ratio at 1:2 and the volume 
of acetone at 5 mL. The different concentrations of CMC (0.1%, 0.2%, 0.3%, 
0.5%) were used to prepare the CMC-CBZ-NPs. NP products of the different 
formulations would be tested for its particle sizes, PDIs, zeta potentials and 
drug loading. The results were then compared.
3.3.2.3 Influence of acetone volume
To determine influence of acetone volume on characteristics of CMC-CBZ-
NPs, the CBZ/CMC mass ratios (1:2) and the concentration of CMC (0.2%) 
were kept constant. The different volumes of acetone (0.5, 1, 2, 3, 5mL) were 
used to prepare the CMC-CBZ-NPs. Products of different formulations would 
be tested for its particle size, PDI, zeta potential and drug loading. The results 
were then compared.
3.3.2.4 Formulation optimization
The CBZ/CMC mass ratio (A), concentration of CMC (B) and volume of 
acetone (C) were selected as main factors. The orthogonal experiment design 
table of the three factors and three levels was shown in Table 3-1. Three 
batches of CMC-CBZ-NPs were prepared using the optimal formulation for 
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verification.
Table 3-1 Factors and levels for formulation optimization
A B C
Factors
CBZ/CMC mass ratios 
(mg/mg)




1 1:1 0.1 0.5
2 1:2 0.2 2
3 1:3 0.5 5
3.3.3 Characterization of CMC-CBZ-NPs
3.3.3.1 Transmission electron microscopic (TEM) studies
Particle morphology was examined by transmission electron microscopy 
(TEM, JEOL 2010). Samples (the nanoparticulate suspensions) were dropped 
into Formvar-coated copper grids, and after complete drying, the samples were 
stained using 2% w/v TPA. Image capture and analysis were done using 
Digital Micrograph and Soft Imaging Viewer Software.
3.3.3.2 Size and zeta Potential analysis of the CMC-CBZ-NPs
Photon correlation spectroscopy (Zetasizer 3000; Malvern Instruments, 
Malvern UK) was used to measure particle size and zeta potential of all drug-
loaded nanoparticles [136]. Before analysis, all samples were diluted with 
appropriate distilled water for measurements. Z-average particle size, 
polydispersity index (PDI), and zeta potential were all measured in triplicates 
at room temperature.
3.3.3.3 Drug-loading studies
The dried CMC-CBZ-NPs samples (5mg) were transferred to a 25 mL 
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volumetric flask. A total volume of 10 mL of methanol was added and the 
dispersion obtained was sonicated for 15min to dissolve CBZ. Samples were 
withdrawn from the undiluted solution using a syringe, then filtered (PTFE 
0.45µm) before detection [135]. The concentration of CBZ in methanol was 
determined by the HPLC. The drug-loading (DL %) can be calculated by
DL%= Amount of drugs in NPs/Total amount of NPs ×100%
Contents of CBZ in the NPs were determined by high performance liquid 
chromatography (HPLC). Quantification of the compounds was carried out by 
measuring the peak areas and comparing the peak areas against that of the 
standards chromatographed under the same condition.
3.3.4 In vitro release 
3.3.4.1 Calibration curve
Standard stock solution of CBZ was prepared by dissolving 10mg accurately 
weighted standard compounds in 10mL methanol. The stock solutions were 
then diluted with phosphate buffer (pH7.4) solution to obtain a series of 
working solutions of 0.5, 0.75, 1.0, 2.0, 5.0 and 10µg/mL respectively. The 
CBZ calibration curve was constructed by plotting the peak area versus 
concentrations.
3.3.4.2 Stability for CBZ in release media
Stability of CBZ in release media was determined by analyzing CBZ samples 
at three different concentrations (0.5, 2, 10µg/mL) in 0, 1, 2, 4, 6, 8, 12, 24 
hours. Samples were put in water bath at 37oC.
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3.3.4.3 In vitro release
In vitro CBZ release from CMC-CBZ-NPs was evaluated using dialysis bag 
diffusion technique [136]. Dialysis bag with a molecular weight cut off of 350 
Da (Sigma-Aldrich Co.) were filled with 2 mL of CMC-CBZ-NPs suspension, 
and then placed into 150 mL PBS (pH 7.4). In vitro CBZ release was 
performed at 37°C with the rotation speed at 300rpm. Aliquots of 1 mL 
samples were collected at predetermined time points (0.25, 0.5, 1, 1.5, 2, 4, 6, 
8, 12 and 24 h), then added with the same volume of fresh release medium 
each time to maintain a constant volume. The samples were filtered with filter 
cartridge (PTFE 0.45µm) before assayed for CBZ by HPLC at 285 nm. 
3.3.4.4 Release mechanism studies
The release kinetics of CBZ from CMC-CBZ-NPs in PBS (pH7.4) was 
evaluated by the respective mathematical model such as the First model, 
Higuchi and Korsmeyer-Peppas Equation.  
3.3.5 In vivo experiment in animals
3.3.5.1 Chromatographic analysis method
Samples of CBZ in plasma and brain tissues were assayed using a modified 
method of HPLC after extraction. HPLC apparatus (Shimadzu LC-20AD, 
Japan) was equipped with C18 analytical column (4.6 × 150 mm, 3.5 μm) 
maintained at room temperature and a Shimadzu SPD- 20A-UV detector with 
wavelength set at 285 nm. The mobile phase consisted of methanol: water (6:4) 
was delivered at a flow rate of 0.4 mL/min. The injection volume was 50 µL.
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3.3.5.2 Preparation of stock solutions，standards and quality control samples
The stock solution of CBZ was prepared by dissolving 10mg of CBZ in 10mL 
acetonitrile and diluting with acetonitrile to produce a concentration of 
500µg/mL, and was stored at -4°C. Then 396μL pure plasma was spiked with 
4 μL of stock solution to make the stock solution in plasma. The stock solution 
of phenacetin (internal standard) was prepared by dissolving 20mg of 
phenacetin in 10mL acetonitrile to produce a concentration of 2mg/mL, and 
was stored at 4oC. The working solution for internal standard (200µg/mL) was 
prepared by diluting the stock solutions with acetonitrile. Quality control (QC) 
samples were prepared in the same way as the calibration standards with blank 
plasma or brain, and QC sample concentrations were 0.1, 0.5, 1 µg/mL. QC 
samples were stored at -20oC until analysis.
3.3.5.3 Drug administration in animals and sample collection
Thirty-six healthy male mice weighing 20~30g were randomly divided into 
two groups, eighteen mice each in the intranasal and the oral administration 
group. For intranasal administration, 25µL per nostril samples were 
administrated intranasally by inserting a polyethylene tube attached to a 
microsyringe approximately 0.7cm into two nostrils as described previously 
[137]. For oral administration, 0.5mL drug was administered by oral gavage. 
The drug solution concentration used for administration in the experiment was 
1 mg/mL. The oral dose was 20 mg/kg and the intranasal dose was 2 mg/kg. 
For all the test groups, blood samples of 0.3mL were withdrawn by cardiac 
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puncture at 0.5, 1, 2, 3, 4, 6 hours after administration [138]. Sample at one 
time point was collected from an individual mouse. Then plasma samples were 
stored at -20°C immediately after collection until analysis. Following the 
completion of blood collection, the skull of the mice was opened after 
separation of the head, and the whole brain was collected. The brain samples 
were rinsed with phosphate buffer and stored immediately at -80°C until 
analysis. In order to determine the concentration of CBZ in the brain, the 
whole brain was weighed and homogenized after mixing in 1:1 (w/v) ratio 
with distilled water.
As a control, eighteen healthy male mice weighing 20~30g were used to given 
drug solution dissolved in HP-β-CD water solution (2mg/kg) intranasally. The 
intranasal administration was given by inserting a polyethylene tube attached 
to a microsyringe approximately 0.7cm into two nostrils. At each time point, 
blood and brain samples were collected using the same method mentioned 
above. After analysis, the results obtained will be compared with the ones 
given by CMC-CBZ-NPs using intranasal administration.
3.3.5.4 Assay of CBZ in plasma and brain tissue samples
The extraction of CBZ from plasma and brain samples was conducted using 
the liquid–liquid extraction (LLE) method. Briefly, an exact 100 μL sample of 
plasma was mixed using vortex with 280 μL of acetonitrile and 20 μL of 
phenacetin working solution (200μg/mL in acetonitrile) as internal standard 
[137]. Then the mixture was centrifuged at 13000 rpm for 10 min. A total of 
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50 μL of the supernatant of the sample was injected into the HPLC. Similar to 
the preparation of plasma samples, for the preparation of brain samples, 100 
μL of the brain-distilled water homogenate was mixed using vortex with 280 
μL acetonitrile and 20 μL phenacetin working solution (200μg/mL in 
acetonitrile) as internal standard and then centrifuged at 13000 rpm for 10 min. 
Finally, 50 μL of the supernatant was injected into the HPLC for analysis. 
3.3.5.5 Method validation
3.3.5.5.1 Method selectivity
To ensure the developed assay was selective for CBZ, eight samples were 
tested as follows: blank plasma or brain tissues samples, blank plasma or brain 
tissues sample spiked with CBZ standard solution, blank plasma or brain 
tissues sample spiked with the internal standards, CBZ treated mice plasma, 
and brain tissues spiked with the internal standard only. All samples were 
subjected to the same extraction procedure for all the eight samples and the 
results were evaluated.
3.3.5.5.2 Calibration curves for plasma and brain tissues samples
Calibration curves were prepared by spiking different volumes of blank 
plasma or brain homogenate with different volumes of CBZ standard solutions 
in plasma to make a total of 100µl solution, to produce the matrix-matched 
calibration standards at concentration of 0.05, 0.1, 0.2, 0.5, 1.0, 5 µg/mL of 
CBZ. Each sample spiked with 20μL internal standards were extracted 
according to the method described above, the peak area ratios of CBZ to the 
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internal standard were plotted against the concentration to get the standard 
curve.
3.3.5.5.3 Method accuracy and precision
Blank plasma or brain homogenate was added to tubes and spiked with CBZ 
standard solution to give the control samples in five replicates containing the 
respective concentration of 0.1, 0.5, 1µg/mL of CBZ. Samples were extracted 
according to the extraction method above and analyzed to detect the 
concentration of CBZ by HPLC; the intra-day variation was recorded. Each 
concentration of the above sample was prepared daily and analyzed for 5 
consecutive days to calculate the inter-day precision.
3.3.5.5.4 Absolute and relative recovery
Absolute recovery: three different concentrations of CBZ in plasma or brain 
tissues were prepared using sample preparation method stated above. Another 
three different concentrations of samples were prepared using mobile phase 
instead of plasma or brain tissues using the same sample preparation method 
stated above. The recovery was tested by comparing the concentrations of 
drug in samples consisting the biological matrices against concentrations in 
samples consisting the mobile phase. 
Relative recovery: three different concentrations of CBZ in plasma or brain 
tissues were prepared using sample preparation method stated above. The 
recovery of the samples was tested by comparing the calculated concentration 
with the nominal drug concentration in the samples and the test was replicated 
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five times.  
3.3.5.5.5 Samples stability test
Short-term temperature stability: Spiked plasma or brain aliquots were first 
refrigerated and the frozen samples were then thawed and kept at room 
temperature for 6h. Post-preparative stability: The stability was conducted by 
re-analyzing extracted QC samples kept under the conditions (4oC) for 24h. 
Freeze-thaw stability: QC plasma or brain samples containing CBZ were 
tested after three freeze (-20oC), thaw (room temperature) cycles. The long-
term stability of CBZ in plasma or brain QC samples (stored in a -80 oC 
freezer) at three different levels was studied for a period of 10 days. These 
samples were then analyzed as described above. The stability of the working 
solutions of CBZ and the internal standard was evaluated by testing their 
potency over 6h at room temperature, the stability of working solutions was 
expressed in the same way as for percentage recovery. 
3.3.5.5.6 Limit of detection and quantitation
The limit of detection was defined as the amount that could be detected with a 
signal-to-noise ratio of 3:1 and the limit of quantitation was the lowest 
concentration that can be determined with acceptable precision signal-to-noise 
ratio of 10:1.
3.4 Results and discussion
3.4.1 Preformulation of CBZ
3.4.1.1 Linearity
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The linear regression analysis of CBZ was constructed by plotting the peak 
area (A) versus concentration (C). According to Table 3-2 and Figure 3-1, the 
standard curve of CBZ: A = 88067C – 30484 (r = 0.9995) was obtained, 
indicating good linear relationships between the peak areas and the 
concentrations in the range of 2.5 - 25 μg/mL.
Table 3-2 Standard curve of carbamazepine for formulation study
Concentration
(C, μg/mL) 2.5 5.0 10 15 20 25
peak area(A) 187929 386870 876699 1303269 1725623 2161885
Standard Curve A = 88067C – 30484（R =0.9995）
Standard Curve
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A
Figure 3-1 Standard curve of CBZ in the concentration range of 2.5 - 25 
μg/mL for formulation study
3.4.1.2 Precision and accuracy
Table 3-3 summarized the intra-day and inter-day precision and accuracy for 
CBZ from three concentrations, respectively. The intra-day and inter-day 
precisions (expressed as % of relative standard deviation, RSD %) were both 
less than 1%. The accuracy ranged from 98.40% to 103.30%. The results 
showed the developed method had good precision and accuracy.
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5 4.92±0.05 98.40 0.97 5.03±0.04 100.60 0.75
15 15.32±0.13 102.13 0.83 15.26±0.10 101.73 0.60
20 20.15±0.18 100.75 0.91 20.66±0.14 103.30 0.65
3.4.1.3 Recovery
The results of recovery were shown in Table 3-4. As shown in the table, all the 
recovery were around 100% (RSD below 1%), indicating the recovery 
fulfilled the requirement. 
Table 3-4 Recoveries of CBZ established by the HPLC method (n = 3)
Measured concentration（μg/mL）
Concentration





5 5.03 5.00 4.99 100.13±0.34 0.34
15 15.01 15.07 15.00 100.18±0.21 0.21
20 20.15 20.29 19.95 100.65±0.70 0.69
3.4.1.4 Solubility of CBZ in solutions of different pH 
CBZ belonged to class II of the biopharmaceutical classification system. 
Compounds in this category had high intestinal permeability and low water 
solubility. Solubility of CBZ in solutions of different pH showed in Table 3-5 
were in good agreement with those reported previously [139, 140]. The results 
indicated that CBZ reaches its highest solubility at pH 2.5 and the next highest 
concentration at pH 8.9, while the lowest concentration at pH 7.0. At other pH 
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values, solubility of samples was all slightly below 200µg/mL, indicating that 
at different pH values, there was no big difference in the solubility of CBZ. 
Table 3-5 Solubility of CBZ in different pH solutions (n=3)
Media pH 1.2 pH 2.5 pH 4.5 pH 6.2 pH 7.0 pH 8.9
C(µg/mL) 188.9 337.8 190.2 177.9 148.6 246.2
Stability of CBZ in different pH solutions was evaluated and finding was 
shown in Table 3-6. CBZ was found stable for 24 hours at room temperature 
in those media of different pH.
Table 3-6 Stability of CBZ in media of different pH
Concentration (µg/mL)
Media
0h 2h 4h 8h 12h 24h
Mean RSD (%)
pH 1.2 217.02 219.38 213.76 215.62 213.59 213.18 215.42 1.13
pH 2.5 349.54 354.37 356.83 348.36 348.05 350.02 351. 20 1.02
pH 4.5 194.73 194.12 203.44 196.19 205.40 193.03 197.82 2.65
pH 6.2 207.67 198.11 199.94 199.73 197.26 196.69 199. 90 2.01
pH 7.0 151.97 154.83 156.94 154.16 154.92 157.67 155.08 1.32
pH 8.9 240.39 250.83 246.54 237.82 251.49 241.99 244.84 2.31
3.4.1.5 Partition coefficient 
The partition coefficients of CBZ were shown in Table 3-7. As indicated in the 
table, all the logP values were around 2.1, which mean that the partition 
coefficient was not affected by different pH values. CBZ had good solubility 
in oil phase since the absolute logP value was over zero. These findings were 
in agreement with previous literature reports [140].
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Table 3-7 Partition coefficient of CBZ in different solvent against octanol 
Solvent P logP
0.1mol/L HCL 135.38 2.13
Water 128.15 2.11
Phosphate buffer (pH 7.4) 119.88 2.08
3.4.2 Preparation of CMC-CBZ-NPs
3.4.2.1 Influence of CBZ/CMC mass ratio
The effects of CBZ/CMC mass ratios on characteristics of the CMC-CBZ-NPs 
were shown in Table 3-8. According to the table, the particle sizes of the NPs 
decreased as the CBZ/CMC mass ratios increased. For zeta potential, it 
represented the stability of colloidal dispersions in the products. Higher zeta 
potential indicateed higher stability of the particles. All the products had an 
absolute value of zeta potential over 30, indicating that the particles were all 
very stable. As the amount of CMC increased, the drug loading increased from 
the CBZ/CMC ratio of 1:1 to 1:2 and decreased thereafter when the 
CBZ/CMC ratio became 1:3. The release profiles of CBZ from CMC-CBZ-
NPs were shown in Figure 3-2. The results showed that drug release increased 
with the increase in the proportion of the drug amount. The order of CBZ 
release rate was 1:1＞1:2＞1:3. 
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1:1 259.3 0.145 -31.2 28.34±0.17
1:2 228.8 0.264 -32.7 36.18±0.23
1:3 204.5 0.285 -34.1 25.79±0.92
















Figure 3-2 Drug release profiles at different CBZ/CMC mass ratios over 24 
hours at 37℃, 300rpm in water bath (n=3)( --■--CBZ/CMC1:1;--●--
CBZ/CMC 1:2;--▲--CBZ/CMC 1:3)
3.4.2.2 Influence of CMC concentration
The effects of CMC concentration on characteristics of the CMC-CBZ-NPs 
were shown in Table 3-9. According to the Table, the particle sizes and PDIs 
of the NPs increased with increase in concentration of CMC. When the 
concentration of CMC was too high, the produced NPs could aggregate, 
leading to an increase in particle sizes. However, the zeta potential was 
slightly decreased as the concentration of CMC increased. Despite this, all 
products still had an absolute value of zeta potential over 30, indicating that 
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the particles were all stable. But the drug loading was increased first and 
decreased as described in the previous section.
Table 3-9 Influence of CMC concentration on the particle characteristics
Concentration Particle size(nm) PDI Zeta potential(mV) DL (%)
0.1% 179.6 0.168 -34.9 25.78±0.16
0.2% 219.3 0.257 -33.5 35.86±0.32
0.3% 254.8 0.282 -33.2 30.45±0.19
0.5% 307.5 0.303 -32.7 23.72±0.28
The effects of different CMC concentration on the in vitro release profiles 
were shown in Figure 3-3. The results showed that drug release was decreased 
by the increase in CMC concentration. The order of CBZ release rate was 
0.1%＞0.2%＞0.3%＞0.5%.


















Figure 3-3 Drug release profiles at different concentration of CMC over 24 
hours at 37 ℃, 300rpm in water bath (n=3) (--■-- CMC0.1%;--●-- 
CMC0.2%;--▲-- CMC0.3%;--▼-- CMC0.5%)
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3.4.2.3 Influence of acetone volume
The effects of acetone volume on characteristics of the CMC-CBZ-NPs were 
shown in Table 3-10. According to the table, the particle size and PDI 
decreased when the acetone volume increased. The smallest value was reached 
when 5mL of acetone was used to dissolve the drug, demonstrating that the 
particle size was small and homogeneous in the solution. The zeta potential 
and the percentage of drug loading also increased with the acetone volume. 
The highest value was achieved when the volume of acetone was 5mL, 
demonstrating that more drugs were encapsulated in the particle and the 
particle was more stable than other particles formulated with 5 mL acetone.
Table 3-10 Influence of acetone volume on the properties of the NPs
Volume (mL) Particle size(nm) PDI Zeta potential(mV) DL (%)
0.5 399.0 0.752 -16.7 15.95±0.25
1 338.8 0.611 -20.6 19.87±0.31
2 257.7 0.473 -26.9 23.04±0.18
5 218.7 0.264 -33.2 33.52±0.16
3.4.2.4 Formulation optimization and verification 
The results of three factors and three levels orthogonal experiment design 
were shown in Table 3-11. K was the average of results in each level under 
each factor (e.g., the average of “1” under A in Table 3-11 to give K1, and 
average of “2” under A to give K2 etc.). R was the difference between the 
highest and lowest values of K in each factor. The importance of each factor 
was determined by the R value. The bigger of R value under the factor, the 
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more important would be this factor. Thus to the particle size, the importance 
of the factors was in the order of A＞B＞C. Since the smaller particle size was 
preferred, the best formulation was A3B2C3. To drug content, the importance 
of effect was C＞A＞B. Since the higher drug content was preferred, the best 
formulation was A2B2C3. After B2 and C3 had been confirmed to be the 
optimized factor, factor A was then scrutinized. For particle size, the 
difference between A2 and A3 (229.6 vs 218.5nm ) was only 5% while for 
drug loading the difference was about 15% (34.85% vs 29.35%). As a result, 
considering the higher drug loading in A2, the optimum formulation should be 
A2B2C3.
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1 1 1 1 239.7 20.84
2 1 2 2 217.9 37.35
3 1 3 3 253.3 26.71
4 2 1 2 238.6 35.69
5 2 2 1 231.7 30.34
6 2 3 3 218.4 38.53
7 3 1 3 195.2 33.92
8 3 2 1 223.5 28.37
9 3 3 2 236.8 25.77
K1 240.0 224.5 231.6
K2 229.6 224.4 231.1
K3 218.5 236.2 222.3
R 21.5 11.8 9.3
Size
K1 28.30 30.15 26.52
K2 34.85 32.02 22.94
K3 29.35 30.34 33.05
R 6.55 1.87 10.11
Drug content
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3.4.3 Characterization of CMC-CBZ-NPs
3.4.3.1 Physical properties of CMC-CBZ-NPs
The CMC-CBZ-NPs suspension was semi-transparent solution with particle 
diameter around 220nm. The product after freeze drying appeared to be white 
powder. Figure 3-4 showed the transmission electron microscopic (TEM) 
photomicrograph. It was evident that the sphere-like particles were of uniform 
size.
Figure 3-4 TEM photomicrographs of CMC-CBZ-NPs
3.4.3.2 CMC-CBZ-NPs size and drug loading of the optimum formulation
According to the results stated above, an optimized formulation determined 
from the orthogonal design experiments was prepared as follows: CBZ (10mg) 
was dissolved in 5mL of acetone, CMC (20mg) was dissolved in 10mL of 
water. The CBZ solution was dropped into CMC solution with magnetic stirrer. 
After forming a complete particles dispersion system, the dispersion was 
sonicated using a sonicate probe for about 30min. Then the mixture was 
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stirred with magnetic stirrer for about 4h to evaporate the organic solvent. The 
obtained nanoparticle suspension was filtrated through 0.45 µm filter 
membrane to remove the unincorporated CBZ aggregates, and the drug-loaded 
nanoparticle suspension was then obtained. The results of three batches CMC-
CBZ-NPs prepared using the optimized formulation were showed in Table 3-
12. The results indicated that the absolute zeta potential values of the CMC-
CBZ-NPs were all over -30mV, suggesting these nanoparticles to have good 
physical stability (i.e., phase separation) in the solution [141, 142].
Table 3-12 Results of optimal experimental condition for preparation of CMC-
CBZ-NPs
No Particle size (nm) PDI Zeta potential(mV) Drug content (%)
1 216.5 0.189 -34.9 33.72±0.33
2 221.3 0.232 -32.1 36.45±0.21
3 218.5 0.276 -33.3 34.96±0.18
3.4.4 In vitro release studies
3.4.4.1 Calibration curve
According to Table 3-13 and Figure 3-3, the standard curve of CBZ: A = 
25430C + 245.09 (r=0.9999) was obtained which indicated good linear 
relationships between the peaks and the concentrations in the range of 0.5 - 10 
μg/mL.
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Table 3-13 Standard calibration curve of CBZ employed for in vitro release 
studies
Concentration
(C, μg/mL) 0.5 0.75 1.0 2.0 5.0 10.0
peak area(A) 12565 19247 25471 52342 126664 254708
Standard Curve A = 25430C + 245.09  (r = 0.9999)
Standard curve













Figure 3-5 Standard calibration curve of CBZ employed for in vitro release 
studies in a concentration range of 0.5-10.0 μg/mL
3.4.4.2 Stability
The drug concentrations in 24 hours were exhibited in Table 3-14. The RSD 
values at three concentrations were all around 1.0% which illustrated that the 
drug was stable for at least 24 hours when the temperature was 37℃.
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0 0.489 1.978 10.176
1 0.506 1.967 10.211
2 0.498 1.976 10.215
4 0.524 1.964 10.213
6 0.502 2.014 10.061
8 0.506 2.002 10.3
12 0.529 1.980 10.266
24 0.518 1.998 10.019
Mean±SD 0.509±0.014 1.985±0.018 10.183±0.096
RSD (%) 2.67 0. 90 0.95
3.4.4.3 In vitro release profile of CBZ from the CMC-CBZ-NPs
The drug release from three batches of CMC-CBZ-NPs prepared using the 
optimized formulation for verification were showed in Figure 3-6. The results 
showed that the in vitro release of CBZ exhibited a biphasic release. The drug 
release rate was faster in the first 4h and reached a plateau at 12h. The initial 
slight burst release could be attributed to CBZ molecules located at or near to 
the surface of CMC-CBZ-NPs.
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Figure 3-6 Release profiles of CBZ from the 3 batches of CMC-CBZ-NPs 
prepared under the optimal experimental condition over 24 hours at 37℃, 
300rpm in water bath (n=3) (--●--batch 1，--▲-- batch 2，--■-- batch 3)
The results of the in vitro drug release experiment were shown in Table 3-15. 
It was found that the release of CBZ from CMC-CBZ-NPs was in accordance 
with the Korsmeyer-peppas model. The release mechanism was evaluated by 
applying the so-called power law with the Korsmeyer-Peppas Equation: 
Q=Ktn, where Q was the cumulative released drug at time t, k was the kinetic 
constant, while n was the diffusion exponent that characterized the drug 
release mechanism. The value of n<0.45 indicated Fickian diffusion, and 0.45 
< n < 0.89 showed non-Fickian diffusion, whereas values of n = 1.0 indicated 
Case II transport kinetics. The result showed that n = 0.3113, indicating CBZ 
release from CMC-CBZ-NPs was Fickian diffusion that was controlled by 
concentration gradient, diffusion distance and degree of swelling of the matrix 
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[143].
Table 3-15 In vitro release kinetics equation fitting results of CMC-CBZ-NPs
Model Equation R2
First order ln(1-Q) = -0.0642 t + 4.0394 0.8769
Higuchi Q = 14.4727 t1/2 + 26.4327 0.9166
Korsmeyer-Peppas ln Q = 0.3113ln t + 3.6316 0.9729
3.4.5 In vivo pharmacokinetic study of the formulated CMC-CBZ-NPs in mice
3.4.5.1 Calibration curve of plasma samples
The results of calibration curve of plasma samples were shown in Table 3-16 
and figure 3-7.Calibration curve were constructed by plotting the peak area 
ratio (R) of CBZ to the internal standard against the concentration (C) of CBZ. 
The calibration curve for CBZ was linear over the range 0.05 - 5μg/mL. The 
regression equation was R =0.0712C – 0.0032, r=0.9995.
Table 3-16 Standard curve of CBZ in plasma (n=5)
Concentration 
(C, μg/mL)
0.05 0.1 0.2 0.5 1 5
Peak area 
ratio (R)
0.002392 0.006124 0.012453 0.0286108 0.068022 0.353176
Standard Curve R = 0.0712C – 0.0032, r = 0.9995
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Figure 3-7 Calibration curve of CBZ in plasma in a concentration range of 
0.05-5μg/mL
3.4.5.2 Calibration curve of CBZ in brain tissues
The results of calibration curve of brain samples were shown in Table 3-17 
and figure 3-8. Calibration curve were constructed by plotting the peak area 
ratio of CBZ to the internal standard against the concentration of CBZ. The 
calibration curve for CBZ was linear over the range 0.05 – 2μg/g. The 
regression equation was R=0.0702C+0.0005, r = 0.9993.
Table 3-17 Standard curve of CBZ in brain tissue (n = 5)
Concentratio
n (C, μg/g)
0.05 0.1 0.2 0.5 1 2
Peak area 
ratio (R)
0.003473 0.007368 0.014349 0.036712 0.072848 0.141233
Standard 
Curve
R = 0.0702C+0.0005, r = 0.9993
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Figure 3-8 Calibration curve for CBZ in brain tissues in a concentration range 
of 0.05-2 μg/g
3.4.5.3 Method selectivity
The method was shown to be selective for the detection of CBZ. The HPLC 
assay was used to screen blank plasma, blank plasma spiked with CBZ, blank 
plasma spiked with internal standard and plasma of mice treated with CMC-
CBZ-NPs. The findings were shown in Figure 3-9. Same experiments were 
carried out for brain tissues. Results were shown in Figure 3-10. The Figures 
showed that the retention times of the internal standard (phenacetin) and CBZ 
were about 7.5min and 11.0 min, and the other plasma or brain endogenous 
components did not interfere with the detection of CBZ and internal standard. 
The methods were shown high selectivity for separation of CBZ and internal 
standard in both matrices.
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               A                                    B
C                                    D                                                                     
Figure 3-9 Typical HPLC chromatogram of blank plasma (A), blank plasma 
spiked with internal standard (B), blank plasma spiked with CBZ (C), and 
plasma sample obtained from a mice that was administrated with CMC-CBZ-
NPs (D).
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              A                                    B
           C                                     D
Figure 3-10 Typical HPLC chromatogram of blank brain tissue (A), brain 
tissue spiked with the internal standard (B), brain tissue spiked with CBZ (C), 
and brain tissue obtained from a mice that was administrated with CMC-CBZ-
NPs (D).
3.4.5.4 Method precision
Table 3-18 showed the results of intra-day and inter-day variation, all the 
variations met the requirement and showed good precision and accuracy of the 
method which was consistent with the biological sample analysis requirement.
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106.67 6.36 0.09±0.006 96.67 6.67
0.5 0.49±0.03 98.67 6.12 0.49±0.02 98.00 4.08
Plasma
(μg/mL)




110.00 3.63 0.10±0.003 100.00 3.10
0.5 0.49±0.03 99.33 4.19 0.49±0.04 97.33 4.28
Brain
(μg/g)
2.0 1.98±0.03 99.00 1.34 1.95±0.08 97.67 4.11
3.4.5.5 Absolute and relative recovery of CBZ from the plasma and brain 
matrices
The absolute recoveries of CBZ from plasma and brain tissues were above 80% 
(Table 3-19). The data proved the suitability of the extraction method for use 
with plasma and brain tissue samples. The relative recovery of CBZ from 
plasma and brain tissue ranged from 96.6% to 99.2%, all the RSD% were 
below 7%, indicating that the recovery fulfilled the requirement.
81
Table 3-19 Recoveries of CBZ from mice plasma and brain tissue (n=5)
Absolute recovery (%) Relative recovery (%)
Concentration
Mean±SD RSD Mean±SD RSD
0.1 84.2±5.5 6.94 99.2±0.4 0.40
0.5 82.4±4.1 4.98 98.4±1.3 1.32
Plasma
(μg/mL)
1.0 80.9±5.3 6.63 99.1±1.1 1.14
0.1 92.2±2.4 2.60 97.2±0.5 0.51
0.5 93.3±1.8 1.93 98.7±1.7 1.75
Brain
(μg/g)
2.0 98.1±1.0 1.02 96.6±1.0 1.06
3.4.5.6 Stability of CBZ in the samples 
Table 3-20 summarized the data from the short-term, freeze-thaw and long-
term stability tests of CBZ in samples，as well as the stability of CBZ post-
sample preparation. The short-term test indicated reliable stability behavior 
under the experimental conditions of the analytical runs. The results of the 
freeze-thaw stability test indicated that the analyte was stable in mouse plasma 
or brain tissue after three cycles of storing at -20℃ and thawing to room 
temperature. The post-sample preparation stability of the QC samples showed 
that CBZ was stable in the sample extract when kept at 4℃ for 24h. The 
findings from the long-term test indicated that storage of the plasma or brain 
tissue containing CBZ at -20℃ was adequate when the samples were kept for 
10 days. Thus, no stability-related problems were anticipated during the 
routine analyses of the samples for the bioavailability study.
82















Short-term 98.73 4.80 96.43 0.83 97.36 3.95
Freeze-thaw 95.48 5.61 98.62 2.47 94.58 5.32
Long-term 94.82 2.64 93.58 4.75 93.75 3.28
Plasma
Post-sample 
preparation 97.69 5.91 95.96 3.69 98.41 4.33
Short-term 95.32 6.53 97.47 1.39 95.37 1.04
Freeze-thaw 99.27 4.77 96.35 2.66 96.84 3.84
Long-term 96.18 2.85 92.41 1.95 98.45 2.19
Brain
Post-sample 
preparation 94.75 3.16 95.88 4.38 93.26 5.22
3.4.5.7 Limit of detection and quantitation
The lowest detectable concentration (LOD) was 15ng/mL with S/N ratio of 
3:1, while the limit of quantification (LOQ) was 50ng/mL with S/N ratio of 
10:1.
3.4.5.8 Pharmacokinetics studies
3.4.5.8.1 The drug concentrations in plasma and brain tissues after oral 
(20mg/kg) and intranasal administration (2mg/kg)
The drug concentrations in plasma after oral and intranasal administration 
were shown in Table 3-21. As indicated, after oral administration, the drug 
concentration reached its peak (4.286μg/mL) at 1 hour after administration. 
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This result illustrated that the drug could be absorbed rapidly and the 
concentration of plasma reached its highest concentration in the first hour after 
oral administration. At 6 hours after administration, the plasma drug 
concentration dropped back to 0μg/mL. In comparison, the highest 
concentration of plasma was achieved later at 2 hours after nasal 
administration. Concentrations at different time points are all around 0.2 
μg/mL. When compared to the concentration of plasma after oral 
administration in Figure 3-11, the concentration of drug in plasma after 
intranasal administration was much lower, less than one-tenth though 
remained steady till 3 hours. At 4 hours, the plasma drug concentration 
dropped back to 0μg/mL. This phenomenon might be due to the much smaller 
nasal dose (2 mg/kg) versus the oral dose (20 mg/kg) administered to the mice. 
This was caused by the practical issue that a much smaller volume (50µL) of 
drug could only be administrated by intranasal administration when compared 
to oral administration (0.5mL). Secondly, that could also be caused by 
different distribution pattern after the respective oral and nasal administration 
of the carboxymethyl chitosan nanoparticles of CBZ.
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Table 3-21 Plasma CBZ concentrations in mice after oral (18 mice) and 
intranasal (18 mice) administration
Intranasal administration (μg/mL) Oral administration (μg/mL)
Time
(h)
mean SD mean SD
0.5 0.151 0.042 3.626 1.111
1 0.130 0.016 4.286 0.445
2 0.315 0.033 3.359 1.355
3 0.262 0.046 2.996 0.859
4 0 0 0.755 0.143
6 0 0 0 0

















Figure 3-11 Mean concentration of plasma-time curve of CBZ in mice after 
oral (20 mg/kg) (18 mice) and intranasal (2 mg/kg) (18 mice) administration 
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of CMC-CBZ-NPs (---△--- oral administration，---○--- intranasal 
administration，---■--- dose normalization of the concentration after oral 
administration)
Table 3-22 and Figure 3-12 showed the drug concentration in brain tissues 
after oral and intranasal administration. After oral administration, the drug 
concentrations in brain were almost 2 times lower than that in plasma. In 
contrast, after nasal administration, the drug concentrations in brain tissues 
were higher (about 50%) than the concentrations in plasma. Nevertheless, the 
concentrations of brain of CBZ were still much higher after oral 
administration than after nasal administration. The difference was obviously 
due to the 10 times difference in the oral (20 mg/kg) and nasal doses (2 
mg/kg).
Table 3-22 Brain tissues CBZ concentrations in mice after oral (18 mice) and 
intranasal (18 mice) administration
Intranasal administration (μg/mL) Oral administration (μg/mL)Time
(h) mean SD mean SD
0.5 0.234 0.005 1.199 0.138
1 0.428 0.077 1.652 0.250
2 0.336 0.062 1.525 0.333
3 0.304 0.014 1.203 0.548
4 0 0 0.959 0.204
6 0 0 0 0
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Figure 3-12 Mean concentration of brain-time curve of CBZ in mice after oral 
(20 mg/kg) (18 mice) and intranasal (2 mg/kg) (18 mice) administration of 
CMC-CBZ-NPs (---△--- oral administration，---○--- intranasal 
administration，---■--- dose normalization of the concentration after oral 
administration)
Since the doses of oral and intranasal administration were different, to have a 
better comparison of these two administration routes, the concentrations were 
normalized to dose over the time. Results were shown in Figure 3-11 and 3-12. 
According to Figure 3-11, although in the first two hours, the normalized drug 
concentration after oral administration was much higher than that after the 
intranasal administration, thereafter, the drug concentrations in both routes 
became similar. It would be interesting to evaluate the drug levels if using 
higher drug concentrations for intranasal dose in further studies. Figure 3-12 
showed the normalized CBZ concentrations in brain after oral and intranasal 
administration of CMC-CBZ-NPs to mice. After intranasal administration, the 
brain CBZ concentration was much higher at almost all time-points than that 
after oral administration. These findings were in accordance with the results 
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from former researchers that following intranasal administration, drug would 
preferentially be delivered into brain by bypassing the BBB through the 
unique connection between the nose and the CNS [141, 142] which indicated 
that more drugs could reach the brain by intranasal administration when given 
the same dose.
3.4.5.8.2 The drug concentration in plasma and brain after intranasal 
administration (2 mg/kg) using CMC-CBZ-NPs and CBZ-solution
The drug concentrations in plasma and brain samples after intranasal 
administration using CBZ-solution were shown in Table 3-23. Mean plasma 
and concentration of brain-time curve in mice after intranasal administration 
(2 mg/kg) of CMC-CBZ-NPs and CBZ-solution were shown in Figure 3-13. 
For both formulations, the drug concentration in the brain reached its peak at 
0.5 hours after drug administration while for plasma it took 1 hour, suggesting 
that the drug could be absorbed rapidly in the brain when given intranasal 
administration. At 3 hours after administration, both the plasma and brain drug 
concentrations using CBZ-solution was undetectable. In comparison, drug 
concentrations in plasma and brain could last for 4 hours using CMC-CBZ-
NPs which illustrated that using CMC-CBZ-NPs as a formulation to deliver 
drugs could reach the brain in a shorter time and could last longer in the brain. 
At each time point, the concentration of brain using CMC-CBZ-NPs were 
higher than ones using CBZ-solution while for concentration of plasma, 
although at the first 1 hour, the concentrations were similar in both 
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formulations, however, after that, the concentrations in the plasma using 
CMC-CBZ-NPs were much higher than ones using CBZ-solution. This 
indicated that more drugs could reach the brain in a shorter time and last 
longer in the brain by intranasal administration using CMC-CBZ-NPs.
Table 3-23 Concentrations of plasma and brain in eighteen mice after 
intranasal administration using CBZ-solution (2 mg/kg)
Plasma (µg/mL) Brain (µg/mL)Time
(h) mean SD mean SD
0.5 0.116 0.070 0.030 0.024
1 0.144 0.129 0.026 0.034
2 0.033 0.058 0.003 0.005
3 0 0 0 0
4 0 0 0 0
6 0 0 0 0

















Figure 3-13 Mean plasma and concentration of brain-time curve of CBZ in 
mice after intranasal administration (2 mg/kg) of CMC-CBZ-NPs (18 mice) 
and CBZ solution (18 mice) (---■--- plasma of CMC-CBZ-NPs, ---○---brain of 
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CMC-CBZ-NPs, ---▲---Plasma of CBZ-solution, ---▽---Brain of CBZ-
solution)
3.4.5.8.3 The pharmacokinetic parameters and brain targeting 
The pharmacokinetic parameters of CBZ after oral and intranasal 
administration of CMC-CBZ-NPs were shown in Table 3-24. It was found that 
despite the 10 times dose difference, the plasma AUC after oral administration 
was 18 times higher than that after intranasal administration (705.62 versus 
37.15min*μg/mL); but the brain AUC after oral administration was only 5 
times higher than that after intranasal administration (302.80 versus 
55.55min*μg/mL). This meant that the drug was preferentially distributed to 
the brain after intranasal administration of the CMC-CBZ-NPs. As mentioned 
earlier on the CBZ concentration, the brain CBZ AUC was found even higher 
than plasma AUC after intranasal administration of the CMC-CBZ-NPs (55.55 
versus 37.15 min*μg/mL). These findings were in good agreement with those 
reported previously [141, 142].
To evaluate the brain targeting characteristics of CMC-CBZ-NPs after oral 
and intranasal administration, the targeting efficiency (Te =AUCbrain/AUCplasma) 
was investigated in this study. If the value of Te was greater than one, it meant 
that this formulation could be delivered into brain more efficiently. The higher 
the Te value, the better the drug could be targeted into the brain. In our study, 
the value of Te for oral administration was 0.43 while for intranasal 
administration it was 1.50, indicating that compared with oral administration, 
intranasal delivery could deliver more drugs into brain and had brain targeting 
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characteristics. Therefore, it could be concluded that intranasal administration 
were more specific in delivering CBZ to the brain as compared to oral 
administration.
Table 3-24 Pharmacokinetic parameters for CMC-CBZ-NPs
Oral Intranasal
Parameters
Plasma Brain Plasma Brain
Tmax(min) 80±34.64 100±69.28 140±34.64 80±34.64
Cmax(µg/mL) 4.33±0.52 1.72±0.20 0.32±0.02 0.46±0.04
AUC(min*µg/mL) 705.62±188.57 302.80±9.48 37.15±1.67 55.55±0.65
MRT(min) 108.54±2.52 120.12±10.50 112.25±1.58 97.63±4.42
Te 0.43 1.50
The pharmacokinetic parameters of CBZ after intranasal administration of 
CMC-CBZ-NPs and CBZ-solution were shown in Table 3-25. The plasma 
AUC after intranasal administration using CMC-CBZ-NPs was about 5 times 
higher than that using CBZ-solution (37.15 versus 8.17 min*μg/mL); and the 
brain AUC after intranasal administration using CMC-CBZ-NPs was more 
than 27 times higher than that using CBZ-solution (55.55 versus 2.04 
min*μg/mL). This meant that the drug was preferentially distributed to the 
brain after intranasal administration using the formulation of CMC-CBZ-NPs. 
For Te value, the value of Te for using CBZ-solution was only 0.25 while for 
CMC-CBZ-NPs it was 1.50, indicating that compared with CBZ-solution, 
using CMC-CBZ-NPs could deliver more drugs into brain and had brain 
targeting characteristics. In conclusion, these results demonstrated that by 
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using the mucoadhesive material in the formulation, the contact time of the 
formulation in the nasal mucosa was increased which result in a better brain 
targeting characteristic. Significantly higher AUC (55.55 ± 0.65) and Cmax 
(0.46 ± 0.04) in brain samples for CMC-CBZ-NPs compared to CBZ- solution 
were attributed to the addition of CMC in the formulation [144].




Plasma Brain Plasma Brain
Tmax(min) 140±34.64 80±34.64 50±17.32 40±17.32
Cmax(µg/mL) 0.32±0.02 0.46±0.04 0.16±0.10 0.04±0.03
AUC(min*µg/mL) 37.15±1.67 55.55±0.65 8.17±5.57 2.04±2.35
MRT(min) 112.25±1.58 97.63±4.42 47.44±18.07 34.65±39.61
Te 1.50 0.25
3.5 Conclusion
Epilepsy was one of the most common chronic neurological disorders, 
affecting about 50 million people all over the world [145]. Despite the 
introduction of newer antiepileptic drugs (AED) and the use of AEDs 
combination therapy, 30% of epileptic patients experienced refractory epilepsy 
[146, 147]. The exact percentages of refractory epileptic patients depended on 
the definition of drug resistant epilepsy (DRE) being adopted [148].  
Studies showed that blood-brain barrier dysfunction might contribute to drug 
resistance in epilepsy [149]. Some transporters including P-glycoprotein (P-gp) 
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might prevent AEDs from entering the brain [149, 150]. As such, our study 
aimed to increase the drug concentration in the brain by using the 
nanoparticles and intranasal administration to enhance the treatment efficacy 
of AEDs.
In this study, a carboxymethyl chitosan nanoparticle of CBZ(CMC-CBZ-NPs) 
was developed and the formulation was administered intranasally with the 
objective to enhance its delivery to the brain. The results indicated that when 
CMC-CBZ-NPs were administered orally, the CBZ brain to plasma exposure 
in AUC was 43%. The value was lower than the reported value of 100% (1:1 
brain to concentration of plasma ratio) in humans [151] and 75% in mice [152]. 
On the other hand, when the CMC-CBZ-NPs were administered intranasally, 
the CBZ brain to plasma exposure in AUC was 150%. This showed that CBZ 
was preferentially delivered to the brain when the CMC-CBZ-NPs were 
administered intranasally. The result was promising, though the delivery of 
CBZ through the intranasal route was limited by the volume/amount of drug 
being administered. However, this limitation could be overcome by increasing 
the drug concentration for intranasal administration or by nasal inhalation. 
In summary, this chapter highlighted the enhancement of the treatment 
efficacy of AEDs by using nanoparticles and intranasal delivery. As in the 
current market, the products of AEDs were administered either orally or 
intravenous injection. Compared with the conventional oral and intravenous 
drug formulations, intranasal drug formulation could provide more direct 
93
delivery of anti-epileptic drugs to the brain, leading to higher treatment 
efficacy. However, intranasal administration was not without limitations. The 
major one was the limited amount of drug that could be administered. Such 
limitation could be overcome by developing more concentrated suspension of 
nanoparticles or by administering larger volume in the form of nebulized fume. 
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Chapter 4 Impact of HP-β-CD on the Delivery of CBZ-loaded CMC-NPs 
into Brain Following Intranasal Administration
4.1 Introduction
In the last decade, the use of the nasal cavity as a route for drug delivery had 
been an area of great interest to the pharmaceutical industry. Advantages of 
intranasal administration include a large surface area for drug absorption, 
rapid achievement of drug levels at targeted site and avoidance of first-pass 
metabolism [153]. However, nasal mucociliary clearance, poor water 
solubility of drug and lack of diffusion towards the brain are some of the most 
important limitations for nasal drug delivery. Finding ways to get therapeutic 
drugs to the brain effectively, safely, and conveniently is becoming more 
important than ever [154]. Various nanoparticle delivery systems have been 
designed for brain targeting, including liposomes, nanoparticles (NPs), and 
polymeric micelles [155]. In our previous work, CBZ-loaded CMC-NPs were 
prepared and tested in vivo using intranasal administration. The findings of our 
former study demonstrated that intranasal delivery could be a promising new 
brain targeting delivery system via the olfactory mucosa for the treatment of 
epilepsy. 
Cyclodextrins (CD) are cyclic oligosaccharides meaning that they are 
composed of sugar molecules which bound together to form a ring. However, 
the natural CDs have limited aqueous solubility, which can be problematic 
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with respect to developing therapeutically relevant drug formulations. 
Chemically modified CD derivatives have been developed to have improved 
aqueous solubility. HP-β-CD (2-hydroxypropyl-β-CD), a hydrophilic 
cyclodextrin derivative is the cheapest, most used and had been extensively 
studied in pharmaceutical research [156]. Compared with β-CD, HP-β-CD has 
better water solubility, could improve bioavailability and stability for certain 
drugs [157] (Figure 4-1).
 
         A                                  B                                                                            
Figure 4-1 Structure of HP- β-CD (A) and CMC (B)
Based on former researchers [68-70], HP- β-CD was assumed to be a 
permeation enhancer to deliver drugs into brain because it could cross the 
blood–brain barrier (BBB). Indeed, CD were widely used to increase the 
delivery or bioavailability of drugs in oral, ocular [158], dermal [159], and 
most importantly in nasal field [160]. Ye et al prepared a β-CD based nano-
drug delivery system and tested it on mice. Results showed that this nano-drug 
delivery system was a potential brain-targeting drug carrier for the treatment 
of neurological diseases [161]. Nonaka et al. compared the drug 
concentrations in plasma, spleen and brain regions after the respective 
intravenous and intranasal injections and demonstrated that compared with 
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intravenous administration, intranasal administration provided about a 40 to 
100 fold improvement in brain targeting versus peripheral tissues. Moreover, 
the author also concluded that targeting of various brain regions might be 
manipulated by the use of various CD [162]. All the findings mentioned above 
testify that by using CD and intranasal delivery, drug permeability into brain 
could be increased.
According to the advantages of both HP-β-CD and CMC, incorporating HP-β-
CD into CMC-NPs might lead to a carrier that possessed the cumulative 
effects of inclusion, size specificity and transport properties of HP-β-CD and 
mucoadhesive properties of CMC. In this chapter, a novel CBZ-loaded CMC-
NPs modified by HP-β-CD as brain targeting delivery system following 
intranasal administration would be prepared with the aim of improving the 
solubility, drug loading and enhancing the brain uptake of the drug.
4.2 Materials
4.2.1 Chemical and reagents
Carbamazepine (CBZ) USP-grade was purchased from Sigma–Aldrich; 
Carboxymethyl chitosan (CMC) was synthesized in the lab；HP-β-CD was 
purchased from Wacker Chemical corp.; Phosphate buffer (pH7.4) was 
purchased from Vivantis Technologies Sdn Bhd (USA). HPLC grade methyl 
alcohol and acetonitrile were purchased from Merck Chemicals Co., All other 
chemical solvents and reagents used were of analytical grade.
4.2.2 Animals
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Adult male C57BL mice aged between 6 and 7 weeks and weighing 20～30 g 
were supplied by local certified animal facility (Comparative Medicine, Center 
for Life Science, National University of Singapore). Mice were housed under 
controlled environment with free access to tap water and standard rodent diet. 
All the experiments involving animals and their care were approved by the 
Institutional Animal Care and Use Committee (IACUC), National University 
of Singapore with the protocol number of R13-4467(A2)14.
4.3 Methods
4.3.1 Preparation of HP-β-CD modified CMC-CBZ-NPs (CD/CMC-CBZ-NPs)
The CD/CMC-CBZ-NPs were prepared using the same preparation method in 
the last chapter. The only difference was that HP-β-CD was added during the 
preparation. Firstly, certain amount of HP-β-CD and CMC (20mg) were 
dissolved together in the distilled water (10mL). Then CBZ was separately 
dissolved in one part of acetone (5mL). The CBZ solution was dropped into 
the polymer solution with magnetic stirrer. After forming completely 
dispersed particles, the dispersions were sonicated using a sonic dismembrator 
(Fisher Scientific Co., Model 500) for about 30min. The mixture was then 
stirred for about 4h to evaporate the organic solvent [163]. A solution with a 
drug concentration of 1mg/mL was obtained as the final product. The dried 
products was obtained after freeze-drying and kept under vacuum for 48 h.
4.3.2 Formulation optimization of CD/CMC-CBZ-NPs
4.3.2.1 Influence of the preparation method
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4.3.2.1.1 External addition of HP-β-CD
Briefly, CBZ (50mg) was dissolved in one part of acetone (5mL); and CMC 
(20mg) was separately dissolved in one part of distilled water (10mL). The 
CBZ solution was dropped into the polymer solution with magnetic stirrer. 
After forming completely dispersed particles, the dispersions were sonicated 
using a sonic dismembrator (Fisher Scientific Co., Model 500) for about 
30min. The mixture was then stirred with magnetic stirrer for about 4h to 
evaporate the organic solvent. Then a specific amount of HP-β-CD indicated 
later in the chapter was added in the mixture. A solution with a drug 
concentration of 1mg/mL was obtained as the final product.
4.3.2.1.2 Internal addition of HP-β-CD
The products were prepared by dissolving certain amount of HP-β-CD and 
CMC (20mg) together in the distilled water (10mL). Then CBZ (50mg) was 
separately dissolved in one part of acetone (5mL). The CBZ solution was 
dropped into the polymer solution with magnetic stirrer. After forming 
completely dispersed particles, the dispersions were sonicated using a sonic 
dismembrator (Fisher Scientific Co., Model 500) for about 30min. The 
mixture was then stirred for about 4h to evaporate the organic solvent. A 
solution with a drug concentration of 1mg/mL was obtained as the final 
product.
4.3.2.2 Influence of the amount of HP-β-CD
To determine the influence of the amount of HP-β-CD on the characteristics of 
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CD/CMC-CBZ-NPs, other conditions were kept as the same. The different 
amounts of HP-β-CD (0.01, 0.02, 0.05g) were used to prepare the CD/CMC-
CBZ-NPs using both internal addition and external addition. Products of 
different formulations would be tested for its particle size, PDI, zeta potential 
and drug loading. 
4.3.2.3 Influence of the rotation speed
To study the influence of the rotation speed, other conditions were kept as the 
same. The amount of HP-β-CD added was kept at 0.02g. Three different 
rotation speeds (200, 400, 800 rpm) were used to prepare the CD/CMC-CBZ-
NPs. Products of different formulations would be tested for its particle size, 
PDI, zeta potential and drug loading. 
4.3.2.4 Influence of the amount of CBZ
To study the influence of the amount of CBZ, other conditions were kept as 
the same. The different amount of CBZ (30, 60，80, 100 mg) was used for the 
stirring. Products of different formulations would be tested for its particle size, 
PDI, zeta potential and drug loading. 
4.3.3 Characterization of CBZ-NPs
4.3.3.1 Size and zeta Potential analysis 
Photon correlation spectroscopy (Zetasizer 3000; Malvern Instruments, 
Malvern UK) was used to measure the size and zeta potential of the colloidal 
systems of all drug-loaded nanoparticles [164]. Before the analysis, all 
samples were diluted with appropriate distilled water for measurements. Z-
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average particle size, polydispersity index (PDI), and zeta potential were all 
measured in triplicate at room temperature. 
4.3.3.2 Drug loading studies
The dried samples (5mg) were transferred to a 25 mL volumetric flask. A total 
volume of 10 mL of methanol was added and the dispersion obtained was 
sonicated for 15min to dissolve CBZ. Samples were withdrawn from the 
undiluted solution using a syringe, then filtered (PTFE 0.45µm) before 
detection [165]. The concentration of CBZ in methanol was determined by the 
HPLC. The drug loading (DL %) can be calculated by
DL%= Amount of drugs in NPs/ Total amount of NPs×100%
Contents of CBZ in the NPs were determined by high performance liquid 
chromatography (HPLC). The HPLC system was consisted of a pump (Model 
LC-20A, Shimadzu, Japan), a reversed-phase C18 column (150×4.5 
mm，3µm) maintained at room temperature, a variable wavelength UV 
detector (Model SPD-20A, Shimadzu, Japan) with wavelength set at 285 nm. 
The mobile phase was composed of 70% methanol and 30% water (v/v) and 
was delivered at a flow rate of 0.4 mL/min. The injection volume was 10µL 
by an autosampler. With the chromatographic conditions, the retention time of 
the analyte was 6.5 min. Quantification of the compounds was carried out by 
measuring the peak areas and comparing to that of the standard samples 
chromatographed under the same condition.
4.3.4 In vitro release study
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In vitro CBZ release from the NPs was evaluated using dialysis bag diffusion 
technique [166]. Briefly, dialysis bag with a molecular weight cut off 350 Da 
(Sigma) were filled with 2mL of CD/CMC-CBZ-NPs, and then placed into 
150mL PBS (pH 7.4). The CBZ release was performed at 37°C with the 
rotation speed at 300rpm. 1mL sample was collected at the determined time 
points (0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 hours), then a same volume of 
fresh release medium was added every time to maintain a constant dialyzing 
solvent volume. The samples were filtered with 0.45um filter before being 
assayed using HPLC. The release kinetics was described via mathematical 
models such as Korsmeyer-Peppas models using regression analysis [167].
4.3.5 Pharmacokinetics study
Fifty-four healthy male mice weighing 20~30g were randomly divided into 
three groups, eighteen mice in each group, the CD/CMC-CBZ-NPs (2mg/kg) 
group, the CD-CBZ-SL (2mg/kg) group and CD/CMC-CBZ-NPs (20mg/kg) 
group. All these groups mentioned above were using intranasal administration 
where 25µL per nostril samples were administrated intranasally by inserting a 
polyethylene tube attached to a microsyringe approximately 0.7cm into two 
nostrils as described previously [167]. For oral administration, 0.5mL drug 
was administered by oral gavage. For all the test groups, blood samples of 
0.3mL were withdrawn by cardiac puncture at 0.5, 1, 2, 3, 4, 6 hours after 
administration [168]. Sample at one time point was collected from an 
individual mouse. Then plasma samples were stored at -20°C immediately 
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after collection until analysis. Following the completion of blood collection, 
the skull of the mice was opened after separation of the head, and the whole 
brain was collected. The brain samples were rinsed with phosphate buffer and 
stored immediately at -80°C until analysis. In order to determine the 
concentration of CBZ in the brain, the whole brain was weighed and 
homogenized after mixing in 1:1 (w/v) ratio with distilled water.
The extraction of CBZ from plasma and brain samples was conducted using 
the liquid–liquid extraction (LLE) method. Briefly, an exact 100 μL sample of 
plasma was well mixed using vortex with 280 μL acetonitrile and 20 μL 
phenacetin, the working internal standard solution (200μg/mL in acetonitrile) 
[169]. Then the mixture was centrifuged at 13000 rpm for 10 min. A total of 
50 μL of the supernatant of the sample was injected into the HPLC. Similar to 
the process of plasma samples, 100 μL of the brain-distilled water homogenate 
was extracted with 280 μL acetonitrile and 20 μL phenacetin working solution 
(200μg/mL in acetonitrile) as internal standard using vortex and then 
centrifuged at 13000 rpm for 10 min. Finally, 50 μL of the supernatant was 
injected into the HPLC for analysis. 
Samples of CBZ in plasma and brain tissues were assayed using a modified 
method of HPLC after extraction. The HPLC system (Shimadzu LC-20AD, 
Japan) was consisted of a C18 analytical column (4.6 × 150 mm, 3.5 μm) 
maintained at room temperature and a Shimadzu SPD-20A-UV detector with 
wavelength set at 285 nm. The mobile phase was made up of methanol: water 
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(6:4) and was delivered at a flow rate of 0.4 mL/min. The injection volume 
was 50 µL.
4.4 Results and discussion
4.4.1 Influence of the amount of HP-β-CD (External addition)
As shown in the Table 4-1 below, the particle size decreased as the amount of 
HP-β-CD increased. On the other hand, the values of PDI were all around 0.5 
and the zeta potential reached its highest absolute value when 0.02g HP-β-CD 
were added into the mixture which indicated that at this condition, the 
particles were more stable than the others. Moreover, the 0.02g HP-β-CD 
condition also had the highest drug loading (55.37±1.35%). According to the 
results, the optimum amount of HP-β-CD that should be added in the mixture 
was 0.02g which not only had a comparatively low particle size, more stable 
particles in the mixture but also had higher drug loading than others. 










0.01 250.6 0.540 -7.31 38.43±0.04
0.02 214.5 0.518 -14.4 55.37±1.35
0.05 189.1 0.438 -12.8 40.20±0.56
The release profiles of CBZ from CD/CMC-CBZ-NP prepared (External 
addition) by different amount of HP-β-CD were shown in Figure 4-2. 
According to the results, the in vitro release was found increased when the 
amount of the HP-β-CD was increased. All the release profiles exhibited a 
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biphasic release mechanism meaning, at the first 10 hours the release rates 
were all fast but slowed down afterwards and reached a plateau at 24 hours. 
However, with the increase of HP-β-CD amount, the burst release at the first 
10 hours was hindered while the release speed afterwards was increased. By 
adding HP-β-CD, drugs that adhere to the surface of CMC-CBZ-NPs could be 
encapsulated in HP-β-CD. Since the HP-β-CD was added after the 
nanoparticles were formed, the difference between the release profiles of 
CMC-CBZ-NPs and CD/CMC-CBZ-NPs are not so big. 
















Figure 4-2 Release profiles of CBZ from CD/CMC-CBZ-NPs (External 
addition) at different HP-β-CD amount （--■-- 0.01g, --●-- 0.02g, --▲-
- 0.05g）
4.4.2 Influence of the amount of HP-β-CD (Internal addition)
According to Table 4-2 below, the particle size increased when the amount of 
HP-β-CD added into the formulation were increased. However, the highest 
PDI and zeta potential values came out when the amount of HP- β-CD was 
0.01g. For drug loading values, the highest drug loading was 61.93±1.39 
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which appeared when the amount of HP-β-CD amount was 0.02g. Thus to 
determine the optimum formulation, the particle size as well as the drug 
loading should be taken into consideration. As a result, the optimum 
formulation should be the one with 0.01g HP-β-CD which had the smallest 
particle size and high drug loading.










0.01 187.08 0.313 -17.7 48.56±1.27
0.02 220.3 0.269 -13.1 61.93±1.39
0.05 222.3 0.290 -13.0 45.44±0.50
The release profiles of CBZ from CD/CMC-CBZ-NPs prepared by internal 
addition using different amount of HP-β-CD were shown in Figure 4-3. 
According to the results, the in vitro release was found first increased then 
decreased when the amount of the HP-β-CD was increased. The release rates 
were all fast in the first 10 hours then the release rates reached a plateau at 24 
hours. But compared with external addition, the burst release of drugs at the 
first 10 hours was hindered while the drug releases afterwards were faster and 
more complete. By adding HP-β-CD together with CMC as a carrier, not only 
drugs could be encapsulated into HP-β-CD but aldo the drug-CD complex 
could be encapsulated inside the nanoparticles. Thus the burst release could be 
hindered. The combination of HP-β-CD and CMC could also help drugs to 
release from the nanoparticles completely. 
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Figure 4-3 Release profiles of CBZ from CD/CMC-CBZ-NP (Internal addition) 
at different HP-β-CD amount （--■-- 0.01g, --●-- 0.02g, --▲-- 0.05g）
Comparing the results of internal and external addition, using internal addition 
of HP-β-CD, although the particle size and zeta potential values were similar 
to the one using external addition, the PDI values of particles prepared by the 
internal addition method was almost half the amount of that prepared by the 
external addition method indicating that nanoparticles prepared by the internal 
addition of HP-β-CD were more stable than ones prepared using external 
addition method. Moreover, the highest drug loading came out when 0.02g of 
HP-β-CD was added using internal addition of HP-β-CD during preparation. 
To sum up, for the addition of HP-β-CD, the optimum method was internal 
addition and the optimum amount of loading drug was 0.02g.
4.4.3 Influence of the rotation speed
As shown in Table 4-3, the particle size of the products decreased as the 
rotation speed increased. However, according to the PDI and zeta potential 
values, the best rotation speed should be 400rpm which had a smallest PDI 
value (0.357) and the highest absolute zeta potential value (-17.1mV). 
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Moreover, the highest drug loading also appeared when the rotation speed was 
400rpm. Thus the optimum rotation speed for formulation preparation should 
be 400rpm.










200 214.7 0.357 -10.9 30.68±0.49
400 200.7 0.308 -17.1 63.10±0.83
800 180.63 0.454 -14.9 41.89±0.56
The release profiles of CBZ from CD/CMC-CBZ-NPs prepared by different 
rotation speed using 0.01g HP-β-CD were shown in Figure 4-4. At the first 10 
hours, the formulation using rotation speed as 800rpm released faster than the 
other two however its final cumulative release value was around 80%. On the 
other hand, although the release rates with rotation speed of 200rpm and 
400rpm in the first 10hours were slow, at 24 hours the 400rpm batch had a 
nearly 100% release indicating that the rotation speed of 400rpm was the most 
suitable for the preparation of the nanoparticles. 
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Figure 4-4 Release profiles of CBZ from CD/CMC-CBZ-NPs at different 
rotation speed （--■-- 200rpm, --●-- 400rpm, --▲-- 800rpm）
4.4.4 Influence of the amount of CBZ
According to Table 4-4 below, the particle size and drug-loading increased 
when the amount of CBZ added into the formulation was increased. However 
the PDI and zeta potential values were all around 0.3 and -16mV respectively. 
The results showed that by adding HP-β-CD, the drug loading of the prepared 
nanoparticles could be largely increased.










30 122.3 0.269 -17.7 48.56±1.27
60 145.5 0.324 -16.6 64.32±3.16
80 192.6 0.369 -17.1 68.93±2.35
100 265.3 0.290 -15.7 73.08±4.21
According to the results shown above, the optimum formulation could be 
obtained as follows:
First dissolve 0.02g of HP-β-CD and CMC (20mg) together in the distilled 
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water (10mL). Then CBZ (100mg) was separately dissolved in one part of 
acetone (5mL). The CBZ solution was dropped into the polymer solution with 
magnetic stirrer (rotation speed at 400rpm). After forming completely 
dispersed particles, the dispersions were sonicated using a sonic dismembrator 
(Fisher Scientific Co., Model 500) for about 30min. The mixture was then 
stirred for about 4h to evaporate the organic solvent. The obtained 
nanoparticle suspension was filtrated through 0.45 µm filter membrane to 
remove the unincorporated CBZ aggregates, and the drug-loaded nanoparticle 
suspensions were obtained. The dried samples was obtained after freeze-
drying and kept under vacuum for 48 h. The results of three batches of 
CD/CMC-CBZ-NPs prepared using the optimal formulation were shown in 
Table 4-5.The results showed that, after modification of HP-β-CD, the particle 
sizes of the final products increased compared with CMC-CBZ-NPs but the 
drug loading became almost twice of the drug loading of CMC-CBZ-NPs (see 
in chapter 3, Page 70).
Table 4-5 Results of three batches of CD/CMC-CBZ-NPs
No Particle size (nm) PDI Zeta potential(mV) DL (%)
1 257.3 0.275 -14.7 70.39±0.77
2 260.9 0.197 -17.2 68.86±1.31
3 248.4 0.246 -16.6 65.44±2.58
4.4.5 In vitro release study
The release profiles of CBZ from the three batches of the optimum 
110
formulation of CMC-CBZ-NPs (refer to Chapter 3) and CD/CMC-CBZ-NPs 
were shown in Figure 4-5. The release of CBZ from the CMC-CBZ-NPs was 
illustrated as a biphasic release. The drug release rate was faster in the first 1-
4h which means the burst release could be attributed to CBZ molecules 
located at or near to the surface of CMC-CBZ-NPs. While at the last few 
hours, the drug release reached a plateau indicating that at the final stage, drug 
release was much slower and more stable which was controlled by degradation. 
On the other hand, the CBZ release profiles from the CD/CMC-CBZ-NPs 
were found to occur in biphasic manner. With an initial slow release phase 
followed by a complete release which illustrated the addition of HP-β-CD 
could not only hinder the burst release but also help the drug release 
completely from nanoparticles. It might be because the drugs that adhere to 
the surface of the nanoparticles might be encapsulated into HP-β-CD which 
leads to a slow release of drugs. Moreover, HP-β-CD might help the 
disintegration process of the nanoparticles which leads to a fast and complete 
release in the second phase. 
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Figure 4-5 Release profiles of CBZ from the CMC-CBZ- NPs (-■-)and 
CD/CMC-CBZ-NPs(-●-) in PBS (pH 7.4) (n=3)
For both CMC-CBZ-NPs and CD/CMC-CBZ-NPs formulations, the in vitro 
release kinetics appeared to be in accordance with the Korsmeyer-peppas 
model. And the equations of these two formulations are as follows: ln Q = 
0.2767ln t + 1.5809, r2 = 0.9577 (CMC-CBZ-NPs), ln Q = 0.5469ln t + 1.2627, 
r2 = 0.9963 (CD/CMC-CBZ-NPs). The n in equation was a diffusion exponent 
that indicates the drug release mechanism. The n value of the first equation 
was 0.276＜0.43，suggesting that the release of CBZ from CMC-CBZ-NPs 
was controlled by Fickian diffusion while for the second equation, n=0.5469 
which was between 0.43 and 0.85, suggesting that CBZ released from 
CD/CMC-CBZ-NPs was non-Fickian diffusion which was controlled both by 
diffusion and disintegration [164].
4.4.6 In vivo pharmacokinetic study
4.4.6.1 Drug concentration in plasma and brain after intranasal administration 
using CD/CMC-CBZ-NPs (2mg/kg)
The drug concentrations in plasma and brain samples after intranasal 
administration were shown in Table 4-6. According to the results shown below, 
 



















we can see that after intranasal administration of CD/CMC-CBZ-NPs, drug 
concentration reached its peak (0.653µg/mL) in plasma samples 1hour after 
administration but it had a sharp decrease in concentration after the Cmax. After 
6 hours, the concentration in plasma sample was close to 0µg/mL. In 
comparison, for the brain samples, the drug could reach the brain rapidly as 
the Cmax (0.558µg/mL) could be achieved in 0.5 hour after administration. In 
the next three hours, the concentrations of drug in the brain samples kept 
steady at around 0.3µg/mL. Then after 6 hours, the drug concentration slowly 
dropped to 0.15µg/mL indicating that the drug could stay longer in the brain 
than in the plasma.  
In vivo results of two different formulations CD/CMC-CBZ-NPs vs CMC-
CBZ-NPs (in Chapter 3) were compared in Table 4-6 and Figure 4-6. For 
CMC-CBZ-NPs, drug concentrations could only be seen in the brain and 
plasma samples for the first 4 hours, after which the concentration of CBZ 
dropped to 0µg/mL. While for CD/CMC-CBZ-NPs, the concentration of CBZ 
in the brain dropped to 0.15µg/mL at 6 hours’ time which meant that by using 
CD/CMC-CBZ-NPs, drug retention times in the plasma and brain were 
increased. Moreover, using CD/CMC-CBZ-NPs, the concentrations at each 
time point were much higher than those using CMC-CBZ-NPs meaning that 
more drugs could be delivered into brain using CD/CMC-CBZ-NPs 
formulation.                                                                            
In additon, the drug concentration reached its maximum in brain in 0.5 hours. 
113
In contrast, it took at least 1 hour for the highest concentration to be reached in 
the plasma. Thus it proved that by using intranasal administration and 
nanoparticles, drugs could reach the brain region faster than in the plasma. As 
a result, CBZ nanoparticles and intranasal administration could be used in an 
emergency situation for epilepsy patients. 
Table 4-6 Plasma and brain CBZ concentration in mice after intranasal 
administration using CD/CMC-CBZ-NPs (18 mice) and CMC-CBZ-NPs (18 
mice) (2mg/kg)
Plasma (µg/mL) Brain (µg/mL)Tim
e
(h) CD/CMC-CBZ-NPs CMC-CBZ-NPs CD/CMC-CBZ-NPs CMC-CBZ-NPs
0.5 0.157±0.107 0.151±0.042 0.558±0.200 0.234±0.065
1 0.653±0.256 0.130±0.056 0.443±0.033 0.428±0.077
2 0.265±0.043 0.315±0.070 0.327±0.114 0.336±0.062
3 0.107±0.024 0.262±0.086 0.266±0.046 0.304±0.014
4 0.077±0.009 0 0.202±0.027 0
6 0.017±0.039 0 0.110±0.0196 0
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Figure 4-6 Mean CBZ plasma and concentration of brain-time curve (n=3) in 
mice after intranasal (2mg/kg in 50ul) administration of CD/CMC-CBZ-NPs 
(18 mice) (-■-plasma,-●-brain) and CMC-CBZ-NPs (18 mice) (-▲-plasma,-
▼-brain)
4.4.6.2 Drug concentration in plasma and brain after intranasal administration 
using CD/CMC-CBZ-NPs (20mg/kg)
Table 4-7 and figure 4-7 showed the drug concentrations in plasma and brain 
samples after oral (20mg/kg) and intranasal administration (20mg/kg). 
According to the results, with the same dose, the drug concentration in brain 
after intranasal administration reached its peak (4.01g/mL) at 0.5 hours which 
was earlier and the value was much higher than that (1.65ug/mL) after the oral 
administration. This means, by using intranasal administration, more drugs 
could be delivered into the brain in a shorter time. In addition, for oral 
administration drug concentrations in brain were much lower than ones in the 
plasma while for intranasal administration, drug concentrations in brain 
samples were much higher than the concentration of plasma meaning that 
CBZ could be preferentially delivered to the brain when the drugs were 
administered intranasally. These findings were in good agreement with the 
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former researches [170, 171].  
Table 4-7 Drug concentrations in plasma and brain after oral (18 mice) and 
intranasal (18 mice) administration (20mg/kg)
Plasma  concentrations (µg/mL) Concentration of brain (µg/mL)
Time
(h)
Oral Intranasal Oral Intranasal
0.5 3.626±1.111 2.080±0428 1.199±0.138 4.013±0.439
1 4.286±0.445 3.593±0.387 1.652±0.250 3.489±0.492
2 3.359±1.355 1.761±0.236 1.525±0.333 1.958±0.228
3 2.996±0.859 0.840±0.383 1.203±0.548 1.604±0.257
4 0.755±0.143 0.299±0.055 0.959±0.204 1.096±0.175
6 0 0.123±0.031 0 0.726±0.137





















Figure 4-7 Mean CBZ plasma and concentration of brain-time curve (n=3) in 
mice after intranasal (18 mice) (20mg/kg) administration (-■-plasma,-●-brain) 
and oral (18 mice) (20mg/kg) administration (-▲-plasma,-▼-brain)
4.4.6.3 Pharmacokinetics and brain targeting studies
The pharmacokinetic parameters of CBZ after intranasal administration of 
CD/CMC-CBZ-NPs and CMC-CBZ-NPs were shown in Table 4-8. As 
indicated in the Table, the AUC of drug concentration in the brain 
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(107.06±15.77 min*µg/mL) after intranasal administration using CD/CMC-
CBZ-NPs was almost twice as much as that in the plasma (60.75±35.46 
min*µg/mL). The Tmax values for both plasma and brain were around 60min. 
For CMC-CBZ-NPs, the AUC of brain (55.55±0.65min*µg/mL) after 
intranasal administration was almost twice as much as the one of the plasma 
(37.15±1.67 min*µg/mL). The Cmax value of plasma was also around two 
times higher than the brain ones. By comparing in vivo results of these two 
formulations, it could be observed that the Tmax values of CMC-CBZ-NPs 
were much higher than that for CD/CMC-CBZ-NPs indicating that drugs 
could be delivered to the brain faster by adding HP-β-CD into the formulation. 
Moreover, the Cmax and AUC values of CD/CMC-CBZ-NPs were higher than 
those using CMC-CBZ-NPs which indicated that more drugs could be 
delivered into brain using formulations modified by HP-β-CD. 
On the other hand, to evaluate the brain targeting characteristics of CD/CMC-
CBZ-NPs and CMC-CBZ-NPs after intranasal administration, the targeting 
efficiency (Te =AUCbrain/AUCplasma) was investigated in this study. If the value 
of Te was greater than one, it meant that this formulation could be delivered 
into brain more efficiently. The higher the Te value, the better the drug could 
be targeted into the brain. In this study, the value of Te for formulation of 
CD/CMC-CBZ-NPs was 1.76 while for formulation of CMC-CBZ-NPs it was 
1.49, indicating that compared with CMC-CBZ-NPs, using formulation of 
CD/CMC-CBZ-NPs could deliver more drugs into brain and had brain 
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targeting characteristics. 
Table 4-8 Pharmacokinetic parameters of CBZ after intranasal administration 
of CD/CMC-CBZ-NPs (18 mice) and CMC-CBZ-NPs (18 mice) (2mg/kg)
CD/CMC-CBZ-NPs CMC-CBZ-NPs
Parameters
Plasma Brain Plasma Brain
Tmax (min) 60±0 60±51.96 140±34.64 80±34.64
Cmax (µg/mL) 0.65±0.76 0.59±0.16 0.32±0.02 0.46±0.04
AUC (min*µg/mL) 60.75±35.46 107.06±15.77 37.15±1.67 55.55±0.65
MRT (min) 135.97±41.03 157.51±4.27 112.25±1.58 97.63±4.42
Te   1.76 1.49
The pharmacokinetic parameters of CBZ after intranasal administration of 
CD/CMC-CBZ-NPs were shown in Table 4-9. As indicated in the table, after 
intranasal administration the AUC value of brain (456.87±53.17 min*µg/mL) 
was almost twice as much as the one of plasma (221.11±76.99 min*µg/mL). 
Moreover, the Cmax value for brain was also about twice the amount of the 
plasma. Compared with oral administration, the AUC value of brain 
(456.87±53.17 min*µg/mL) using intranasal administration was almost twice 
as much as the brain AUC value (241.39±15.24 min*µg/mL) after oral 
administration. For the brain targeting characteristics, the Te value after 
intranasal administration was 2.07 which was almost five times higher than the 
oral one (0.41). This meant that by intranasal administration, more drugs could 
be delivered into brain compared with oral administration. This was consistent 
with the conclusion of a former study [172].
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Table 4-9 Pharmacokinetic parameters of CBZ after oral (18 mice) (20mg/kg 




Plasma Brain Plasma Brain
Tmax (min) 80±34.64 100±69.28 30±0 50±17.32
Cmax (µg/mL) 4.33±0.52 1.717±0.20 2.08±0.43 4.75±1.63
AUC (min*µg/mL) 595.44±159.39 241.39±15.24 221.11±76.99 456.87±53.17
MRT (min) 92.26±2.88 95.58±5.57 92.78±8.10 84.43±11.36
Te 0.41 2.07
4.5 Conclusion
Epilepsy was one of the diseases that was difficult to be treated well by the 
conventional dosage forms. The target site of antiepileptic drugs was in the 
central nervous system which was well protected by the blood-brain barrier. 
To address this problem, nasal delivery might be a viable approach as nasal 
delivery had been proved by former researchers [96-98] that it could reach the 
brain by bypassing the blood-brain barrier. To minimize the clearance thus 
enhance the drug amount entering the brain, mucoadhesive material such as 
chitosan had been adopted as a carrier for nasal drug formulation. The 
absorption enhancing mechanism of chitosan was suggested to be a 
combination of mucoadhesion and an effect on the opening of tight junctions 
[173]. Moreover, to enhance the drug permeability to the brain, HP-β-CD 
which could increase solubility, improve drug-loading rate and entrapment 
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efficiency and/or enhance absorption of drug was added to modify the CMC-
CBZ-NPs in our study.
To evaluate the feasibility of developing brain-targeted nasal delivery system, 
with or without HP-β-CD modified CBZ-loaded carboxymethyl chitosan 
nanoparticles (CD/CMC-CBZ-NPs or CMC-CBZ-NPs) were prepared by 
modified emulsion evaporation method. And the physicochemical properties 
of these nanoparticles were characterized. A high performance liquid 
chromatography (HPLC) method was set up to determine drug loading and 
drug concentrations in mice plasma and brain samples. The pharmacokinetic 
parameters were calculated by WinNonlin. And the brain-targeted trend was 
evaluated by the value of the index AUCbrain / AUCplasma.
Results up to date showed that the CMC-CBZ-NPs and CD/CMC-CBZ-NPs 
had mean diameters of 218.5 nm vs.255.5 nm, the polydispersity index of 
0.232 vs. 0.239, zeta potential of -33.43 mv vs. -16.2 mv and drug loading of 
35.04±1.37 % vs. 68.23±2.53% respectively. The drug release from the two 
NPs in vitro appeared to be in accordance with the Korsmeyer-peppas model 
suggesting that CBZ release profile from the NPs was controlled both by 
diffusion and degradation. The results indicated that the presence of HP-β-CD 
had no critical impact in the NPs formation process. However, the mean 
diameter, zeta potential, drug-loading and drug release were varied 
accordingly to the concentration of CDs added during the preparation process. 
After intranasal administration of the two NPs, the highest drug concentrations 
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were reached faster and last longer in the brain than in the plasma. By 
comparing the AUC values, HP-β-CD modified nanoparticles exhibited a 
significant improvement in the drug absorption (60.75 vs 37.15 min*µg/mL in 
plasma and 107.06 vs 55.55 min*µg/mL in brain). Compared with oral 
administration, inranasal administration gave an AUCbrain / AUCplasma value 
over one indicating that intranasal administration had brain targeting 
characteristics.
In conclusion, in this study, a HP-β-CD modified carboxymethyl chitosan 
nanoparticle of carbamazepine (CD/CMC-CBZ-NPs) was developed and the 
formulation was administered intranasally with the objective to enhance its 
delivery to the brain. Results so far indicated that CD/CMC-CBZ-NPs 
formulation had better delivery of drug to the plasma and brain than the CMC-
CBZ-NPs formulation. Comparing intransal delivery with the oral 
administration, at the same dose, more drugs could be found to deliver into 
brain using intransal administration. This study also highlighted the 
enhancement of the treatment efficacy of AEDs by using HP-β-CD modified 
nanoparticles and intranasal delivery. As in the current market, the products of 
AEDs were administered either orally or through intravenous injection. 
Compared with the conventional oral and intravenous drug formulations, 
intranasal drug formulation which modified by HP-β-CD could provide more 
direct delivery of anti-epileptic drugs to the brain, leading to higher treatment 
efficacy.
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Chapter 5 HP-β-CD Modified Scutellarin-loaded Chitosan Nanoparticles 
for Brain Targeting Delivery following Intranasal Administration
5.1 Introduction
It is estimated that there are 31 million stroke survivors all around the world 
and about 6 million deaths are due to cerebrovascular diseases [174]. Thus 
ischemic cerebrovascular disease has become one of the most severe causes of 
death and disability that affecting people all around the world. Every year, it 
will take away nearly 12 million people’s life which constitutes almost one 
quarter of the total deaths numbers worldwide. Since the risk for having such 
disease goes up significantly after 65 years of age, and we are now facing an 
aging population, the treatment of ischemic cerebrovascular disease is badly 
needed.
Scutellarin (SCU, showed in Figure 5-1C), a flavone glucuronide of 5, 6, 4′ - 
trihydroxyflavone-7-O-glucoronide, was the primary effective constituent in 
breviscapine extracted from Chinese herb of Erigeron breviscapus (vant.) 
Hand-Mazz[175]. It was also chosen to be the marker component used by the 
Chinese Pharmacopoeia to evaluate the quality of Herba Erigerontis 
Breviscapi (Chinese Pharmacopoeia Commission, 2015). Nowadays, various 
pharmacological studies had demonstrated that SCU had a series of protective 
effects including dilate blood vessel, improve microcirculation, decrease the 
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viscosity of blood, and had the bioactivities associated with protective effects 
in the brain and heart, hypercholesterolemia suppression, platelet aggregation 
inhibition, fibrinolysis and anticoagulation [176]. For clinical use, oral and 
injectable doses of SCU were developed for the treatment of coronary heart 
disease, angina pectoris, myocardial ischemia, stroke, and cerebral thrombotic 
diseases since early 1970s [177, 178]. The daily dose for adults ranged from 
50 to 200 mg [179, 180]. In previous animal studies, SCU had demonstrated a 
stronger protective effect against cardio- and cerebro-vascular ischemia in rats 
[181, 182].
Figure 5-1 Chemical structure of CS (A), TPP (B) and SCU (C)
Although SCU had been used clinically for a long period of time, its poor 
water solubility, poor bioavailability and short half-life still inevitably limited 
its wide applications [183, 184]. Firstly, it had low solubility in both water 
(0.056 mg/mL) and lipid (logP = - 2.56 in PBS at pH 4.2). For current use, 
SCU was dissolved in aqueous solution with disodium ethylenediamine tetra 
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acetate (EDTA–2Na) which could mediate cation equilibrium in vivo. 
Moreover, the low lipid solubility of SCU also meant fewer drugs could pass 
through the blood-brain barrier [185]. Secondly, due to the low permeability 
of blood-brain barrier, SCU showed low activity against cerebral infarction in 
rat MCAO model. Thirdly, the absolute bioavailability of SCU after oral 
administration in Beagle dogs was only 0.4 ± 0.19% [186]. Pharmacokinetic 
studies showed that the elimination half-life of SCU in dog plasma was only 
1.0 min [187]. Therefore, finding a new dosage form and a novel delivery 
route for SCU was necessary for the ischemic cerebrovascular disease 
treatment.
The nasal route had been recognized as an important potential route for drug 
delivery to the brain. However, a limitation of nasal drug delivery was the 
mucociliary clearance that reduced the time available for adsorption within the 
nasal cavity. With mucoadhesive materials, the time for drug absorption in 
nasal cavity could be extended. Chitosan (CS, Figure 5-1A)) was one such 
material that had been shown to be mucoadhesive. The free amino groups not 
only enabled the formation of chitosan salts with organic and inorganic acids 
which could bind to the nasal mucosal membrane leading to an increased 
retention time as a good absorption enhancer; but also could induce an 
intermolecular or intramolecular ionic gelation reaction with sodium 
tripoplyphosphate (TPP) when preparing the chitosan nanoparticles (Figure 5-
1B).
124
The aims of this chapter were to prepare SCU-loaded chitosan nanoparticles 
(NPs) by ion cross-linking reaction and optimized the formulation variables 
using the response surface methodology (RSM): a three-level, three factor 
Box–Behnken design (BBD). The NPs were characterized in terms of particle 
size, entrapment efficiency and in vitro release behavior and the results were 
compared with the release profile of the drug solution. In vivo tests were 
performed on mice for pharmacokinetic studies using intranasal drug delivery. 
Compared with the oral administration and the standard SCU solution 
respectively, intranasal delivery with the optimum nanoparticle formulation 
demonstrated a significant tendency of brain-targeting of SCU, which 
indicated a certain feasibility to develop a brain-targeted nasal delivery system 
for SCU [188].
5.2 Materials 
5.2.1 Chemical and reagents
SCU (>98%) was purchased from Wuhan Yuancheng Gongchuang Science 
and technology Co. Ltd, China; medium molecular weight chitosan(CS) was 
supplied by Aldrich Chemical Company; Pluronic F-68 was provided by 
BASF cooperation; Sodium tripolyphosphate (TPP) and rutin trihydrate were 
purchased from Sigma-Aldrich; Sodium hydroxide (1mol/L) was obtained 
from Merck Chemicals Co., Ltd (Germany); Methanol and acetonitrile were 
HPLC grade and purchased from Merck Chemicals Co.; all other chemical 
solvents and reagents used were of analytical grade.
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5.2.2 Animals
Adult male C57BL mice aged between 6 to 7 weeks and weighing 20–30 g 
were supplied by local certified animal facility (Comparative Medicine, Center 
for Life Science, National University of Singapore). Mice were housed under 
controlled environment with free access to tap water and standard rodent diet. 
All the experiments involving animals and their care were approved by the 
Institutional Animal Care and Use Committee (IACUC), National University 
of Singapore with the protocol number of R13-4467(A2)14.
5.3 Methods
5.3.1 Preformulation of SCU
5.3.1.1 HPLC method for SCU
A high performance liquid chromatography (HPLC) method was constructed 
to determine SCU concentration in samples. The HPLC system was consisted 
of a pump (Model LC-20A, Shimadzu, Japan), a reversed-phase C18 column 
(150×4.5 mm，3µm) maintained at room temperature, a variable wavelength 
UV detector (Model SPD-20A, Shimadzu, Japan) with wavelength set at 335 
nm. The mobile phase was composed of 30% acetonitrile and 70% water 
(using phosphoric acid to adjust pH to 2.5) and was delivered at a flow rate of 
0.5 mL/min [189]. The injection volume was 20µL and samples were injected 
by an autosampler. With the chromatographic conditions, the retention time 
was 4.5 min. Quantification of the compounds was carried out by measuring 
the peak areas and comparing with that of the standards chromatographed 
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under the same condition. 
5.3.1.2 Calibration curve 
Primary standard stock solution of SCU was prepared by dissolving 5mg 
accurately weighed standard compounds in 10mL methyl alcohol. The stock 
solution was then diluted with methyl alcohol to obtain a series of working 
solutions of 5.0, 10, 15, 20, 25 and 50µg/mL, respectively. The SCU 
calibration curve was constructed by plotting the peak area versus 
concentrations.
5.3.1.3. Assay precision and accuracy 
Precision and accuracy of the assay were determined in replicates of five (n=5) 
of three different concentrations of SCU (5, 15, 25µg/mL) on the same day 
(intra-day) and also on 5 consecutive days (inter-day). The precision was 
expressed as the intra-day and inter-day coefficient of variation (%). The 
accuracy was calculated as the percent of the determined concentration to the 
nominal concentration.
5.3.1.4. Recovery
To determine the recovery of SCU by the HPLC method, the samples were 
spiked with SCU at concentrations of 5, 15, 25µg/mL. At each concentration, 
3 replicates of samples were measured. The resulting peak area was used to 
calculate the concentrations by referring to the calibration curve, and the 
results were then compared to the added concentrations to provide the 
recovery values.
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5.3.1.5. Solubility and stability 
An excessive amount of SCU was added to different solvents (pH 1.2, 2.5, 4.5, 
5.3, 6.1, 6.8, 7.4) prepared using a different ratio of Na2HPO4 and NaH2PO4 
solutions. The suspension was equilibrated with shaking speed at 80 rpm and 
temperature at 25±1°C in a shaking water bath. Aliquots were drawn and 
filtered through 0.45µm filters at designated times and assayed by HPLC. 
Solubility was determined until the variation of three consecutive readings did 
not differ by >4%. 
The stability of SCU during the sample storing and processing procedures was 
fully evaluated by analyzing the filtrate stored under room temperature (25°C) 
for different times (0, 2, 4, 8, 12, 24h) respectively. The obtained results were 
compared with the 0 h concentration of SCU to determine the stability.
In addition, we also tested the drug stability in the solvents at different pH (pH 
5.3, 6.8 and 7.4) at 37℃. 0.1% EDTA-2Na as an antioxidant was added into 
the solvents (pH 5.3, 6.8 and 7.4) as solvents with antioxidant while others 
remain the same as solvents without antioxidant. Then SCU were dissolved 
separately into these with/without antioxidants solvents to prepare a series of 
SCU solutions (concentration: 10µg/mL). The stability of SCU was fully 
evaluated by analyzing the filtrate stored at 37℃ for different times (0, 6, 12, 
24h) respectively. 
5.3.1.6 Oil /water partition coefficient 
Oil/water partition coefficient was the ratio of concentrations of SCU in a 
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mixture of two immiscible phases at equilibrium. These coefficients were a 
measure of the difference in solubility of the compound in these two phases. 
For this experiment, octanol in 5 mL was used as the oil phase and different 
solvents with pH 1.2, 3.0, 5.3, 6.5, 7.4 also in 5 mL were used as the 
respective water phases. Generally speaking, the larger the coefficient, the 
more soluble the compound would be in the oil phase and vice versa. To 
conduct the experiment, octanol was first added to different solvents 
respectively and the mixture was then shaken overnight. The water phase was 
separated from the octanol after equilibrium. Then SCU was added to the 
respective water phase and returned to the octanol. The mixture was shaken 
for another 24h. The water phase was separated after centrifugation at 
3000rpm for 10min and the concentration of SCU in the water phase was 
tested using HPLC and was compared with the water phase without the drug. 
The experiment was repeated for three times. The formula for calculation is as 
follows:
P= (C0-Cw)/ Cw
where P was Oil /water partition coefficient, C0 was initial concentration of 
drug in water phase, Cw was drug concentration in water phase after 
equilibrium.
5.3.2 Formulation of HP-β-CD modified SCU-loaded CS nanoparticles 
(CD/CS- SCU-NPs)
5.3.2.1 Preparation of solutions
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5.3.2.1.1 Preparation of CS solutions
The CS solution was prepared by dissolving 250mg CS into 50mL 0.2% acetic 
acid solution (V/V) [190]. Then the mixture was stirred using a magnetic 
stirrer for 2 hours at the temperature of 40°C. A series of working solutions 
with CS amount of 10, 15, 20mg were diluted with 0.2% acetic acid solution.
5.3.2.1.2 Preparation of the TPP solutions
The TPP solution was prepared by dissolving 250mg TPP into 50mL distilled 
water. A series of working solutions with TPP concentration of 0.5, 1.0, 1.5, 
2.0, 2.5mg/mL (W/V) were diluted with distilled water.
5.3.2.1.3 Preparation of HP-β-CD solutions
The HP-β-CD solution was prepared by dissolving certain amount of HP-β-
CD into 1mg/mL TPP solution to obtain a series of working solutions with 
HP-β-CD concentration of 0.1%, 0.2%, 0.4%(W/V).
5.3.2.2 Preparation of CD/CS-SCU-NPs
The CD/CS-SCU-NPs were prepared by a modified ionic gelation method 
reported previously [191, 192]. Briefly, SCU was dissolved in one part of 
methyl alcohol; certain amount of pluronic F-68 as a stabilizer was added into 
4mL CS solution and mixed well. Use sodium hydroxide (1mol/L) to adjust 
the pH. The SCU solution was dropped into the CS solution with magnetic 
stirrer. Then 1mL of TPP solution containing certain amount of HP-β-CD was 
added into the drug solution drop by drop with magnetic stirrer. After forming 
completely dispersed particles, the dispersions were sonicated using a sonic 
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dismembrator (Fisher Scientific Co., Model 500) for about 30min. Then the 
mixture was stirred with magnetic stirrer for about 2h to evaporate the organic 
solvent. The obtained nanoparticle suspension was filtered through 0.45 µm 
filter membrane to remove the unincorporated SCU aggregates, and the drug-
loaded nanoparticle suspensions were obtained. The dried CD/CS-SCU-NPs 
was obtained after freeze-drying and kept under vacuum for 48 h.
5.3.2.3 Preparation of SCU solutions (SCU-SL)
The SCU-SL was prepared by dissolving SCU into pH 6.8 phosphate buffer 
solution containing 0.1% EDTA-2Na.
5.3.3 Formulation development  
5.3.3.1 Influence of CS/TPP mass ratio
The concentration of CS and TPP were both kept as 1mg/mL, the amount of 
pluronic F-68 was kept as 40mg and SCU added was kept as 1mg/mL. The pH 
and the rotation speed were kept as the same. The different CS/TPP mass 
ratios (3:1, 5:1, 7:1) were used to prepare the CD/CS-SCU-NPs. Products of 
different formulations were then tested for their particle size, PDI, zeta 
potential and entrapment efficiency. The results were compared.
5.3.3.2 Influence of CS amount 
The CS/TPP mass ratio was kept as 5:1, the concentration of SCU, the 
concentration of Pluronic F-68, the pH of solution and the rotation speed were 
kept as the same. The different amount of CS (10, 15, 20mg) were used to 
prepare the CD/CS-SCU-NPs. Products of different formulations were then 
131
tested for their particle size, PDI, zeta potential and entrapment efficiency. 
5.3.3.3 Influence of the pH of solution
The CS/TPP mass ratio, the concentration of CS, the concentration of Pluronic 
F-68, the concentration of SCU and the rotation speed were kept as the same. 
The different pH value of solution (pH 4.0, 5.0, 6.0) were adjusted by sodium 
hydroxide and used to prepare the CD/CS-SCU-NPs. Products of different 
formulations will be tested for its particle size, PDI, zeta potential and 
entrapment efficiency. 
5.3.3.4 Influence of HP-β-CD concentration
The CS/TPP mass ratio, the concentration of CS, the concentration of SCU, 
the concentration of Pluronic F-68, the pH and the rotation speed were kept as 
the same. The different concentrations of HP-β-CD (0.1%, 0.2%, 0.4%) were 
used to prepare the CD/CS-SCU-NPs. Products of different formulations were 
then tested for its particle size, PDI, zeta potential and entrapment efficiency.
5.3.3.5 Influence of the rotation speed
The CS/TPP mass ratio, the concentration of CS, the concentration of SCU, 
the concentration of Pluronic F-68, the concentration of HP-β-CD and the pH 
value were kept as the same. The different rotation speed (300, 500, 800rpm) 
were used to prepare the CD/CS-SCU-NPs. Products of different formulations 
were then tested for its particle size, PDI, zeta potential and entrapment 
efficiency. 
5.3.3.6 Influence of the SCU concentration
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The CS/TPP mass ratio, the concentration of CS, the concentration of HP-β-
CD, the concentration of Pluronic F-68, the pH value of solution and the 
rotation speed were kept as the same. The different SCU concentrations (0.5, 1, 
2, 4 mg/mL) were added into the formulation. Products of different 
formulations were then tested for their particle size, PDI, zeta potential and 
entrapment efficiency. 
5.3.3.7 Influence of the Pluronic F-68 amount
The CS/TPP mass ratio, the concentration of CS, the concentration of SCU, 
the concentration of HP-β-CD, the pH value of CS solution and the rotation 
speed were kept as the same. The different Pluronic F-68 amounts (0, 30, 40, 
50 mg) were added into the formulation. Products of different formulations 
were then tested for their particle size, PDI, zeta potential and entrapment 
efficiency. 
5.3.3.8 Formulation optimization
In this section, Box–Behnken design (BBD) was specifically selected since it 
was a popular template for RSM which requireed only three-levels of each 
process factor and with only a few runs, all the possible combinations could be 
covered. In this design, the experimental region was assumed to be a cube, and 
experiments were performed at points corresponding to midpoint of each edge 
and replicated experiments at the center of this multidimensional cube [193]. 
The complete design consisted of 17 experimental points that included 12 
factor points and 5 replications at the center point. The non-linear quadratic 
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model generated by the design is as follows:
Y=b0 +b1A +b2B +b3C +b12AB +b13AC +b23BC+b11A2 +b22B2 +b33C2
Where Y denoted the measured response (dependant variable) associated with 
each factor-level combination; A, B, and C were the independent variables. 
The coefficients of the polynomial equation were represented by b0 (intercept), 
b1, b2, and b3 (linear effects), b11, b22, and b33 (quadratic effects), and b12, b13, 
and b23 (interaction effects). The terms AB, BC, AC and A2, B2, C2 
represented the interaction and quadratic terms, respectively. Based on the 
preliminary experiments, the added amount of TPP (A, mg), CS (B, mg) and 
pluronic F-68 (C, mg) were selected as main factors, while particle size (Y1) 
and entrapment efficiency (Y2) were selected as two response factors [194]. 
The response surface design table of the three factors and three levels were 
showed in Table 5-1. Software named Design Expert (Version 9.0.6) was used 
to analyze the experimental data and perform multiple regressions to obtain 
the coefficients of the quadratic polynomial model. The quality of the fitted 
model was expressed by the coefficient of determination R2, and its statistical 
significance was determined by F-test. Three batches of CD/CS-SCU-NPs 
prepared using the optimal formulation was used for verification.
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A: TPP added (mg) 1 2 3
B: CS added (mg) 10 15 20
C: Pluronic F-68 added (mg) 30 40 50
Y1: particle size (nm)
Y2: entrapment efficiency (%)
5.3.4 Characterization of CD/CS-SCU-NPs
5.3.4.1 Size and Zeta Potential
Photon correlation spectroscopy (Zetasizer 3000; Malvern Instruments, 
Malvern UK) was used to measure particle size and zeta potential of all drug-
loaded nanoparticles [195]. All samples were diluted with appropriate amount 
of distilled water for measurements. Z-average particle size, polydispersity 
index (PDI), and zeta potential were measured in triplicate at room 
temperature. 
5.3.4.2 Entrapment efficiency 
The entrapment efficiency was determined by centrifugation method as 
reported previously. 1mL of CD/CS-SCU-NPs was centrifuged at 10000 rpm 
for 15min (4℃) and the clear supernatant solutions were obtained. After 
dilution by 10-flod methanol, concentrations of SCU in the supernatant (free 
drug) were determined by HPLC. The entrapment efficiency (EE %) could be 
calculated by the following formula:
EE (%) = (Ctotal –Cfree)/ Ctotal × 100%
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Where Cfree was the SCU concentration in the supernatant after centrifugation 
while Ctotal was the initial amount of drug added during the preparation 
of CD/CS-SCU-NPs.
5.3.5 In vitro release studies
5.3.5.1 Calibration curve
Standard stock solution of SCU was prepared by dissolving 10 mg accurately 
weighed standard compounds in 10mL methanol. The stock solutions were 
then diluted with phosphate buffer (pH6.8) solution containing 0.1% EDTA-
2Na to obtain a series of working solutions of 0.5, 1.0, 2.5, 5.0 and 7.5, 
10µg/mL respectively. The SCU calibration curve was constructed by plotting 
the peak area versus concentrations.
5.3.5.2 In vitro release
In vitro SCU release from CD/CS-SCU-NPs and SCU-SL were evaluated 
using dialysis bag diffusion technique [195]. Dialysis bag with a molecular 
weight cut off 350 Da (Sigma-Aldrich Co.) were filled with 2 mL of CD/CS-
SCU-NPs suspension, and then placed into 150 mL PBS (pH6.8) containing 
0.1% EDTA-2Na. In vitro SCU release was performed at 37 °C with the 
rotation speed at 300rpm. 1mL samples were collected at predetermined time 
points (0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h), then the withdrawn samples 
were replaced with the same volume of fresh release medium to maintain a 
constant total volume. The samples were filtered with filter cartridge (PTFE 
0.45µm) before assayed by HPLC for SCU at 335 nm. 
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5.3.5.3 Release mechanism studies
The release kinetics of SCU from CD/CS-SCU-NPs in PBS (pH6.8) 
containing 0.1% EDTA-2Na was evaluated by different mathematical model 
such as the First model, Higuchi and Korsmeyer-Peppas Equation.  
5.3.6 In vivo experiment in animals
5.3.6.1 Chromatographic analysis method
Samples of SCU in plasma and brain tissues were assayed using a modified 
method of HPLC after extraction. The HPLC system (Shimadzu LC-20AD, 
Japan) was consisted of a C18 analytical column (4.6 × 150 mm, 3.5 μm) 
maintained at room temperature and a Shimadzu SPD- 20A-UV detector with 
wavelength set at 335 nm. The mobile phase was composed of 22% 
acetonitrile and 78% water (using phosphoric acid to adjust pH to 2.5) and was 
delivered at a flow rate of 0.5 mL/min [189]. The injection volume was 20 µL.
5.3.6.2 Preparation of stock solutions, standards and quality control samples
The stock solution of SCU was prepared by dissolving 5mg of SCU in 5mL 
methyl alcohol and dilute with methyl alcohol to produce a concentration of 
100µg/mL, and was stored at -4°C. The standard working solutions were used 
to spike blank plasma samples either for calibration curves of SCU or for 
quality control (QC) in prestudy validation and during the pharmacokinetic 
study. Then we took 396μL pure plasma and spiked with 4 μL of stock 
solution to make the stock solution in plasma. The stock solution of rutin 
trihydrate (internal standard) was prepared by dissolving 10mg of rutin 
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trihydrate in 5mL methyl alcohol to produce a concentration of 2mg/mL, and 
was stored at -4°C. The working solution for internal standard (100µg/mL) 
was prepared by diluting the stock solutions with methyl alcohol. Quality 
control (QC) samples were prepared in the same way as calibration standards 
with blank plasma or brain, and QC sample concentrations were 0.12, 1, 2 
µg/mL. QC samples were stored at -20°C until analysis.
5.3.6.3 Drug administration in animals and samples collection
Thirty-six healthy male mice weighing 20-30g were divided into two groups, 
the intranasal and the oral administration group. For intranasal administration, 
25µL per nostril samples were administrated intranasally by inserting a 
polyethylene tube attached to a microsyringe approximately 0.7cm into two 
nostrils as described previously. For oral administration, 0.5mL drug solution 
was administered by oral gavage. The concentration of drug solution used for 
administration in the experiment was 2 mg/mL. The oral dose and the 
intranasal dose were both 4 mg/kg. For all the groups tested, blood samples of 
0.3mL were withdrawn by cardiac puncture at 0.5, 1, 2, 3, 4, 6, 8 hours after 
administration as described previously. Sample at one time point was collected 
from an individual mouse. Then plasma samples were stored at -20°C 
immediately after collection until analysis. Following the completion of blood 
collection, the scull of the mice was opened after separation of the head, and 
the whole brain was collected. The brain samples were rinsed with phosphate 
buffer and stored immediately at -80°C until analysis. In order to determine 
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the concentration of SCU in the brain, the whole brain was weighed and 
homogenized after mixing in 1:1 (w/v) ratio with distilled water.
5.3.6.4 Assay of SCU in plasma and brain tissue samples
SCU was assayed using a modified method of HPLC after extraction. Briefly, 
an exactly 100 μL sample of plasma was well mixed with 20μL phosphoric 
acid and 20 μL rutin trihydrate working solution (100μg/mL in methyl alcohol) 
as an internal standard using vortex [190]. Phosphoric acid, as an acidic 
modifier was used to adjust the pH of plasma samples, in order to improve the 
recovery of SCU by suppressing its ionization [196]. The addition of 
phosphoric acid to plasma also denatured and precipitated proteins, which 
helped to release the bound organic components, including SCU [194]. SCU 
in the plasma was extracted by adding 0.4 mL methyl alcohol and shaking for 
5 minutes. Then the mixture was centrifuged at 14000 rpm for 10 min. A total 
of 20 μL of the supernatant of the sample was injected into the HPLC. Similar 
to the process of plasma samples, 100 μL of the brain-distilled water 
homogenate was extracted with 20μL phosphoric acid, 20 μL rutin trihydrate 
working solution (100μg/mL in methyl alcohol) and 0.4mL methyl alcohol 
using vortex and then centrifuged at 14000 rpm for 10 min. Finally, 20 μL of 
the supernatant was injected into the HPLC for analysis. 
5.3.6.5 Method validation
5.3.6.5.1 Method selectivity
To ensure the developed assay was selective for SCU, eight samples were 
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tested as follows: blank plasma or brain tissues samples, blank plasma or brain 
tissues sample spiked with SCU standard solution, blank plasma or brain 
tissues sample spiked with internal standards and SCU treated mice plasma or 
brain tissues spiked with internal standards, then the samples went subjected to 
the same extraction procedure for all the eight samples and the results were 
evaluated.
5.3.6.5.2 Calibration curves for plasma and brain tissues samples
Calibration curves were prepared by spiking different volumes of blank 
plasma or brain homogenate with different volumes of SCU standard solutions 
in plasma to make a total of 100μl solution, to produce the matrix-matched 
calibration standards at concentrations of 0.06, 0.12, 0.3, 1.0, 2.0, 3.0 µg/mL 
of SCU. Each sample that was spiked with 20μL internal standards were 
extracted according to the method described above, the peak area ratios of 
SCU to the internal standard were plotted against the concentration to get the 
standard curve.
5.3.6.5.3 Method accuracy and precision
Blank plasma or brain homogenate was added to tubes and spiked with SCU 
standard solution to make different concentrations of SCU (0.12, 1.0, 
2.0µg/mL). 5 replicate samples from each of the above concentrations were 
prepared. Samples were extracted according to the extraction method above 
and analyzed to detect the concentration of SCU by HPLC; the intra-day 
variation was recorded. Each concentration of the above sample was prepared 
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daily in a single sample and analyzed for 5 consecutive days to calculated 
inter-day precision.
5.3.6.5.4 Absolute and relative recovery
Absolute recovery: three different concentrations of SCU in plasma or brain 
tissues were prepared using the sample preparation method stated above. 
Another three different concentrations of samples were prepared using mobile 
phase instead of plasma or brain tissues by the same sample preparation 
method stated above. The recovery was tested by comparing the concentration 
of drug in the two groups of samples.
Relative recovery: three different concentrations of SCU in plasma or brain 
tissues were prepared using sample preparation method stated above. The 
recovery of the three samples was tested by comparing the calculated 
concentration with the nominal drug concentration in the samples and the test 
was replicated five times.  
5.3.6.5.5 Samples stability test
Short-term stability: Stored spiked plasma or brain aliquots were thawed and 
kept at room temperature for 6h. Post-preparative stability: The stability was 
conducted by re-analyzing extracted QC samples kept under the conditions (-
4°C) for 24h. Freeze-thaw stability: QC plasma or brain samples containing 
SCU were tested after three freeze (-20°C), thaw (room temperature) cycles. 
Long-term stability of SCU in plasma or brain was studied for a period of 10 
day by employing QC samples at the three different levels. These samples 
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were then analyzed as described above. The stability of the working solutions 
of SCU and the internal standard was evaluated by testing their potency over 
6h at room temperature, the stability of the working solutions was expressed in 
the same way as for percentage recovery. 
5.3.6.5.6 Limit of detection and quantitation
The limit of detection was defined as the amount that could be detected with a 
signal-to-noise ratio of 3:1 and the limit of quantitation was the lowest 
concentration that can be determined with acceptable precision signal-to-noise 
ratio of 10:1.
5.4 Results and discussion
5.4.1 Preformulation of SCU
5.4.1.1 Linearity
The linear regression analysis of SCU was constructed by plotting the peak 
area (A) versus concentration (C). According to Table 5-2 and Figure 5-2, the 
standard curve of SCU: A = 79154C – 34250 (r = 0.9995) was obtained, 
indicating good linear relationships between the peak areas and the 
concentrations in the range of 5.0～50 μg/mL.
Table 5-2 Standard curve of SCU for formulation study
Concentration
(C, μg/mL)
5.0 10 15 20 25 50
peak area(A) 403706 807043 1267994 1617684 2062568 4231703
Standard Curve A = 79154C – 34250（R2 =0.9995）
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Figure 5-2 Standard curve of SCU for formulation study
5.4.1.2 Assay precision and accuracy
The developed method showed good precision and accuracy. Table 5-3 
summarized the intra-day and inter-day precision and accuracy for SCU from 
three concentrations respectively. The intra-day and inter-day precisions 
(expressed as % of relative standard deviation, RSD %) were both less than 
1%. The accuracy ranged from 98.90% to 106.00%. 















5 5.19±0.03 103.80 0.57 5.30±0.03 106.00 0.51
15 15.00±0.07 100.00 0.46 15.05±0.06 100.30 0.38
25 24.72±0.05 98.90 0.20 24.89±0.06 99.56 0.25
5.4.1.3 Recovery
The results of recovery were shown in Table 5-4. According to the table, all 
the RSD were below 1%, indicating the recovery fulfilled the requirement. 
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Table 5-4 Recoveries of SCU established by the HPLC method (n = 3)
Measured concentration（μg/mL）Concentration






5 5.01 5.02 5.05 100.48±0.41 0.41
15 15.01 15.07 15.00 100.06±0.22 0.22
20 20.15 20.29 19.95 100.00±0.19 0.19
5.4.1.4 Solubility and stability
Solubility of SCU in different pH solutions at 25±1°C was shown in Table 5-5. 
The results indicated that as the pH increased in the media, the solubility of 
SCU also increased. It might be due to the carboxyl group in SCU which 
under basic condition will form a salt thus increase its solubility in the solution. 









Stability of SCU in different pH solutions at room temperature was evaluated 
and the results are shown in Table 5-6. As can be seen in the table, SCU was 
more stable under acidic conditions (pH 1.2-5.3). The stability decreased when 
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pH value increased. It might be due to the oxidization of aglycone under 
alkaline condition where SCU could easily open the ring and degrade (Figure 
5-3).
Table 5-6 Stability of SCU in different pH solutions (25°C)
Remaining (%)Time
(h) pH1.2 pH2.5 pH4.5 pH5.3 pH6.1 pH6.8 pH7.4
0 100 100 100 100 100 100 100
2 99.87 100.07 99.94 100.37 99.09 98.76 98.13
4 99.62 100.93 99.78 99.58 97.28 98.30 96.49
8 99.24 99.9 0 98.47 99.41 96.04 96.62 94.36
12 98.50 99.57 98.02 98.74 95.57 94.22 91.72
24 97.75 98.15 97.84 97.02 92.39 90.59 86.35
Figure 5-3 The oxidization reaction of aglycone in SCU
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The influence of the antioxidant to the stability of SCU at 37℃ was shown in 
Table 5-7 and Figure 5-3. With the increase of the pH and temperature, the 
stability of SCU solution decreased. However, by adding the antioxidant, the 
stability of the SCU solution could be significantly increased. Thus for in vitro 
release study in later section, phosphate buffer solution (pH 6.8) with 0.1% 
EDTA-2Na was chosen as the release medium. The oxidation of drugs could 
be catalyzed by metal ion. EDTA-2Na, as a hexadentate ("six-
toothed") ligand and chelating agent, could bind the metal ions thus prevent 
the oxidation of SCU.
Table 5-7 Stability of SCU in different pH media（37°C）
Remaining (%)Tim
e
(h) pH5.3 pH5.3+2%ETDA pH6.8 pH6.8+2%ETDA pH7.4 pH7.4+2%ETDA
0 100 100 100 100 100 100
6 98.85 99.95 93.73 99.88 83.36 99.32
12 97.10 99.57 83.39 99.89 71.41 98.87
24 95.28 99.84 69.55 99.77 39.15 98.37
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Figure 5-4 The remaining of SCU content in pH 5.3（-■-）, 
pH5.3+2%ETDA(-●-), pH6.8(-▲- ), pH6.8+2%ETDA (-▼-), pH7.4(-◆-), 
pH7.4+2%ETDA (-＊-) at 37℃
5.4.1.5 Partition coefficient
The partition coefficients of SCU were shown in Table 5-8. As indicated in the 
table, the logP values decreased when the pH values increased and SCU could 
be slightly dissolved in the water. According to former studies, drugs could 
only pass through the biological membrane when the logP value was between 
-1 and 2. For SCU, the logP values were not within this range which meant it 
could not pass through the membrane easily meaning that SCU might had bad 
bioavailability in human body. Thus CD and CS were chosen as carrier 
meterials to help deliver more drugs into brain.
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Table 5-8 Partition coefficient of SCU in different solvent against octanol
Solvent P logP
0.1mol/L HCL（pH 1.2) 1.926 0.285
（pH 3.0) 1.284 0.109
Water（pH 5.3) 0.515 -0.288
phosphate buffer (pH 6.5) 0.378 -0.423
phosphate buffer (pH 7.4) 0.167 -0.777
5.4.2 Formulation optimization
5.4.2.1 Influence of CS/TPP mass ratio
The effects of CS/TPP mass ratios on characteristics of the CD/CS-SCU-NPs 
were shown in Figure 5-5 and Table 5-9. According to the table, the lowest 
particle size (290.3nm) came out when the CS/TPP mass ratio was 5:1. It 
might be due to the fact that two CS molecules and a TPP molecule could 
form the closest structure thus the minimum particle size could be obtained. 
Moreover, the PDI values increased as the CS/ TPP mass ratio increased. For 
zeta potential, it represented the stability of colloidal dispersions in the 
products. The higher the value, the more stable of particles would be. As 
shown in Table 5-10, all zeta potential values were over 20 except the one 
with 3:1 CS/TPP mass ratio which was only 4.10. For entrapment efficiency, 
as the CS/TPP mass ratio increased, the entrapment efficiency decreased. 
However, for the highest entrapment efficiency (CS/TPP mass ratio3:1), its 
particle size was almost twice as the other two and its zeta potential value was 
only 4.1 meaning that this formulation had larger particle size and was not 
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stable. Thus considering all the conditions, the optimum CS/TPP mass ratio 
was 5:1. 
Figure 5-5 Schematic synthesis of chitosan–TPP nanoparticles. Chitosan binds 
to pyrophosphate through ionotropic gelation and generates CS-TPP gel 
complex. [197]









3:1 616.5 0.121 4.10 77.67±0.46
5:1 290.3 0.140 27.3 42.49±0.37
7:1 338.3 0.182 28.4 29.02±0.16
5.4.2.2 Influence of CS amount
The effects of CS concentration on characteristics of the CD/CS-SCU-NPs 
were shown in Table 5-10. According to the Table, the lowest particle size 
(290.3nm) as well as the PDI (0.140) came out when the CS concentration was 
15mg. It might be because when the concentration of CS was too high; the 
produced nanoparticles could aggregate, leading to an increase of particle 
sizes. For zeta potential, all zeta potential values were over 20 except the one 
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with 10mg of CS which was only 6.07. For entrapment efficiency, as the CS 
concentration increased, the entrapment efficiency decreased. Although for 
10mg of CS amount, the entrapment efficiency was as high as 93.10%, its 
particle size and PDI values were much higher than others while the zeta 
potential value was only 6.07. Thus the optimum CS amount used in the 
formulation was 15mg.









10 427.6 0.580 6.07 93.10±0.03
15 290.3 0.140 27.3 42.49±0.37
20 582.3 0.212 33.4 27.85±0.09
5.4.2.3 Influence of HP-β-CD concentration
The effects of HP-β-CD concentration on characteristics of the CD/CS-SCU-
NPs were shown in Table 5-11. According to the Table, the particle sizes for 
all three formulations were all around 300nm meanwhile their PDI values 
were all around 0.2. Moreover, all products had a value of zeta potential 
around 27mV, indicating that the particles were all stable. The differences 
between the entrapment efficiency values were not so big and the highest 
value was reached when the HP-β-CD concentration was 0.4% w/v. In 
conclusion, the optimum concentration for HP-β-CD was 0.4%. However, 
since the differences between characteristics of the final products were not so 
big among various HP-β-CD concentrations, this factor would not be further 
studied in the response surface design.
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0.1% 316.2 0.213 27.6 44.59±0.09
0.2% 290.3 0.191 27.3 42.49±0.37
0.4% 302.3 0.182 28.7 50.07±0.07
5.4.2.4 Influence of the pH value of solution
The effects of the pH of solution on characteristics of the CD/CS-SCU-NPs 
were shown in Table 5-12. According to the Table, the particle size increased 
as the pH value increased. When pH value was less than 4.0, the nanoparticles 
were difficult to be formed mainly because that most of the phosphate groups 
in TPP were occupied by H+ thus the electrostatic attraction between 
phosphate groups in TPP and NH3+ group in CS were blocked. The highest 
zeta potential value (27.3mV) was obtained when the pH value was 4.0. Since 
the particle size was much larger at pH 5.0 and 6.0, despite that the entrapment 
efficiency at these two pH were much higher, the optimum pH value of CS 
solution for the formulation should be at pH 4.0.









4.0 290.3 0.140 27.3 42.49±0.37
5.0 740.7 0.886 7.54 82.56±0.04
6.0 1102 0.946 4.48 64.62±0.02
5.4.2.5 Influence of the rotation speed
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The effects of the rotation speed on characteristics of the CD/CS-SCU-NPs 
were shown in Table 5-13. According to the Table, the particle size of the 
formulations decreased as the rotation speed increased while at the same time 
the PDI values increased. Although the lowest particle size (211.5nm) and the 
highest entrapment efficiency (73.44%) were achieved when the rotation 
speed was 800 rpm, its zeta potential value is only 3.53mV indicating that 
these particles were not stable in the solution. Based on the results shown 
above, the optimum rotation speed should be at 500 rpm.
Table 5-13 Influence of the rotation speed on the particle characteristics





300 296.5 0.103 22.9 41.12±1.71
500 290.3 0.140 27.3 42.49±0.37
800 211.5 0.198 3.53 73.44±0.13
5.4.2.6 Influence of the SCU concentration
The effects of the SCU concentration on characteristics of the CD/CS-SCU-
NPs were shown in Table 5-14. According to the Table, the particle size as 
well as the PDI values increased as the amount of SCU added into the 
formulation increased. However, the zeta potential value decreased as the SCU 
amount increased, indicating that the particles were more stable when the SCU 
concentration was less than 2.0mg/mL. The entrapment efficiency, same as 
particle size, was increased as the drug concentration increased. However, 
when the drug concentration exceeded 2.0mg/mL, the entrapment efficiency 
decreased. This suggested that only a certain amount of drugs could be 
152
encapsulated in the nanoparticles. The drug that could not be encapsulated 
would be adsorbed onto the surface of the nanoparticles. Considering the 
particle size and stability, 2.0mg/mL will be the maximum amount of SCU 
that could be loaded in the nanoparticles.









0.5 315.1 0.149 24.9 32.52±0.25
1.0 290.3 0.140 27.3 42.49±0.37
2.0 464.1 0.200 20.6 91.83±0.12
4.0 689.7 0.328 12.9 77.59±0.05
5.4.2.7 Influence of the Pluronic F-68 amount
The effects of the Pluronic F-68 amount on characteristics of the CD/CS-SCU-
NPs were shown in Table 5-15. According to the Table, the particle size 
decreased as the amount of Pluronic F-68 added into the formulation increased. 
Pluronic F-68 as a stabilizer, could assist the separation of nanoparticles thus 
increase the stability of the nanoparticles. Otherwise, the prepared 
nanoparticles were easy to form aggregates thus leading to an increase of 
particle size. The highest entrapment efficiency value came out when the 
amount of Pluronic F-68 added was 40mg whereas the difference between the 
entrapment efficiency at each amount was not so big. Considering the particle 
size and stability, 40-50mg wouldl be the optimum amount of Pluronic F-68 
which could be added into the nanoparticles.
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0 815.0 0.998 20.6 91.83±0.12
30 464.1 0.200 -0.558 87.39±0.17
40 312.3 0.386 0.869 90.38±0.05
50 199.42 0.451 2.30 93.08±0.04
5.4.2.8 Formulation optimization and verification
A systematic optimization was carried out using response surface 
methodology (RSM) for estimating the effect of formulation variables (A, B, 
and C) on dependent variables (Y1 and Y2). A three-factor, three-level Box-
Behnken statistical experimental design was used to optimize the formulation 
variables and the response surface methodology requires 17 experiments. The 
experimental data, including independent variables along with their low (-), 
medium (0), and high (+) levels and responses for all 17 experimental runs 
were summarized in Table 5-16 [199]. The value of overall desirability (OD) 
was calculated by Hassan method. For particle size, the smaller the size, the 
better of nanoparticles, thus d1 = dmin= (Ymax-Yi)/(Ymax-ymin) while for drug 
content the bigger the drug content, the better of nanoparticles, thus d2 = dmax= 
(Yi-Ymin)/(Ymax-Ymin). As a result, the value of OD equaled to OD = (d1×d2)1/n. 
The experimental results were fitted into non-linear response surface model. 
The polynomial models for OD could be represented by the equation:
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OD=0.74+0.29A-0.13B+0.017C-0.11AB+0.16AC+0.017BC-0.35A2-0.080C2
(R2 = 0.9477, Adj R2 = 0.8954, F = 18.11, P = 0.0002).
Table 5-16 Results of response surface design
A B C













1 0 -1 1 350.2 64.86 0.7796
2 0 1 -1 522.7 54.52 0.4799
3 1 0 1 320.0 42.35 0.5988
4 0 -1 -1 194.9 54.57 0.8396
5 0 0 0 386.8 67.43 0.7544
6 1 -1 0 168.8 65.39 0.9747
7 1 0 -1 293.5 31.35 0.4746
8 -1 0 -1 489.0 17.11 0.0960
9 -1 1 0 682.1 20.23 0
10 -1 -1 0 348.8 15.83 0
11 0 0 0 386.8 67.43 0.7544
12 1 1 0 528.1 67.99 0.547
13 0 1 1 515.3 53.96 0.487
14 0 0 0 386.8 67.43 0.7544
15 0 0 0 386.8 67.43 0.7544
16 0 0 0 386.8 67.43 0.7544
17 -1 0 1 510.5 19.71 0.1576
The 3D response surface graphs of the effect between each factor were shown 
in Figure 5-4. Figure 5-4 (A) displayed the combined effect of TPP added 
amount and CS added amount on OD by keeping the pluronic F-68 added 
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amount at 40mg. The plot in Figure 5-4(B) revealed the combined effect of 
TPP added amount and the pluronic F-68 added amount while keeping CS 
added amount at 10 mg on OD. The response surface plot in Figure 5-4(C) 
displayed the combined effect of CS added amount and pluronic F-68 added 
amount by keeping TPP added amount at 2mg on OD. By means of this 
method, there were 10 solutions to obtain smaller particle size and higher 
entrapment efficiency. One of the optimal conditions obtained with 
desirability at 0.975 were 2.5 mg for TPP added amount, 10.1mg for CS added 
amount, and 40mg for pluronic F-68 with the predicted OD of 0.985. 
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                                  A
                                  B
C
Figure 5-6 3D response surface graphs of the effect of Factor A&B on OD 
value (A), Factor A&C on OD value (B) and Factor B&C on OD value (C)
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According to the results stated above, an optimized result from the response 
surface design experiments using Design expert software based on the effects 
of three factors was described as follows: SCU (10mg) was dissolved in 3mL 
of methyl alcohol; Pluronic F-68 (40mg) was dissolved in 0.2% CS solution 
(10mg), using sodium hydroxide to adjust the pH of the mixture to 4.0. The 
SCU solution was dropped into CS solution with magnetic stirrer. Then HP-β-
CD (20mg) and TPP (2.5mg) were dissolved in 1mL distilled water and the 
mixture was added into the CS solution with drug. After forming completely 
dispersed particles, the dispersions were sonicated using a sonic dismembrator 
(Fisher Scientific Co., Model 500) for about 30min. Then the mixture was 
stirred with magnetic stirrer for about 2h to evaporate the organic solvent. The 
obtained nanoparticle suspension was filtrated through 0.45 µm filter 
membrane to remove the unincorporated SCU aggregates, and the drug-loaded 
nanoparticle suspension was then obtained. The results of three batches 
CD/CS-SCU-NPs prepared using the optimization formulation are showed in 
Table 5-17. As canbe seen in table 5-17, nanoparticles in all three batches 
have a particle size around 200 and entrapment efficiency around 70% which 
is in good agreement with the former study done by Wei et al. [195].
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Table 5-17 Results of optimal experimental condition for preparation of 
CD/CS-SCU-NP
No Particle size(nm) PDI Zeta potential(mV) EE (%)
1 239.5 0.545 26.0 73.41±1.31
2 230.7 0.669 23.4 69.52±0.15
3 225.2 0.658 25.9 70.10±0.92
5.4.3 In vitro release studies
5.4.3.1 Calibration curve
According to Table 5-18 and Figure 5-5, the standard curve of SCU: A = 
40919C–4851.8 (r=0.9973) was obtained which indicated good linear 
relationships between the peaks and the concentrations in the range of 0.5～10 
μg/mL.
Table 5-18 Standard calibration curve of SCU employed for in vitro release 
studies
Concentration(μg/mL) 0.5 1.0 2.5 5.0 7.5 10.0
Peak area(A) 7912 25887 106588 209760 301069 399178
Standard Curve A = 40919C – 4851.8  (r = 0.9973)
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Figure 5-7 Standard calibration curve of SCU employed for in vitro release 
studies
5.4.3.2 In vitro release profile of SCU from the CD/CS-SCU-NPs
The drug release from three batches of CD/CS-SCU-NPs prepared using the 
optimal formulations for verification were shown in Figure 5-6. The results 
showed that the in vitro release of SCU exhibited a biphasic release. In the 
first 8 hours, drug was released slowly as a zero degree release and the drug 
release reached a plateau at 12 hours. And finally at 24 hours, almost 80% of 
the total drug was released from the nanoparticles. On the contrary, the drug 
release from SCU-SL was fast and complete. In the first 2 hours, most of the 
drugs were released from the solution.
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Figure 5-8 Release profiles of SCU from the CD/CS-SCU-NPs prepared under 
the optimal experimental condition (n=3)
Table 5-19 showed that the release of SCU from CD/CS-SCU-NPs was in 
accordance with Higuchi equation, indicating that SCU release was controlled 
both by diffusion and degradation. 
Table 5-19 In vitro release kinetics equation fitting results
Model Equation R2
Zero order Q = 3.628t +14.561 0.8147
First order Ln (1-Q) = -0.0642 t + 4.0394 0.7125
Higuchi Q = 19.6237 t1/2 – 2.4455 0.9792
Korsmeyer-Peppas ln Q = 1.4734ln t + 2.3355 0.7901
5.4.4 In vivo pharmacokinetic study in mice
5.4.4.1 Calibration curve of plasma samples
Calibration curve was constructed by plotting the peak area ratio (R) of SCU 
to the internal standard against the concentration (C) of SCU. The calibration 
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curve for SCU was linear over the range of 0.06 - 3μg/mL. The regression 
equation was R =0.1287C + 0.0235, r=0.9907 (Table 5-21).
Table 5-20 Standard curve of SCU in plasma (n=5)
Concentration(μg/mL) 0.06 0.12 0.3 1 2 3
Peak area ratio(R) 0.0230 0.0492 0.0708 0.1712 0.2840 0.3999
Standard Curve R =0.1287C + 0.0235,  r=0.9907
Figure 5-9 Calibration curve of SCU in plasma
5.4.4.2 Calibration curve of brain samples
Calibration curve were constructed by plotting the peak area ratio (R) of SCU 
to the internal standard against the concentration (C) of SCU. The calibration 
curve for SCU was linear over the range of 0.06 - 3μg/mL. The regression 
equation was R =0.1169C + 0.0164, r=0.9947 (Table 5-22).
Table 5-21 Standard curve of SCU in plasma (n=5)
Concentration 
(μg/mL)
0.1 0.2 0.5 1 2 5
Peak area ratio(R) 0.0173 0.0375 0.0611 0.1442 0.2495 0.3628
Standard Curve R =0.1169C + 0.0164,  r=0.9947
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Figure 5-10 Calibration curve of SCU in brain tissue
5.4.4.3 Method selectivity
The method was shown to be selective for the detection of SCU. The HPLC 
assay was used to screen blank plasma, blank plasma spiked with SCU, blank 
plasma spiked with internal standard and plasma of mice treated with SCU. 
The findings were shown in Figure 5-9. Same experiments were carried out 
for brain tissues. Results were shown in Figure 5-10. The Figures showed that 
the retention times of the internal standard (rutin trihydrate) and SCU were 
about 4.7min and 6.3 min, and the other plasma or brain endogenous 
components did not interfere with the detection of SCU and internal standard. 
The methods were shown high selectivity for separation of SCU and internal 
standard in both matrices.
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Figure 5-11 Typical HPLC chromatogram of blank plasma (A), blank plasma 
spiked with internal standard (B), blank plasma spiked with SCU (C), and 
plasma sample obtained from a mice that was administrated with SCU (D).
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Figure 5-12 Typical HPLC chromatogram of blank brain (A), blank brain 
spiked with internal standard (B), blank brain spiked with SCU (C), and brain 
sample obtained from a mice that was administrated with SCU (D).
5.4.4.4 Method precision
Table 5-22 showed the results of intra-day and inter-day variation, all the 
variations met the requirement and showed good precision and accuracy of the 
method which was consistent with the biological sample analysis requirement.
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0.12 0.12±0.005 101.46 3.97 0.11±0.005 87.78 4.89
1.0 1.12±0.03 111.66 2.69 0.97±0.04 97.50 3.99
Plasma
(μg/mL)
2.0 1.98±0.05 99.25 2.38 1.96±0.05 98.11 2.62
0.12 0.12±0.006 103.47 5.03 0.11±0.005 91.67 4.68
1.0 1.09±0.05 108.56 5.05 0.89±0.05 88.90 5.31Brain(μg/g)
2.0 2.07±0.06 103.72 2.93 1.80±0.03 90.07 1.77
5.4.4.5 Absolute and relative recovery of SCU from the plasma and brain 
matrices
The absolute recoveries of SCU from plasma and brain tissues were above 80% 
(Table 5-23). The datas proved the suitability of the extraction method used 
for plasma and brain tissue samples. The relative recovery of SCU from 
plasma and brain tissue ranged from 88.90% to 98.11% and the absolute 
recovery ranged from 74.10% to 90.58%. All the RSD% values were below 
7%, indicating that the recovery fulfilled the requirement.
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Table 5-23 Recoveries of SCU from mice plasma and brain tissue (n=5)
Absolute recovery (%) Relative recovery (%)
Concentration
Mean±SD RSD Mean±SD RSD
0.12 76.46±0.04 4.68 90.57±0.04 4.68
1.0 75.50±0.04 5.31 88.90±0.05 5.31
Plasma
(μg/mL)
2.0 83.16±0.01 1.77 90.08±0.02 1.76
0.12 74.10±0.04 4.89 91.97±0.06 6.43
1.0 82.80±0.03 3.99 94.10±0.02 2.17Brain(μg/g)
2.0 90.58±0.02 2.62 98.11±0.03 2.62
5.4.4.6 Stability of SCU in the samples 
Table 5-24 summarized the datas from the short-term, freeze-thaw and long-
term stability tests of SCU in samples，as well as the stability of SCU post-
sample preparation. The short-term test indicated reliable stability behavior 
under the experimental conditions of the analytical runs. The results of the 
freeze-thaw stability test indicated that the analyze was stable in mouse 
plasma or brain tissue after three cycles of storing at -20°C and thawing to 
room temperature. The post-sample preparation stability of the QC samples 
showed that SCU was stable in the sample extract when kept at 4°C for 24h. 
The findings from the long-term test indicated that storage of the plasma or 
brain tissue containing SCU at -20°C was adequate when the samples were 
kept for 10 days. Thus, no stability-related problems were anticipated during 
the routine analyses of the samples for the bioavailability study.
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Short-term 96.49 5.31 98.24 4.38 94.77 2.47
Freeze-thaw 98.95 4.29 95.86 2.97 96.36 3.21
Long-term 94.92 3.18 94.58 5.73 95.12 5.32
Plasma
Post-sample 
preparation 97.36 2.77 98.37 2.25 98.44 6.71
Short-term 95.32 6.53 97.47 1.39 95.37 1.04
Freeze-thaw 99.27 4.77 96.35 2.66 96.84 3.84
Long-term 96.18 2.85 92.41 1.95 98.45 2.19Brain
Post-sample 
preparation 94.75 3.16 95.88 4.38 93.26 5.22
5.4.4.7 Limit of detection and quantitation
The lowest detectable concentration (LOD) was 15ng/mL with S/N ratio of 
3:1, while the limit of quantification (LOQ) was 50ng/mL with S/N ratio of 
10:1.
5.4.4.8 Pharmacokinetics studies
5.4.4.8.1 The drug concentrations in plasma and brain after intranasal and oral 
administration (4mg/kg) using CD/CS-SCU-NPs
Table 5-25 and 5-26 showed the drug concentrations in plasma and brain after 
intranasal and oral administration using CD/CS-SCU-NPs. As indicated, after 
intranasal administration, the brain drug concentration reached its peak 
(7.16μg/mL) at 0.5 h. In comparison, the highest concentration of plasma was 
achieved later at 2 hours which corresponded with the former publication 
[192]. Moreover, at each time points, drug concentrations in brain samples 
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were more than two times higher than in plasma. The results illustrated that 
when using intranasal administration, more drugs could be delivered into brain 
tissues in a shorter time indicating its brain targeting characteristics when 
using intranasal administration. Even at 8 hours, the drug concentration in the 
brain is still quite high meaning that using intranasal administration could also 
increase the retention time of drug in the brain.
Table 5-25 Mean brain and concentration of plasmas in mice after intranasal 
administration (4mg/kg) using CD/CS-SCU-NPs (n = 3)
Brain (μg/mL) Plasma (μg/mL)
Time(h)
mean SD mean SD
0.5 7.16 0.22 2.06 0.20
1 6.46 0.41 2.30 0.62
2 5.20 0.26 2.73 0.39
3 4.86 0.06 2.69 0.96
4 4.74 0.18 1.78 0.24
6 4.14 0.31 1.72 0.23
8 3.61 0.89 1.40 0.13
On the other hand, the brain drug concentration reached its peak (2.967μg/mL) 
at 1 h after oral administration. Compared with the concentration of brain after 
intranasal administration, it took longer time for drug to reach the brain after 
oral administration. Moreover, the highest drug concentration in brain after 
oral administration was much lower than the one using intranasal 
administration (2.967μg/mL vs 7.1587μg/mL). However, for oral 
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administration, the drug concentration in brain was still higher than in the 
plasma which means using nanoparticles as a drug carrier could enhance the 
brain targeting characteristics of the drug. It had a significant tendency of 
brain-targeting property when compared to oral administration and 
intravenous injection, indicating a feasibility of developing a brain-targeted 
nasal delivery system for scutellarin.
Table 5-26 Mean concentration of brain and concentration of plasma in mice 
after oral administration (4mg/kg) using CD/CS-SCU-NPs (n = 3)
Brain (μg/mL) Plasma (μg/mL)
Time(h)
mean SD mean SD
0.5 2.80 0.63 1.90 1.20
1 2.97 0.41 1.80 0.55
2 2.85 0.11 2.04 0.57
3 2.86 0.74 1.92 0.24
4 2.62 0.18 1.68 0.08
6 2.29 0.19 1.39 0.08
8 1.95 0.27 1.11 0.16
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Table 5-27 Mean concentration of brain and concentration of plasma in mice 
after intranasal (4mg/kg) and oral administration (4mg/kg) using CD/CS-SCU-
NPs (n = 3)
Intranasal Oral
Brain (μg/mL) Plasma (μg/mL) Brain (μg/mL) Plasma (μg/mL)
Time(h
)
Mean SD Mean SD Mean SD Mean SD
0.5 7.16 0.22 2.06 0.20 2.80 0.63 1.90 1.20
1 6.46 0.41 2.30 0.62 2.97 0.41 1.80 0.55
2 5.20 0.26 2.73 0.39 2.85 0.11 2.04 0.57
3 4.86 0.06 2.69 0.96 2.86 0.74 1.92 0.24
4 4.74 0.18 1.78 0.24 2.62 0.18 1.68 0.08
6 4.14 0.31 1.72 0.23 2.29 0.19 1.39 0.08
8 3.61 0.89 1.40 0.13 1.95 0.27 1.11 0.16
The Mean brain and concentration of plasma-time curve of SCU in mice after 
intranasal and oral administration of CD/CS-SCU-NPs were shown in Figure 
5-11. Compared with the oral administration, the drug concentrations in brain 
using intranasal administration are significantly higher than others. These 
results indicated that giving CD/CS-SCU-NPs by intranasal administration 
could deliver more drugs into brain than in the plasma and have brain 
targeting characteristics. 
171
Figure 5-13 Mean plasma and concentration of brain-time curve of SCU in 
mice after intranasal (--■--brain, --●--plasma) and oral (--▲--brain, --▼--
plasma) administration of CD/CS-SCU-NPs (4 mg/kg)
5.4.4.8.2 The drug concentration in plasma and brain after intranasal 
administration using CD/CS-SCU-NPs and SCU-SL (4mg/kg)
The drug concentrations in plasma and brain samples after intranasal 
administration using SCU-SL were shown in Table 5-28. According to the 
Table, after intranasal administration using SCU-SL, the drug concentration in 
the plasma was higher than that in the brain, indicating that SCU-SL did not 
have brain targeting characteristics. Nevertheless, similar to CD/CS-SCU-NPs, 
the drug could reach the brain faster and last longer than in the plasma which 
suggested that using intranasal administration, drug could easily reach the 
brain in a shorter time. The mean plasma and brain concentration time curve 
of SCU in mice after intranasal administration of CD/CS-SCU-NPs and SCU-
SL were shown in Figure 5-13. As can be seen in the figure，at each time 




















point, the concentration of brain using CD/CS-SCU-NPs was higher than that 
using SCU-SL. This indicated that more drugs could reach the brain in a 
shorter time and last longer in the brain by intranasal administration using 
CD/CS-SCU-NPs.
Table 5-28 Plasma and brain tissues SCU concentrations in mice after 
intranasal administration using SCU-SL (n=3)
Brain (µg /mL) Plasma (µg /mL)
Time(h)
mean SD Mean SD
0.5 2.781 0.813 4.690 2.209
1 2.325 1.208 5.954 3.229
2 2.149 0.526 2.800 2.071
3 2.043 0.729 2.203 1.316
4 2.053 0.218 1.554 0.378
6 2.065 0.327 1.390 0.356
8 2.018 0.467 1.048 0.021
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Figure 5-14 Mean plasma and concentration of brain-time curve of SCU in 
mice after intranasal (4 mg/kg) administration of CD/CS-SCU-NPs (--▲-- 
brain, --▼--plasma) and SCU-SL (--■-- brain, --◆-- plasma)
5.4.4.8.3 The pharmacokinetic parameters and brain targeting 
The pharmacokinetic parameters of SCU after oral and intranasal 
administration of CD/CS-SCU-NPs were shown in Table 5-29. It was found 
that since the dose for both oral an intranasal administration were the same 
(4mg/kg), the plasma AUC after oral administration was only about 80% of 
the one after intranasal administration (760.46 versus 924.51min*μg/mL); but 
the brain AUC after oral administration was only about 40% of the one after 
intranasal administration (1186.90 versus 2652.95min*μg/mL). This meant 
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that the drug was preferentially distributed to the brain after intranasal 
administration. As mentioned earlier, the brain AUC was about twice the 
amount of the plasma AUC after intranasal administration of the CD/CS-SCU-
NPs (2652.95 versus 924.51 min*μg/mL).  
To evaluate the brain targeting characteristics of CD/CS-SCU-NPs after oral 
and intranasal administration, the targeting efficiency (Te =AUCbrain/AUCplasma) 
was investigated in this study. If the value of Te was greater than one, it meant 
that this formulation could be delivered into brain more efficiently. The higher 
the Te value, the better the drug could be targeted into the brain. In our study, 
the value of Te for oral administration was 1.56 while for intranasal 
administration it was 2.87 which was about twice of the value after oral 
administration, indicating that although using the CD/CS-SCU-NPs, both the 
oral and intranasal administration showed a brain targeting characteristic. 
Compared with oral administration, using intranasal administration could 
deliver more drugs into brain and had brain targeting characteristics. These 
findings were in good agreement with the study done before [198]. Therefore, 
it could be concluded that intranasal administration were more specific in 
delivering SCU to the brain as compared to oral administration.
175
Table 5-29 Pharmacokinetic parameters for CD/CS-SCU-NPs
Oral Intranasal
Parameters
plasma brain plasma brain
Tmax(min) 70±45.83 90±79.37 140±34.64 30±0
Cmax(µg/mL) 2.60±0.46 3.10±0.13 2.84±0.54 21.16±24.37
AUC
(min*µg/mL) 760.46±29.80 1186.90±25.65 924.51±85.20 2652.95±650.32
MRT(min) 224.06±10.53 230.32±3.94 169.97±5.09 223.76±10.76
Te 1.56 2.87
The pharmacokinetic parameters of SCU after intranasal administration of 
CD/CS-SCU-NPs and SCU-SL were shown in Table 5-30. The plasma AUC 
after intranasal administration using CD/CS-SCU-NPs was close to the one 
that using SCU-SL(924.51 versus 1078.29 min*μg/mL); and the brain AUC 
after intranasal administration using CD/CS-SCU-NPs was almost 3 times 
higher than that using SCU–SL (2652.95 versus 945.02 min*μg/mL). This 
meant that the drug was preferentially distributed to the brain after intranasal 
administration using the formulation of CD/CS-SCU-NPs. For Te value, the 
value of Te by using SCU-SL was only 0.88 while by using CD/CS-SCU-NPs 
it was 2.87, indicating that compared with SCU-SL, using CD/CS-SCU-NPs 
could delivered more drugs into brain and had brain targeting characteristics. 
In conclusion, these results demonstrated that by using the mucoadhesive 
material in the formulation, the contact time of the formulation in the nasal 
mucosa was increased which result in a better brain targeting characteristic. 
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Significantly higher AUC (2652.95±650.32) and Cmax (21.16±24.37) in brain 
samples for CD/CS-SCU-NPs compared to SCU-SL were attributed to the 
addition of CS and HP-β-CD in the formulation. 




Plasma Brain Plasma Brain
Tmax(min) 140±34.64 30±0 40±17.32 140±91.65
Cmax(µg/mL) 2.84±0.54 21.16±24.37 7.13±6.29 2.21±0.04
AUC
(min*µg/mL) 924.51±85.20 2652.95±650.32 1078.29±663.99 945.02±30.52
MRT(min) 169.97±5.09 223.76±10.76 189.20±36.21 249.58±5.16
Te 2.87 0.88
5.5 Conclusion
In this chapter, a HP-β-CD modified scutellarin loaded chitosan nanoparticles 
(CD/CS-SCU-NPs) weer prepared using an ionic gelation method. Based on 
the result of single factor evaluation, the main factors that affect the 
preparation of CD/CS-SCU-NPs were the CS/TPP mass ratio, the amount of 
CS and amount of Pluronic F-68. The optimized formulation and preparation 
parameters were determined by response surface design using Design expert 
Version 9.0.6. The particle size, PDI and zeta potential of the nanoparticles 
prepared were estimated by nano-zetasizer. The entrapment efficiency of SCU 
in nanoparticles was determined by HPLC.
According to the results, it was demonstrated that the particle sizes of the 
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optimum formulation were all around 200nm, PDI values around 0.5, zeta 
potential values around 25 and entrapment efficiency around 70%, indicating 
that the products of the optimum formulation had a nano-grade particle size, 
the particles were stable in the solution and around 70% of the SCU could be 
entrapped into the nanoparticles. 
For the in vivo studies, results up to date showed that compared with oral 
administration, intranasal administration would result in much higher drug 
concentrations in the brain which meant that at the same drug dose, more 
drugs could be delivered into brain through intranasal administration. 
In conclusion, results in this chapter illustrated that using the HP-β-CD 
modified chitosan nanoparticles to load drugs and using intranasal 
administration were more specific in delivering SCU to the brain.
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Chapter 6 Conclusion and future research
6.1 Conclusion
Central nervous system diseases are diseases that could affect the spinal cord 
or brain. Such diseases could be treated by surgery or by drug treatment. 
Unfortunately, for the latter approach, drug delivery to the brain for treatment 
of the central nervous system diseases is often hampered by the blood brain 
barrier. Thus developing strategies to bypass the blood brain barrier and 
deliver sufficient drug to brain have become one of the most important 
challenges in research today. To tackle these challenges, intranasal delivery of 
nanoparticles has come into our consideration in this study. For intranasal 
delivery, former studies have proved that drug delivery through nostrils could 
bypass the blood brain barrier thus increase the treatment efficacy of drugs for 
central nervous system diseases. Nevertheless, the mucociliary clearance in 
the nostril could decrease the drug contact time in the nostrils, leading to less 
drug to be delivered into brain. To overcome this limitation, mucoadhesive 
material-chitosan was used in this study to modify the drug retention in the 
nasal cavity and to improve the bioavailability of drug using intranasal 
delivery.
In the second chapter, a carboxymethyl grafted chitosan was synthesized and 
characterized by FT-IR and MNR. Such chitosan derivative could be dissolved 
in the water, thus facilitating the preparation of chitosan nanoparticles. Then in 
the third chapter, carbamazepine was used as a model drug and prepared a 
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carboxymethyl chitosan modified carbamazepine loaded nanoparticles using a 
modified emulsion evaporation method. Products were then characterized 
using zeta-sizer and TEM to test their size and morphology. By comparing the 
results, the optimum formulation of the nanoparticles was determined and 
three bathes of the optimum formulation were prepared. All of the products 
prepared by optimum formulation had a particle size around 200nm and drug 
loading was around 35%. The TEM result of the nanoparticles showed that 
these nanoparticles had a round shape and uniform size. After that, the 
optimum formulation was tested in vitro on the drug release in a phosphate 
buffer solution; and the in vivo pharmacokinetics after oral and intranasal 
administration were evaluated in mice. For the in vitro study, the release 
mechanism of the formulation was found to be in accordance with the 
Korsmeyer-Peppas equation, and the drugs release from the nanoparticles was 
Fickian diffusion that was controlled by concentration gradient, diffusion 
distance and degree of swelling of the matrix. For in vivo study, our results 
showed that when the nanoparticles were administered intranasally, the 
carbamazepine brain to plasma exposure in AUC was 150% indicating that the 
drug was preferentially delivered to the brain when the formulation was 
administered intranasally.
Unfortunately, due to the limitation of the amount of drugs that could be 
delivered through the nostril, the drug concentrations in the brain after 
intranasal administration were still lesser than the ones using oral 
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administration. To overcome this limitation and further improve the 
permeability of drugs into the brain, HP-β-CD was adopted to modify the 
carboxymethyl chitosan nanoparticles and its effects on preparation of 
nanoparticles and drug delivery to brain were studied in the fourth chapter. In 
this chapter, the same method was used to prepare and characterize the 
nanoparticles, the only difference was that HP-β-CD was added to complex 
the drug in the preparation. According to the results, the sizes of the 
nanoparticles prepared from the modified method were all around 100nm 
which was about half of the size of the nanoparticles prepared in earlier 
method reported in Chapter 3; while for drug loading, the HP-β-CD modified 
nanoparticles had a drug loading around 50% which was much higher than the 
ones without using HP-β-CD. These results indicated that using HP-β-CD to 
prepare nanoparticles could have much smaller size and higher drug loading. 
For in vitro study, the release mechanism of HP-β-CD modified nanoparticles 
was also in accordance with the Korsmeyer-peppas model. In this model, the 
release processes of the nanoparticles were divided into two stages: in the first 
stage, drug that adhered near to the surface of the nanoparticles might be 
encapsulated inside the HP-β-CD cavity, leading to a slower release rate. 
While in the second stage, HP-β-CD might help the disintegration process of 
the nanoparticles. Thus at 24 hours, the cumulative release of CD/CMC-CBZ-
NPs reached almost 100% which was much higher than that of the CMC-
CBZ-NPs (80%). For the in vivo study, when oral and intranasal 
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administration were using the same dose, the drugs could reach brain faster, 
last longer and have higher brain concentrations by using intranasal 
administration than by using oral administration. The pharmacokinetic study 
also showed that using HP-β-CD modified nanoparticles and intranasal 
administration gave better brain targeting characteristics. 
Since HP-β-CD modified chitosan nanoprticulate delivery system has been 
proved to be effective in drug delivery into brain, we proposed to use the same 
method to prepare formulation for other drugs. In chapter 5, scutellarin, a 
traditional Chinese medicine used for the treatment of ischemic 
cerebrovascular disease, was chosen as a model drug for formulation 
development. In the clinical situation, scutellarin has only been given as 
tablets and injections. The drug has a low bioavailability in human body and 
so far there is no chitosan based nanoparticles developed for scutellarin. 
Moreover, compared with oral and intravenous administration, nasal delivery 
may have feasibility to have brain targeting characteristics, thus we proposed 
to develop a brain-targeted nasal delivery system for scutellarin. The 
scutellarin nanoparticles were prepared using chitosan and HP-β-CD and the 
optimum formulation was determined by the response surface design approach. 
The analysis of the experimental data was done using software, Design Expert 
version 9.0.6. Size and drug loading of the optimum formulation were tested. 
As a result, the particle sizes of the optimum formulation were found to be 
around 200nm and the drug loading was around 70%. For in vitro study, the 
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release of SCU from the nanoparticles exhibited a biphasic release and was in 
accordance with Higuchi equation.
For the in vivo study, our results showed that compared with oral 
administration, intranasal administration resulted in much higher drug 
concentrations in the brain indicating that at the same drug dose, more drug 
was delivered to the brain by intranasal administration. The drug 
concentrations in the brain using nanoparticles were much higher than that 
with the SCU-SL formulation, suggesting that the formulation of nanoparticles 
could help to deliver more drugs into brain.
The novelty of this thesis includes: (a) Choosing chitosan and its derivative 
CMC as carrier materials to prepare nanoparticles using solvent evaporation 
and ionic gelation methods. The effect of HP-β-CD on drug loading and 
particle size of nanoparticles has also been discussed. (b) Based on the 
different physicochemical characteristics of chemical drug (CBZ) as well as 
natural drug (SCU), different carrier materials were chosen to prepare the 
nanoparticles. (c) Using intranasal administration to bypass the blood-brain 
barrier. Compared with oral administration, intranasal administration of the 
developed nanoparticles was shown to give better the brain targeting efficacy 
of the test drugs in our study. 
In conclusion, our study aimed to prepare a HP-β-CD modified chitosan 
nanoparticles to deliver drug into brain using intranasal administration. Our 
findings proved that such nanoparticulate delivery system has brain targeting 
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characteristics and more drugs could be delivered into brain using intranasal 
administration.
6.2 Future direction
According to the investigations described in this thesis, there are still some 
important issues to be addressed:
1. The different pharmaceutical formulations prepared in this thesis should be 
further optimized in order to increase the entrapment efficiency and 
encapsulation efficiency of the nanoparticles thus improving the treatment 
efficacy of the model drugs.
2. Some imaging contrast agents could be added in the appropriate formulation 
for bioimaging to monitor the drug transportation in the body which could 
better evaluate the brain targeting characteristics of the formulations.
3. Transgenic mice models could be used to further investigate the therapeutic 
efficacy of the delivery system and drug formulations in the treatment of 
central nervous system diseases.
4. More drugs for the treatment of central nervous system diseases, such as 
haloperidol, aripiprazole and rivastigimine could be adopted to establish an 
intranasal delivery system using the nanoparticulate formulation.
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